{"PMC7167797": [["INTRODUCTIONDisulfides are the most common covalent interactions within a protein molecule involved in cross\u2010linking of sequentially distant residues.", [["INTRODUCTIONDisulfides", "CHEMICAL", 0, 22], ["INTRODUCTIONDisulfides", "SIMPLE_CHEMICAL", 0, 22], ["protein molecule", "PROTEIN", 74, 90], ["a protein molecule", "TREATMENT", 72, 90], ["protein molecule", "OBSERVATION", 74, 90], ["distant residues", "OBSERVATION", 133, 149]]], ["By bringing about entropic destabilization of the unfolded state, disulfides can confer stability on the protein.1, 2 Disulfide engineering is thus an important method of enhancing protein stability.", [["disulfides", "CHEMICAL", 66, 76], ["Disulfide", "CHEMICAL", 118, 127], ["disulfides", "SIMPLE_CHEMICAL", 66, 76], ["enhancing", "OBSERVATION_MODIFIER", 171, 180], ["protein stability", "OBSERVATION", 181, 198]]], ["Although the removal of a naturally\u2010occurring disulfide in a protein molecule results in destabilization, the introduction of a non\u2010naturally occurring disulfide bridge does not typically result in stabilization of the protein molecule.3, 4, 5 This might be a consequence of the energetic penalty required for rearrangement of residues surrounding the cysteines to accommodate the disulfide, as well as due to loss of favorable interactions involving the original wild\u2010type (WT) residues.2 Alternatively, the conformational characteristics of the disulfide formed might be energetically unfavorable.", [["disulfide", "CHEMICAL", 46, 55], ["disulfide", "CHEMICAL", 152, 161], ["cysteines", "CHEMICAL", 352, 361], ["disulfide", "CHEMICAL", 381, 390], ["disulfide", "CHEMICAL", 547, 556], ["protein molecule", "PROTEIN", 61, 77], ["protein molecule", "PROTEIN", 219, 235], ["wild\u2010type (WT) residues", "PROTEIN", 464, 487], ["the removal", "TREATMENT", 9, 20], ["a naturally\u2010occurring disulfide", "TREATMENT", 24, 55], ["a non\u2010naturally occurring disulfide bridge", "TREATMENT", 126, 168], ["the protein molecule", "PROBLEM", 215, 235], ["the energetic penalty", "PROBLEM", 275, 296], ["rearrangement of residues", "TREATMENT", 310, 335], ["the cysteines", "TREATMENT", 348, 361], ["the disulfide", "TREATMENT", 377, 390], ["loss of favorable interactions", "PROBLEM", 410, 440], ["the original wild\u2010type (WT) residues", "TREATMENT", 451, 487], ["destabilization", "OBSERVATION_MODIFIER", 89, 104], ["stabilization", "OBSERVATION", 198, 211], ["protein molecule", "OBSERVATION", 219, 235], ["energetic penalty", "OBSERVATION", 279, 296], ["might be", "UNCERTAINTY", 564, 572], ["energetically", "OBSERVATION_MODIFIER", 573, 586], ["unfavorable", "OBSERVATION", 587, 598]]], ["A study of cross\u2010strand disulfides in antiparallel \u03b2\u2010sheets had previously shown that while disulfides formed at the non\u2010hydrogen bonded registered pairs are stabilizing, those in the hydrogen bonded positions are destabilizing.5, 6 Hence, an understanding of disulfides in the context of protein structures could provide valuable information for protein engineering.", [["non\u2010hydrogen", "CHEMICAL", 117, 129], ["disulfides", "CHEMICAL", 24, 34], ["disulfides", "CHEMICAL", 92, 102], ["non\u2010hydrogen", "CHEMICAL", 117, 129], ["hydrogen", "CHEMICAL", 184, 192], ["disulfides", "CHEMICAL", 260, 270], ["cross\u2010strand disulfides", "SIMPLE_CHEMICAL", 11, 34], ["disulfides", "SIMPLE_CHEMICAL", 92, 102], ["antiparallel \u03b2\u2010sheets", "PROTEIN", 38, 59], ["A study of cross\u2010strand disulfides in antiparallel \u03b2\u2010sheets", "TEST", 0, 59], ["protein structures", "PROBLEM", 289, 307], ["protein engineering", "TREATMENT", 347, 366], ["hydrogen bonded", "OBSERVATION", 184, 199]]], ["Engineered disulfides can also act as conformational constraints and to validate protein models.7 Hence, it is important to understand the conformational determinants of disulfides formed within and between different types of secondary structures.INTRODUCTIONIntrahelical disulfides are a characteristic feature of active sites of several oxidoreductases.8, 9 In addition to playing an important functional role, they also stabilize the protein.3 The importance of the CXXC (CYS\u2010X\u2010X\u2010CYS tetrapeptide) motif at the N\u2010termini of helices in catalysis of redox reactions is well known.10, 11, 12, 13, 14 This motif has been aptly described as a rheostat in the active site of oxidoreductases.9 The motif can be highly reducing as in thioredoxin or highly oxidizing as in DsbA.15, 16, 17 Altering the two XX residues alters the reduction potential of the disulfide.", [["disulfides", "CHEMICAL", 11, 21], ["disulfides", "CHEMICAL", 170, 180], ["tetrapeptide", "CHEMICAL", 487, 499], ["DsbA.15", "CHEMICAL", 767, 774], ["disulfide", "CHEMICAL", 850, 859], ["disulfides", "SIMPLE_CHEMICAL", 170, 180], ["CXXC", "GENE_OR_GENE_PRODUCT", 469, 473], ["oxidoreductases", "GENE_OR_GENE_PRODUCT", 672, 687], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 729, 740], ["oxidoreductases", "PROTEIN", 339, 354], ["CXXC", "PROTEIN", 469, 473], ["CYS", "PROTEIN", 475, 478], ["\u2010X", "PROTEIN", 480, 482], ["CYS tetrapeptide) motif", "PROTEIN", 483, 506], ["N\u2010termini of helices", "PROTEIN", 514, 534], ["oxidoreductases", "PROTEIN", 672, 687], ["thioredoxin", "PROTEIN", 729, 740], ["INTRODUCTIONIntrahelical disulfides", "TREATMENT", 247, 282], ["several oxidoreductases", "PROBLEM", 331, 354], ["the CXXC (CYS\u2010X\u2010X\u2010CYS tetrapeptide) motif", "TREATMENT", 465, 506], ["redox reactions", "PROBLEM", 551, 566], ["thioredoxin", "TREATMENT", 729, 740], ["the two XX residues", "TREATMENT", 792, 811], ["the disulfide", "TREATMENT", 846, 859], ["active", "OBSERVATION_MODIFIER", 315, 321], ["several", "OBSERVATION_MODIFIER", 331, 338], ["oxidoreductases", "OBSERVATION", 339, 354]]], ["The redox potential variation and the change in activity of several oxidoreductases have been studied following mutation of the XX residues.8, 15, 18, 19, 20, 21, 22 The CXXC motif in oxidoreductases has also been shown to play a role in conferring substrate specificity.23 The CXXC motif is a characteristic feature of the thioredoxin fold.", [["CXXC", "GENE_OR_GENE_PRODUCT", 278, 282], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 324, 335], ["oxidoreductases", "PROTEIN", 68, 83], ["CXXC motif", "PROTEIN", 170, 180], ["oxidoreductases", "PROTEIN", 184, 199], ["CXXC motif", "PROTEIN", 278, 288], ["thioredoxin fold", "PROTEIN", 324, 340], ["The redox potential variation", "PROBLEM", 0, 29], ["several oxidoreductases", "TREATMENT", 60, 83], ["the XX residues", "TREATMENT", 124, 139], ["The CXXC motif in oxidoreductases", "TEST", 166, 199], ["The CXXC motif", "TEST", 274, 288], ["the thioredoxin fold", "PROBLEM", 320, 340], ["redox", "OBSERVATION", 4, 9], ["potential variation", "OBSERVATION", 10, 29], ["change", "OBSERVATION_MODIFIER", 38, 44], ["thioredoxin fold", "OBSERVATION", 324, 340]]], ["Minor variations in the fold structure and active site leads to a diverse collection of proteins with varying functions.24 Homology searches for oxidoreductases carrying CXXC motifs has revealed the presence of proteins with CXXC derived sequences like CXXS, CXXT, TXXC, and SXXC.", [["CXXS", "GENE_OR_GENE_PRODUCT", 253, 257], ["CXXT", "GENE_OR_GENE_PRODUCT", 259, 263], ["TXXC", "GENE_OR_GENE_PRODUCT", 265, 269], ["SXXC", "GENE_OR_GENE_PRODUCT", 275, 279], ["oxidoreductases", "PROTEIN", 145, 160], ["CXXC motifs", "PROTEIN", 170, 181], ["CXXC", "PROTEIN", 225, 229], ["CXXS", "PROTEIN", 253, 257], ["CXXT", "PROTEIN", 259, 263], ["TXXC", "PROTEIN", 265, 269], ["SXXC", "PROTEIN", 275, 279], ["Minor variations in the fold structure", "PROBLEM", 0, 38], ["active site", "PROBLEM", 43, 54], ["oxidoreductases carrying CXXC motifs", "PROBLEM", 145, 181], ["CXXC derived sequences", "TEST", 225, 247], ["CXXS", "TEST", 253, 257], ["CXXT", "TEST", 259, 263], ["TXXC", "TEST", 265, 269], ["variations", "OBSERVATION_MODIFIER", 6, 16], ["fold structure", "OBSERVATION", 24, 38], ["active", "OBSERVATION_MODIFIER", 43, 49], ["site", "OBSERVATION_MODIFIER", 50, 54], ["diverse", "OBSERVATION_MODIFIER", 66, 73], ["collection", "OBSERVATION", 74, 84], ["varying", "OBSERVATION_MODIFIER", 102, 109]]], ["These CXXC derived sequences also occur at the N\u2010termini of helices and are believed to confer redox activity.25", [["CXXC", "GENE_OR_GENE_PRODUCT", 6, 10], ["CXXC", "PROTEIN", 6, 10], ["These CXXC derived sequences", "TEST", 0, 28], ["redox activity", "OBSERVATION", 95, 109]]]], "63ce8dc2b5abe467ae29a0a9dbebc8beb8eccf63": [["The first mobile phones became commercially available in 1983, and in 1999 the first smartphone to achieve mass adoption within a country was released in Japan.", [["mass", "OBSERVATION", 107, 111]]], ["Globally smartphone use has grown rapidly, so that by 2012 there were over one billion in use worldwide.", [["rapidly", "OBSERVATION_MODIFIER", 34, 41]]], ["Smartphones and other portable electronic devices present both opportunities to improve infection prevention and control (IPC), as exemplified in this article, as well as challenges around their cleaning and decontamination in healthcare environments.", [["infection", "DISEASE", 88, 97], ["Smartphones", "TREATMENT", 0, 11], ["other portable electronic devices", "TREATMENT", 16, 49], ["infection prevention", "TREATMENT", 88, 108], ["infection", "OBSERVATION", 88, 97]]]], "dcf6cf371a350038df834f05c6d7486c802ccb60": [["obtain epidemiologic information on URI and to determine the specific virus types associated with URI and their ability to induce AOM and OME.Study design and subjects.This was a prospective, longitudinal cohort study designed to capture all symptomatic episodes of URI that occurred in children during a 1-year period, to study the incidence and characteristics of URI that is complicated by OM.", [["AOM", "DISEASE", 130, 133], ["OME", "DISEASE", 138, 141], ["URI", "DISEASE", 266, 269], ["URI", "DISEASE", 366, 369], ["OM", "DISEASE", 393, 395], ["children", "ORGANISM", 287, 295], ["children", "SPECIES", 287, 295], ["URI", "PROBLEM", 36, 39], ["the specific virus types", "PROBLEM", 57, 81], ["URI", "PROBLEM", 98, 101], ["OME", "PROBLEM", 138, 141], ["longitudinal cohort study", "TEST", 192, 217], ["URI", "PROBLEM", 266, 269], ["URI", "PROBLEM", 366, 369], ["URI", "OBSERVATION", 266, 269], ["URI", "OBSERVATION", 366, 369]]], ["The study was performed at the University of Texas Medical Branch (Galveston, TX) and was approved by the Institutional Review Board; written informed consent was obtained for all subjects.", [["The study", "TEST", 0, 9]]], ["Healthy children living in Galveston who had received medical care at the University of Texas Medical Branch were recruited from the primary care clinic and via advertisements in the local newspaper and at local day care centers.", [["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16], ["medical care", "TREATMENT", 54, 66]]], ["Children were enrolled at the ages of 6 months to 3 years.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["They could be asymptomatic or have had URI or AOM at the time of enrollment.", [["AOM", "DISEASE", 46, 49], ["asymptomatic", "PROBLEM", 14, 26], ["URI", "PROBLEM", 39, 42], ["AOM", "PROBLEM", 46, 49], ["URI", "OBSERVATION", 39, 42], ["AOM", "OBSERVATION", 46, 49]]], ["Children with chronic medical problems or an anatomical or physiological defect of the ear or nasopharynx were excluded from the study.", [["ear", "ANATOMY", 87, 90], ["nasopharynx", "ANATOMY", 94, 105], ["Children", "ORGANISM", 0, 8], ["ear", "ORGAN", 87, 90], ["nasopharynx", "ORGAN", 94, 105], ["Children", "SPECIES", 0, 8], ["chronic medical problems", "PROBLEM", 14, 38], ["an anatomical or physiological defect of the ear or nasopharynx", "PROBLEM", 42, 105], ["the study", "TEST", 125, 134], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["physiological defect", "OBSERVATION", 59, 79], ["ear", "ANATOMY", 87, 90], ["nasopharynx", "ANATOMY", 94, 105]]], ["During the year, parents were asked to notify the study office as soon as the child began to have symptoms of a cold or URI (e.g., nasal congestion, rhinorrhea, cough, sore throat, or fever).", [["nasal", "ANATOMY", 131, 136], ["URI", "DISEASE", 120, 123], ["nasal congestion", "DISEASE", 131, 147], ["rhinorrhea", "DISEASE", 149, 159], ["cough", "DISEASE", 161, 166], ["sore throat", "DISEASE", 168, 179], ["fever", "DISEASE", 184, 189], ["child", "ORGANISM", 78, 83], ["nasal", "ORGANISM_SUBDIVISION", 131, 136], ["symptoms", "PROBLEM", 98, 106], ["a cold", "PROBLEM", 110, 116], ["URI", "PROBLEM", 120, 123], ["nasal congestion", "PROBLEM", 131, 147], ["rhinorrhea", "PROBLEM", 149, 159], ["cough", "PROBLEM", 161, 166], ["sore throat", "PROBLEM", 168, 179], ["fever", "PROBLEM", 184, 189], ["URI", "OBSERVATION", 120, 123], ["nasal", "ANATOMY", 131, 136], ["congestion", "OBSERVATION", 137, 147]]], ["Children were seen by a study physician as soon as possible after the onset and were observed a few days later to assess whether there were complications of OM; parents were compensated for time and travel.", [["OM", "DISEASE", 157, 159], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["Study personnel also provided 2 home visits during weeks 2 and 3 of the URI to perform tympanometry.", [["the URI", "PROBLEM", 68, 75], ["tympanometry", "TEST", 87, 99]]], ["If the tympanogram findings remained abnormal after 3 weeks, testing was repeated every 2 weeks until the findings were normal or the next URI episode occurred.", [["the tympanogram findings", "TEST", 3, 27], ["testing", "TEST", 61, 68], ["the next URI episode", "PROBLEM", 130, 150]]], ["Parents were advised to bring the child for examination whenever they suspected the child to have any AOM symptom.Study design and subjects.At each visit, information was collected on specific URIrelated symptoms; tympanometry was performed, and the child's ears were examined using pneumatic otoscopy by trained investigators (T.C., K.R., and J.A.P.).", [["ears", "ANATOMY", 258, 262], ["AOM", "DISEASE", 102, 105], ["child", "ORGANISM", 34, 39], ["ears", "ORGAN", 258, 262], ["child", "SPECIES", 250, 255], ["examination", "TEST", 44, 55], ["any AOM symptom", "PROBLEM", 98, 113], ["specific URIrelated symptoms", "PROBLEM", 184, 212], ["tympanometry", "TEST", 214, 226], ["pneumatic otoscopy", "TEST", 283, 301]]], ["OM was considered to have complicated URI if it occurred within 28 days after the onset of URI, unless new-onset URI occurred during this period; in that case, OM was considered to have complicated the most recent URI.", [["URI", "DISEASE", 91, 94], ["URI", "DISEASE", 113, 116], ["complicated URI", "PROBLEM", 26, 41], ["URI", "PROBLEM", 91, 94], ["URI", "PROBLEM", 113, 116], ["the most recent URI", "PROBLEM", 198, 217], ["URI", "OBSERVATION", 38, 41], ["URI", "OBSERVATION", 91, 94], ["URI", "OBSERVATION", 113, 116], ["URI", "OBSERVATION", 214, 217]]], ["AOM was defined as the acute onset of symptoms (fever, irritability, or earache), signs of tympanic membrane inflammation, and presence of fluid, as documented by pneumatic otoscopy and/or tympanometry.", [["tympanic membrane", "ANATOMY", 91, 108], ["fluid", "ANATOMY", 139, 144], ["AOM", "DISEASE", 0, 3], ["fever", "DISEASE", 48, 53], ["irritability", "DISEASE", 55, 67], ["earache", "DISEASE", 72, 79], ["inflammation", "DISEASE", 109, 121], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 91, 108], ["fluid", "ORGANISM_SUBSTANCE", 139, 144], ["AOM", "PROBLEM", 0, 3], ["symptoms", "PROBLEM", 38, 46], ["fever", "PROBLEM", 48, 53], ["irritability", "PROBLEM", 55, 67], ["earache", "PROBLEM", 72, 79], ["tympanic membrane inflammation", "PROBLEM", 91, 121], ["fluid", "PROBLEM", 139, 144], ["pneumatic otoscopy", "TEST", 163, 181], ["tympanometry", "PROBLEM", 189, 201], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["tympanic membrane", "ANATOMY", 91, 108], ["inflammation", "OBSERVATION", 109, 121], ["fluid", "OBSERVATION", 139, 144]]], ["Children who received a diagnosis of AOM were treated on the basis of the standard of care [19] .", [["AOM", "DISEASE", 37, 40], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["AOM", "PROBLEM", 37, 40], ["AOM", "OBSERVATION", 37, 40]]], ["OME was considered to have complicated URI if new fluid and/or an air-fluid bubble was visualized or if a new type B tympanogram result was obtained without signs of tympanic membrane inflammation.", [["fluid", "ANATOMY", 50, 55], ["tympanic membrane", "ANATOMY", 166, 183], ["OME", "DISEASE", 0, 3], ["inflammation", "DISEASE", 184, 196], ["fluid", "ORGANISM_SUBSTANCE", 50, 55], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 166, 183], ["OME", "PROBLEM", 0, 3], ["complicated URI", "PROBLEM", 27, 42], ["new fluid", "PROBLEM", 46, 55], ["an air-fluid bubble", "PROBLEM", 63, 82], ["a new type B tympanogram result", "TEST", 104, 135], ["tympanic membrane inflammation", "PROBLEM", 166, 196], ["complicated", "OBSERVATION_MODIFIER", 27, 38], ["URI", "OBSERVATION", 39, 42], ["new", "OBSERVATION_MODIFIER", 46, 49], ["fluid", "OBSERVATION", 50, 55], ["air", "OBSERVATION", 66, 69], ["fluid bubble", "OBSERVATION", 70, 82], ["tympanic membrane", "ANATOMY", 166, 183], ["inflammation", "OBSERVATION", 184, 196]]], ["New middle ear effusion was defined as the presence of middle ear effusion without a type B tympanogram finding having been documented in the previous 30 days.", [["ear", "ANATOMY", 11, 14], ["ear", "ANATOMY", 62, 65], ["ear effusion", "DISEASE", 11, 23], ["ear effusion", "DISEASE", 62, 74], ["ear", "ORGAN", 11, 14], ["ear", "ORGAN", 62, 65], ["New middle ear effusion", "PROBLEM", 0, 23], ["middle ear effusion", "PROBLEM", 55, 74], ["a type B tympanogram finding", "PROBLEM", 83, 111], ["middle", "ANATOMY_MODIFIER", 4, 10], ["ear", "ANATOMY", 11, 14], ["effusion", "OBSERVATION", 15, 23], ["middle", "ANATOMY_MODIFIER", 55, 61], ["ear", "ANATOMY", 62, 65], ["effusion", "OBSERVATION", 66, 74]]], ["Children with AOM and OME in each ear were counted as having AOM.", [["ear", "ANATOMY", 34, 37], ["AOM", "DISEASE", 14, 17], ["OME", "DISEASE", 22, 25], ["AOM", "DISEASE", 61, 64], ["Children", "ORGANISM", 0, 8], ["ear", "ORGAN", 34, 37], ["Children", "SPECIES", 0, 8], ["AOM", "PROBLEM", 14, 17], ["OME", "PROBLEM", 22, 25], ["AOM", "PROBLEM", 61, 64], ["AOM", "OBSERVATION", 14, 17], ["OME", "OBSERVATION", 22, 25], ["ear", "ANATOMY", 34, 37]]], ["The day of onset of OM during the course of URI was determined from day 1 (the first day of symptoms) to the first day of diagnosis.Study design and subjects.In addition to parent's self-reported URI, the study personnel called the parents twice monthly to determine whether there were any current URI symptoms and occurrence of any URI or AOM episodes missed since prior contact.", [["OM", "DISEASE", 20, 22], ["AOM", "DISEASE", 340, 343], ["URI", "PROBLEM", 44, 47], ["symptoms", "PROBLEM", 92, 100], ["URI", "PROBLEM", 196, 199], ["any current URI symptoms", "PROBLEM", 286, 310], ["any URI", "PROBLEM", 329, 336], ["AOM episodes", "PROBLEM", 340, 352]]], ["The University of Texas Medical Branch is the sole provider of pediatric health care in Galveston; diseases diagnosed and treated in our children are likely to be noted in our medical records.", [["children", "ORGANISM", 137, 145], ["children", "SPECIES", 137, 145], ["diseases", "PROBLEM", 99, 107]]], ["URI and AOM episodes not seen by the study group but captured from parent's interviews or from medical records were recorded as \"missed episodes.\"Study design and subjects.Virologic studies.", [["AOM", "DISEASE", 8, 11], ["URI", "PROBLEM", 0, 3], ["AOM episodes", "PROBLEM", 8, 20], ["Virologic studies", "TEST", 172, 189]]], ["Respiratory specimens were collected for virus studies at the initial URI visit and at subsequent visits only if AOM was diagnosed.", [["Respiratory specimens", "ANATOMY", 0, 21], ["AOM", "DISEASE", 113, 116], ["Respiratory specimens", "CANCER", 0, 21], ["Respiratory specimens", "TEST", 0, 21], ["virus studies", "TEST", 41, 54], ["AOM", "PROBLEM", 113, 116]]], ["Nasal swab specimens were collected for viral culture; nasopharyngeal secretions were collected for respiratory syncytial virus (RSV) antigen detection by EIA (performed only during RSV season) and for virus detection by molecular techniques (performed at the Medical College of Wisconsin; Milwaukee) on culture-and RSV-EIA-negative specimens [20, 21] .Study design and subjects.Real-time RT-PCR was performed with the PRISM 7300 Sequence Detection System (Applied Biosystems).", [["Nasal swab specimens", "ANATOMY", 0, 20], ["nasopharyngeal secretions", "ANATOMY", 55, 80], ["specimens", "ANATOMY", 333, 342], ["respiratory syncytial virus", "DISEASE", 100, 127], ["Nasal swab specimens", "ORGANISM_SUBSTANCE", 0, 20], ["nasopharyngeal secretions", "ORGANISM_SUBSTANCE", 55, 80], ["respiratory syncytial virus", "ORGANISM", 100, 127], ["RSV", "ORGANISM", 129, 132], ["RSV", "ORGANISM", 182, 185], ["RSV", "ORGANISM", 316, 319], ["syncytial virus (RSV", "SPECIES", 112, 132], ["respiratory syncytial virus", "SPECIES", 100, 127], ["RSV", "SPECIES", 129, 132], ["RSV", "SPECIES", 182, 185], ["RSV", "SPECIES", 316, 319], ["Nasal swab specimens", "TEST", 0, 20], ["viral culture", "TEST", 40, 53], ["nasopharyngeal secretions", "PROBLEM", 55, 80], ["respiratory syncytial virus", "PROBLEM", 100, 127], ["EIA", "TEST", 155, 158], ["virus detection", "TEST", 202, 217], ["culture", "TEST", 304, 311], ["RSV", "TEST", 316, 319], ["EIA", "TEST", 320, 323], ["specimens", "TEST", 333, 342], ["nasopharyngeal", "ANATOMY", 55, 69]]], ["Positive and negative results were determined with the autoanalysis software and were rechecked manually.", [["the autoanalysis software", "TEST", 51, 76], ["negative", "OBSERVATION", 13, 21]]], ["For RNA viruses, the first stage conditions were 50\u040aC for 30 min followed by 95\u040aC for 15 min, 94\u040aC for 15 s, and 60\u040aC for 60 s for 45 cycles; for adenovirus, the conditions were 95\u040aC for 15 min, 94\u040aC for 15 s, 55\u040aC for 30 s, and 72\u040aC for 35 s for 45 cycles.Study design and subjects.For adenovirus detection (hexon gene), the limit of detection was TCID 50 /mL.", [["50\u040aC", "CHEMICAL", 49, 53], ["95\u040aC", "CHEMICAL", 77, 81], ["adenovirus", "ORGANISM", 146, 156], ["adenovirus", "ORGANISM", 287, 297], ["hexon gene", "DNA", 309, 319], ["adenovirus", "SPECIES", 146, 156], ["adenovirus", "SPECIES", 287, 297], ["RNA viruses", "PROBLEM", 4, 15], ["the first stage conditions", "PROBLEM", 17, 43], ["adenovirus", "PROBLEM", 146, 156], ["adenovirus detection", "TEST", 287, 307], ["viruses", "OBSERVATION", 8, 15]]], ["The limit of detection for coronavirus 2 1 \u03eb 10 OC43/229E (N gene) and NL63 (N gene) were 10 \u03ea2 TCID 50 / mL and 10 \u03ea1 TCID 50 /mL, respectively; for rhinovirus (5 NTR gene), it was 10 \u03ea2 TCID 50 /mL; and for enterovirus (5 NTR), it was 10 \u03ea2 TCID 50 /mL.", [["coronavirus 2", "ORGANISM", 27, 40], ["OC43", "GENE_OR_GENE_PRODUCT", 48, 52], ["229E", "GENE_OR_GENE_PRODUCT", 53, 57], ["NL63", "GENE_OR_GENE_PRODUCT", 71, 75], ["rhinovirus", "ORGANISM", 150, 160], ["5 NTR", "ORGANISM", 162, 167], ["enterovirus", "ORGANISM", 209, 220], ["coronavirus 2 1 \u03eb 10 OC43/229E (N gene", "DNA", 27, 65], ["NL63 (N gene", "DNA", 71, 83], ["coronavirus", "TEST", 27, 38], ["OC43", "TEST", 48, 52], ["NL63", "TEST", 71, 75], ["TCID", "TEST", 96, 100], ["rhinovirus", "PROBLEM", 150, 160], ["enterovirus", "PROBLEM", 209, 220]]], ["Analytical specificity was determined for each assay using American Type Culture Collection strains of adenovirus, enterovirus, OC43, 229E, rhinovirus, and influenza A virus; no cross-reactivity was detected.", [["influenza A virus", "DISEASE", 156, 173], ["adenovirus", "ORGANISM", 103, 113], ["enterovirus", "ORGANISM", 115, 126], ["OC43", "GENE_OR_GENE_PRODUCT", 128, 132], ["229E", "GENE_OR_GENE_PRODUCT", 134, 138], ["rhinovirus", "ORGANISM", 140, 150], ["influenza A virus", "ORGANISM", 156, 173], ["influenza A virus", "SPECIES", 156, 173], ["adenovirus", "SPECIES", 103, 113], ["influenza A virus", "SPECIES", 156, 173], ["Analytical specificity", "TEST", 0, 22], ["each assay", "TEST", 42, 52], ["American Type Culture", "TEST", 59, 80], ["Collection strains", "TEST", 81, 99], ["adenovirus", "PROBLEM", 103, 113], ["enterovirus", "PROBLEM", 115, 126], ["OC43", "TEST", 128, 132], ["rhinovirus", "PROBLEM", 140, 150], ["influenza A virus", "PROBLEM", 156, 173], ["cross-reactivity", "PROBLEM", 178, 194]]], ["Validation using clinical samples demonstrated sensitivity of 95% (19 of 20 samples) versus tissue culture and 100% specificity (95% CI, 88%-100%) for adenovirus, sensitivity of 93% (13 of 14) and 97% specificity (95% CI, 83%-100%) for rhinovirus, and sensitivity of 75% (6 of 8) and 100% specificity (95% CI, 88%-100%) for enterovirus.", [["samples", "ANATOMY", 26, 33], ["samples", "ANATOMY", 76, 83], ["tissue culture", "ANATOMY", 92, 106], ["enterovirus", "DISEASE", 324, 335], ["tissue", "TISSUE", 92, 98], ["adenovirus", "ORGANISM", 151, 161], ["rhinovirus", "ORGANISM", 236, 246], ["enterovirus", "ORGANISM", 324, 335], ["adenovirus", "SPECIES", 151, 161], ["clinical samples", "TEST", 17, 33], ["sensitivity", "TEST", 47, 58], ["tissue culture", "TEST", 92, 106], ["specificity", "TEST", 116, 127], ["CI", "TEST", 133, 135], ["adenovirus", "PROBLEM", 151, 161], ["sensitivity", "TEST", 163, 174], ["specificity", "TEST", 201, 212], ["CI", "TEST", 218, 220], ["rhinovirus", "PROBLEM", 236, 246], ["sensitivity", "TEST", 252, 263], ["specificity", "TEST", 289, 300], ["CI", "TEST", 306, 308], ["enterovirus", "PROBLEM", 324, 335]]], ["RT-PCR with electronic microarray detection (NanoChip 400 system; Namogen) was performed for detection of RSV, parainfluenza types 1-3, and influenza A and B virus, as described elsewhere [21] .Study design and subjects.Statistical methods.", [["parainfluenza", "DISEASE", 111, 124], ["RSV", "ORGANISM", 106, 109], ["parainfluenza types 1-3", "ORGANISM", 111, 134], ["influenza A", "ORGANISM", 140, 151], ["B virus", "ORGANISM", 156, 163], ["parainfluenza", "SPECIES", 111, 124], ["B virus", "SPECIES", 156, 163], ["RSV", "SPECIES", 106, 109], ["influenza A", "SPECIES", 140, 151], ["B virus", "SPECIES", 156, 163], ["RT-PCR", "TEST", 0, 6], ["electronic microarray detection", "TEST", 12, 43], ["RSV", "PROBLEM", 106, 109], ["parainfluenza types", "PROBLEM", 111, 130], ["influenza A and B virus", "PROBLEM", 140, 163], ["RSV", "ANATOMY", 106, 109]]], ["The relationship of AOM or OME with a virus was analyzed using the general estimating equations approach, which treats the child as the unit of analysis while accounting for the multiple episodes of correlated data from each child.", [["AOM", "DISEASE", 20, 23], ["OME", "DISEASE", 27, 30], ["AOM", "PROBLEM", 20, 23], ["OME", "PROBLEM", 27, 30], ["a virus", "PROBLEM", 36, 43], ["the general estimating equations approach", "TREATMENT", 63, 104], ["analysis", "TEST", 144, 152], ["AOM", "OBSERVATION", 20, 23]]], ["The repeated binary outcome of OM status was analyzed with a binomial distribution, logit link function, and AR(1) correlation structure.", [["AR", "PROTEIN", 109, 111]]], ["Analyses were conducted in the Genmod procedure in SAS software (SAS Institute) [22] .", [["the Genmod procedure", "TREATMENT", 27, 47]]], ["Rate ratios were calculated using Episheet 2001, Spreadsheets for the Analysis of Epidemiologic Data, by Rothman [23] .", [["Rate ratios", "TEST", 0, 11]]], ["The episode-level culture-and molecular-positive rates of virus detection results were analyzed using Pearson x 2 statistics.Subjects.During the period January 2003 through March 2006, a total of 294 children were enrolled in the study; 46% entered the study in the first year of life, 42% in the second year, and 12% in the third year.", [["children", "ORGANISM", 200, 208], ["children", "SPECIES", 200, 208], ["The episode", "TEST", 0, 11], ["level culture", "TEST", 12, 25], ["molecular", "TEST", 30, 39], ["virus detection", "TEST", 58, 73], ["the study", "TEST", 226, 235], ["the study", "TEST", 249, 258]]], ["Demographic characteristics and risk factor data are shown in table 1.", [["risk factor data", "TEST", 32, 48]]], ["Overall, the total duration of follow-up was 256 child-years; the median duration of follow-up per subject was 12 months (mean duration, 9.8 months).Subjects.Overall URI and OM episodes.", [["Overall URI", "PROBLEM", 158, 169], ["OM episodes", "PROBLEM", 174, 185], ["URI", "OBSERVATION", 166, 169], ["OM episodes", "OBSERVATION_MODIFIER", 174, 185]]], ["A total of 1295 URI epi- ).", [["URI epi", "TEST", 16, 23]]], ["P ! .005 b Rate ratio for subjects aged 6-11 months versus those aged 24-35 months, 2 (95% CI, 1.1-3.6;Subjects.).", [["P", "DNA", 0, 1], ["b Rate ratio", "TEST", 9, 21], ["CI", "TEST", 91, 93]]], ["P p .01 sodes were documented during 256 child-years (a rate of 5.06 episodes per child-year); the median age at the time of URI onset was 17.7 months.", [["URI onset", "PROBLEM", 125, 134]]], ["Another 26 AOM episodes without URI symptoms were documented.", [["AOM", "DISEASE", 11, 14], ["Another 26 AOM episodes", "PROBLEM", 0, 23], ["URI symptoms", "PROBLEM", 32, 44]]], ["Patients accounting for 867 episodes (67%) of URI and for 6 episodes of AOM without URI were seen by the study group.", [["URI", "DISEASE", 46, 49], ["AOM", "DISEASE", 72, 75], ["URI", "DISEASE", 84, 87], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["URI", "PROBLEM", 46, 49], ["AOM", "PROBLEM", 72, 75], ["URI", "PROBLEM", 84, 87]]], ["Overall, there were 1839 study visits, 647 home or day care visits, and 4972 tympanograms obtained.Subjects.Of all URI episodes, 414 (32%) were complicated by AOM.", [["AOM", "DISEASE", 159, 162], ["tympanograms", "TEST", 77, 89], ["all URI episodes", "PROBLEM", 111, 127], ["AOM", "PROBLEM", 159, 162], ["URI episodes", "OBSERVATION", 115, 127], ["AOM", "OBSERVATION", 159, 162]]], ["The rate of AOM-complicated URI among episodes observed by the study group was 37%; the rate among missed URI episodes was 22%.", [["AOM", "DISEASE", 12, 15], ["URI", "DISEASE", 28, 31], ["AOM", "PROBLEM", 12, 15], ["complicated URI", "PROBLEM", 16, 31], ["episodes", "PROBLEM", 38, 46], ["the study group", "TEST", 59, 74], ["the rate", "TEST", 84, 92], ["missed URI episodes", "PROBLEM", 99, 118], ["AOM", "OBSERVATION", 12, 15], ["complicated", "OBSERVATION_MODIFIER", 16, 27], ["URI", "OBSERVATION", 28, 31]]], ["With consideration of the 26 episodes of AOM that did not involve symptoms of URI, the total number of AOM episodes captured was 440 (1.72 episodes per child-year).", [["AOM", "DISEASE", 41, 44], ["URI", "DISEASE", 78, 81], ["AOM", "DISEASE", 103, 106], ["AOM", "PROBLEM", 41, 44], ["symptoms", "PROBLEM", 66, 74], ["URI", "PROBLEM", 78, 81], ["AOM episodes", "PROBLEM", 103, 115], ["URI", "OBSERVATION", 78, 81]]], ["The median age at the onset of AOM was 15.9 months.Subjects.Of 294 subjects, 201 subjects were observed for the entire 12 month-period; the remainder dropped out before 1 year had passed.", [["AOM", "DISEASE", 31, 34], ["subjects", "ORGANISM", 81, 89], ["AOM", "PROBLEM", 31, 34], ["AOM", "OBSERVATION", 31, 34]]], ["The frequency of URI for each subject ranged from 0 to 19 cases per year (figure 1).", [["URI", "PROBLEM", 17, 20], ["URI", "OBSERVATION", 17, 20]]], ["Six subjects had no URIs (as determined by parent reports and chart reviews), and 7 experienced 112 URI episodes in 1 year.", [["URIs", "PROBLEM", 20, 24], ["112 URI episodes", "PROBLEM", 96, 112]]], ["Frequencies of URI and AOM by age at enrollment and sex are shown in table 2.Subjects.Virologic findings.", [["AOM", "DISEASE", 23, 26], ["URI", "PROBLEM", 15, 18], ["AOM", "PROBLEM", 23, 26], ["Virologic findings", "TEST", 86, 104], ["URI", "OBSERVATION", 15, 18]]], ["Of 867 URI episodes seen by the study group, specimens were collected during the first visit for 864; Table 3 lists the 708 viruses detected in 547 (63%) of 864 URI episodes.", [["specimens", "ANATOMY", 45, 54], ["specimens", "CANCER", 45, 54], ["URI episodes", "PROBLEM", 7, 19], ["specimens", "TEST", 45, 54], ["URI episodes", "PROBLEM", 161, 173]]], ["One virus was detected in 422 episodes (77%), 2 viruses were detected in 92 episodes, 3 viruses were detected in 30 episodes, and 4 viruses were detected in 3 episodes.AOM-and OME-complicated URI associated with specific viruses.For the 864 URI episodes observed by the study group that had available virus data, the incidence of URI complicated by AOM was 37% (319 of 864 episodes); 39% of AOM episodes were bilateral, 24% were right-side AOM, and 36% were left-side AOM.", [["AOM", "DISEASE", 168, 171], ["OME", "DISEASE", 176, 179], ["URI", "DISEASE", 192, 195], ["URI", "DISEASE", 330, 333], ["AOM", "DISEASE", 349, 352], ["AOM", "DISEASE", 391, 394], ["AOM", "DISEASE", 440, 443], ["AOM", "DISEASE", 468, 471], ["AOM", "SIMPLE_CHEMICAL", 168, 171], ["One virus", "PROBLEM", 0, 9], ["2 viruses", "PROBLEM", 46, 55], ["3 viruses", "PROBLEM", 86, 95], ["4 viruses", "PROBLEM", 130, 139], ["AOM", "PROBLEM", 168, 171], ["OME", "PROBLEM", 176, 179], ["complicated URI", "PROBLEM", 180, 195], ["specific viruses", "PROBLEM", 212, 228], ["the 864 URI episodes", "PROBLEM", 233, 253], ["the study", "TEST", 266, 275], ["virus data", "TEST", 301, 311], ["URI", "PROBLEM", 330, 333], ["AOM", "PROBLEM", 349, 352], ["AOM episodes", "PROBLEM", 391, 403], ["virus", "OBSERVATION", 4, 9], ["URI", "OBSERVATION", 192, 195], ["viruses", "OBSERVATION", 221, 228], ["URI", "OBSERVATION", 330, 333], ["bilateral", "ANATOMY_MODIFIER", 409, 418], ["right", "ANATOMY_MODIFIER", 429, 434], ["AOM", "OBSERVATION", 440, 443], ["left", "ANATOMY_MODIFIER", 458, 462], ["AOM", "OBSERVATION", 468, 471]]], ["AOM was diagnosed on days 1-24 in the course of URI, with the peak occurring on days 3-5; the median time was day 4 (figure 2).AOM-and OME-complicated URI associated with specific viruses.In 28 of 864 URI episodes, middle ear effusion (type B tympanogram) was already present within the 30 days before URI onset; these chronic middle ear effusions were excluded from consideration for new-onset OME.", [["middle ear effusion", "ANATOMY", 215, 234], ["middle ear effusions", "ANATOMY", 327, 347], ["AOM", "DISEASE", 0, 3], ["AOM", "DISEASE", 127, 130], ["OME", "DISEASE", 135, 138], ["URI", "DISEASE", 151, 154], ["ear effusion", "DISEASE", 222, 234], ["chronic middle ear effusions", "DISEASE", 319, 347], ["OME", "DISEASE", 395, 398], ["AOM", "SIMPLE_CHEMICAL", 127, 130], ["ear", "ORGAN", 222, 225], ["ear", "ORGAN", 334, 337], ["AOM", "PROBLEM", 0, 3], ["URI", "PROBLEM", 48, 51], ["AOM", "PROBLEM", 127, 130], ["OME", "PROBLEM", 135, 138], ["complicated URI", "PROBLEM", 139, 154], ["specific viruses", "PROBLEM", 171, 187], ["URI episodes", "PROBLEM", 201, 213], ["middle ear effusion", "PROBLEM", 215, 234], ["type B tympanogram", "PROBLEM", 236, 254], ["URI onset", "PROBLEM", 302, 311], ["these chronic middle ear effusions", "PROBLEM", 313, 347], ["new-onset OME", "PROBLEM", 385, 398], ["URI", "OBSERVATION", 48, 51], ["URI", "OBSERVATION", 151, 154], ["viruses", "OBSERVATION", 180, 187], ["middle", "ANATOMY_MODIFIER", 215, 221], ["ear", "ANATOMY", 222, 225], ["effusion", "OBSERVATION", 226, 234], ["chronic", "OBSERVATION_MODIFIER", 319, 326], ["middle", "ANATOMY_MODIFIER", 327, 333], ["ear", "ANATOMY", 334, 337], ["effusions", "OBSERVATION", 338, 347], ["OME", "OBSERVATION", 395, 398]]], ["The incidence of OMEcomplicated URI was 24% (203 of 836 episodes); 23% of cases were right-side OME, 27% were left-side OME, and 51% were bilateral OME.", [["OME", "DISEASE", 96, 99], ["OME", "DISEASE", 120, 123], ["OME", "DISEASE", 148, 151], ["OMEcomplicated URI", "PROBLEM", 17, 35], ["cases", "TEST", 74, 79], ["OME", "TEST", 96, 99], ["URI", "OBSERVATION", 32, 35], ["right", "ANATOMY_MODIFIER", 85, 90], ["left", "ANATOMY_MODIFIER", 110, 114], ["bilateral", "ANATOMY_MODIFIER", 138, 147], ["OME", "OBSERVATION", 148, 151]]], ["The overall incidence of URI complicated by OM (i.e., AOM and OME) was 61%.", [["URI", "DISEASE", 25, 28], ["OM", "DISEASE", 44, 46], ["AOM", "DISEASE", 54, 57], ["OME", "DISEASE", 62, 65], ["URI", "PROBLEM", 25, 28], ["OM", "PROBLEM", 44, 46], ["AOM", "PROBLEM", 54, 57], ["URI", "OBSERVATION", 25, 28]]], ["The time of OME diagnosis in the course of URI is also shown in figure 2 ; median time was day 3.", [["OME", "DISEASE", 12, 15], ["URI", "PROBLEM", 43, 46]]], ["Figure 3 illustrates the rate of OM-complicated URI for the 7 respiratory viruses; table 4 shows the rate of OM-complicated URI, the median day of diagnosis, and the age of the subjects at the time of onset of URI, AOM, and OME, by virus type.", [["URI", "DISEASE", 210, 213], ["AOM", "DISEASE", 215, 218], ["OME", "DISEASE", 224, 227], ["complicated URI", "PROBLEM", 36, 51], ["the 7 respiratory viruses", "PROBLEM", 56, 81], ["complicated URI", "PROBLEM", 112, 127], ["URI", "PROBLEM", 210, 213], ["AOM", "PROBLEM", 215, 218], ["OME", "PROBLEM", 224, 227], ["URI", "OBSERVATION", 48, 51], ["URI", "OBSERVATION", 124, 127], ["URI", "OBSERVATION", 210, 213]]], ["For each virus (except herpes simplex virus), the median age at onset of AOM was lower than that at onset of URI, suggesting that children who developed AOM were younger children.", [["herpes simplex virus", "DISEASE", 23, 43], ["AOM", "DISEASE", 73, 76], ["AOM", "DISEASE", 153, 156], ["herpes simplex virus", "ORGANISM", 23, 43], ["AOM", "PATHOLOGICAL_FORMATION", 73, 76], ["children", "ORGANISM", 130, 138], ["children", "ORGANISM", 170, 178], ["herpes simplex virus", "SPECIES", 23, 43], ["children", "SPECIES", 130, 138], ["children", "SPECIES", 170, 178], ["herpes simplex virus", "SPECIES", 23, 43], ["each virus", "PROBLEM", 4, 14], ["herpes simplex virus", "PROBLEM", 23, 43], ["AOM", "PROBLEM", 73, 76], ["URI", "PROBLEM", 109, 112], ["AOM", "PROBLEM", 153, 156], ["AOM", "OBSERVATION", 73, 76], ["URI", "OBSERVATION", 109, 112]]], ["Coronavirus, RSV, and adenovirus were among the viruses associated with a higher rate of AOM.", [["AOM", "DISEASE", 89, 92], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 0, 11], ["RSV", "ORGANISM", 13, 16], ["adenovirus", "ORGANISM", 22, 32], ["AOM", "PATHOLOGICAL_FORMATION", 89, 92], ["RSV", "SPECIES", 13, 16], ["adenovirus", "SPECIES", 22, 32], ["Coronavirus", "PROBLEM", 0, 11], ["RSV", "PROBLEM", 13, 16], ["adenovirus", "PROBLEM", 22, 32], ["the viruses", "PROBLEM", 44, 55], ["RSV", "OBSERVATION", 13, 16], ["AOM", "OBSERVATION", 89, 92]]], ["The episode data shown in table 4 were analyzed using the general estimating equations approach, which treated the child as the unit of analysis, thus accounting for the multiple correlated episodes in each child.", [["The episode data", "TEST", 0, 16], ["the general estimating equations approach", "TREATMENT", 54, 95], ["analysis", "TEST", 136, 144]]], ["The overall model indicated that age ( ) was the stron-P ! .001 gest predictor of AOM development after URI, followed by virus type ( ), controlling for sex ( ), race P p .05 P p .19 ( ), and ethnicity ( ).", [["AOM", "DISEASE", 82, 85], ["AOM", "PATHOLOGICAL_FORMATION", 82, 85], ["AOM", "PROBLEM", 82, 85], ["URI", "PROBLEM", 104, 107]]], ["For age, the OR was 0.96 P p .92 P p .75 (95% CI, 0.94-0.98), meaning that, for each additional month of age in the URI episode, the chances of developing AOM decreased by 4%.", [["AOM", "DISEASE", 155, 158], ["p", "TEST", 27, 28], ["P", "TEST", 33, 34], ["p", "TEST", 35, 36], ["CI", "TEST", 46, 48], ["the URI episode", "PROBLEM", 112, 127], ["AOM", "PROBLEM", 155, 158], ["URI", "OBSERVATION", 116, 119], ["AOM", "OBSERVATION", 155, 158], ["decreased", "OBSERVATION_MODIFIER", 159, 168]]], ["Table 5 compares the differences among the rates of AOM associated with specific viruses.", [["AOM", "DISEASE", 52, 55], ["AOM", "PROBLEM", 52, 55]]], ["For OME outcome, general estimating equations data revealed statistical significance only for age (OR, 0.98; 95% CI, 0.96-0.99;AOM-and OME-complicated URI associated with specific viruses.).", [["OME", "DISEASE", 4, 7], ["OME", "DISEASE", 135, 138], ["OME outcome", "PROBLEM", 4, 15], ["general estimating equations data", "TEST", 17, 50], ["CI", "TEST", 113, 115], ["AOM", "TEST", 127, 130], ["OME", "PROBLEM", 135, 138], ["complicated URI", "PROBLEM", 139, 154], ["URI", "OBSERVATION", 151, 154]]], ["P p .03 AOM rate determined by virus diagnostic methods.", [["AOM rate", "TEST", 8, 16]]], ["Because molecular assays are more sensitive than conventional viral diagnostic assays, which likely detect virus only when it is present in larger quantities (i.e., a high viral load), we compared the rate of AOM associated with specific viruses detected by different methods (table 6) .", [["AOM", "DISEASE", 209, 212], ["AOM", "PATHOLOGICAL_FORMATION", 209, 212], ["molecular assays", "TEST", 8, 24], ["conventional viral diagnostic assays", "TEST", 49, 85], ["virus", "PROBLEM", 107, 112], ["a high viral load", "PROBLEM", 165, 182], ["AOM", "PROBLEM", 209, 212], ["specific viruses", "PROBLEM", 229, 245], ["larger", "OBSERVATION_MODIFIER", 140, 146], ["viruses", "OBSERVATION", 238, 245]]], ["For each virus, the AOM rate was higher in cases diagnosed with viral culture, compared with those diagnosed with molecular assays.", [["AOM", "DISEASE", 20, 23], ["AOM", "PATHOLOGICAL_FORMATION", 20, 23], ["each virus", "PROBLEM", 4, 14], ["the AOM rate", "TEST", 16, 28], ["viral culture", "TEST", 64, 77], ["molecular assays", "TEST", 114, 130]]], ["Overall, cases diagnosed with culture were associated with a higher rate of AOM, compared with cases diagnosed with molecular methods (P p ). .001DISCUSSIONWe have demonstrated a high susceptibility of young children to URI and a strikingly high rate of OM complications.", [["AOM", "DISEASE", 76, 79], ["URI", "DISEASE", 220, 223], ["AOM", "PATHOLOGICAL_FORMATION", 76, 79], ["children", "ORGANISM", 208, 216], ["children", "SPECIES", 208, 216], ["culture", "TEST", 30, 37], ["a higher rate of AOM", "PROBLEM", 59, 79], ["URI", "PROBLEM", 220, 223], ["OM complications", "PROBLEM", 254, 270], ["AOM", "OBSERVATION", 76, 79]]], ["Our statistical model identified the age of the child as the most important factor of AOM-complicated URI.", [["AOM", "DISEASE", 86, 89], ["AOM", "PROBLEM", 86, 89], ["complicated URI", "PROBLEM", 90, 105], ["URI", "OBSERVATION", 102, 105]]], ["The 2 viruses most commonly detected during URI were rhinovirus and adenovirus.", [["rhinovirus", "ORGANISM", 53, 63], ["adenovirus", "ORGANISM", 68, 78], ["The 2 viruses", "PROBLEM", 0, 13], ["URI", "PROBLEM", 44, 47], ["rhinovirus", "PROBLEM", 53, 63], ["adenovirus", "PROBLEM", 68, 78], ["rhinovirus", "OBSERVATION", 53, 63]]], ["Although adenovirus was associated with high rate of AOM-complicated URI, rhinovirus was associated with lower rate than that of coronavirus, RSV, and adenovirus.", [["AOM", "DISEASE", 53, 56], ["URI", "DISEASE", 69, 72], ["adenovirus", "ORGANISM", 9, 19], ["rhinovirus", "ORGANISM", 74, 84], ["coronavirus", "ORGANISM", 129, 140], ["RSV", "ORGANISM", 142, 145], ["adenovirus", "ORGANISM", 151, 161], ["adenovirus", "SPECIES", 9, 19], ["RSV", "SPECIES", 142, 145], ["adenovirus", "SPECIES", 151, 161], ["adenovirus", "PROBLEM", 9, 19], ["high rate of AOM", "PROBLEM", 40, 56], ["complicated URI", "PROBLEM", 57, 72], ["rhinovirus", "PROBLEM", 74, 84], ["lower rate", "PROBLEM", 105, 115], ["coronavirus", "PROBLEM", 129, 140], ["RSV", "PROBLEM", 142, 145], ["adenovirus", "PROBLEM", 151, 161], ["AOM", "OBSERVATION", 53, 56], ["URI", "OBSERVATION", 69, 72], ["rhinovirus", "OBSERVATION", 74, 84], ["coronavirus", "OBSERVATION", 129, 140]]], ["Our data emphasize the close relationship between viral URI and OM and suggest that one strategy to reduce OM incidence is to prevent viral URI in young children.DISCUSSIONThe relative role of specific virus types in AOM reported in previous studies has been inconclusive, because different virus detection methods were used.", [["viral URI and OM", "DISEASE", 50, 66], ["OM", "DISEASE", 107, 109], ["AOM", "DISEASE", 217, 220], ["children", "ORGANISM", 153, 161], ["AOM", "PATHOLOGICAL_FORMATION", 217, 220], ["children", "SPECIES", 153, 161], ["Our data", "TEST", 0, 8], ["viral URI", "PROBLEM", 50, 59], ["viral URI", "PROBLEM", 134, 143], ["specific virus types", "PROBLEM", 193, 213], ["AOM", "PROBLEM", 217, 220], ["previous studies", "TEST", 233, 249], ["different virus detection methods", "PROBLEM", 281, 314], ["virus types", "OBSERVATION", 202, 213]]], ["Henderson et al. [24] used viral culture and reported that RSV, adenovirus, and influenza virus were closely associated with AOM; the incidence of AOM associated with rhinovirus URI was the lowest.", [["RSV, adenovirus, and influenza virus", "DISEASE", 59, 95], ["AOM", "DISEASE", 125, 128], ["AOM", "DISEASE", 147, 150], ["rhinovirus URI", "DISEASE", 167, 181], ["RSV", "ORGANISM", 59, 62], ["adenovirus", "ORGANISM", 64, 74], ["influenza virus", "ORGANISM", 80, 95], ["AOM", "PATHOLOGICAL_FORMATION", 125, 128], ["AOM", "PATHOLOGICAL_FORMATION", 147, 150], ["rhinovirus", "ORGANISM", 167, 177], ["influenza virus", "SPECIES", 80, 95], ["RSV", "SPECIES", 59, 62], ["adenovirus", "SPECIES", 64, 74], ["influenza virus", "SPECIES", 80, 95], ["viral culture", "TEST", 27, 40], ["RSV", "PROBLEM", 59, 62], ["adenovirus", "PROBLEM", 64, 74], ["influenza virus", "PROBLEM", 80, 95], ["AOM", "PROBLEM", 125, 128], ["AOM", "PROBLEM", 147, 150], ["rhinovirus URI", "PROBLEM", 167, 181], ["RSV", "OBSERVATION", 59, 62], ["rhinovirus", "OBSERVATION", 167, 177]]], ["Ruuskanen et al. [25] used conventional viral assays and reported similar results.", [["conventional viral assays", "TEST", 27, 52]]], ["Vesa et al. [26] found that URI associated with RSV and rhinovirus had a higher rate of AOM than did URI associated with adenovirus, but these authors used PCR alone for detection of rhinovirus and antigen detection for detection of other viruses.", [["AOM", "DISEASE", 88, 91], ["RSV", "ORGANISM", 48, 51], ["rhinovirus", "ORGANISM", 56, 66], ["AOM", "PATHOLOGICAL_FORMATION", 88, 91], ["adenovirus", "ORGANISM", 121, 131], ["rhinovirus", "ORGANISM", 183, 193], ["RSV", "SPECIES", 48, 51], ["adenovirus", "SPECIES", 121, 131], ["rhinovirus", "SPECIES", 183, 193], ["URI", "PROBLEM", 28, 31], ["RSV", "PROBLEM", 48, 51], ["rhinovirus", "PROBLEM", 56, 66], ["AOM", "PROBLEM", 88, 91], ["URI", "PROBLEM", 101, 104], ["adenovirus", "PROBLEM", 121, 131], ["PCR", "TEST", 156, 159], ["rhinovirus", "PROBLEM", 183, 193], ["antigen detection", "TEST", 198, 215], ["other viruses", "PROBLEM", 233, 246], ["URI", "OBSERVATION", 28, 31], ["RSV", "OBSERVATION", 48, 51], ["rhinovirus", "OBSERVATION", 56, 66], ["rhinovirus", "OBSERVATION", 183, 193], ["viruses", "OBSERVATION", 239, 246]]], ["Pitkaranta et al. [27] used RT-PCR and reported that rhinovirus (35%) was the most common virus found in cases of nasopharyngeal secretions and/or middle ear effusion in children with AOM (the rates for RSV and coronavirus were 28% and 17%, respectively), although the children in that study were relatively old (median age, 30 months).", [["nasopharyngeal secretions", "ANATOMY", 114, 139], ["middle ear effusion", "ANATOMY", 147, 166], ["nasopharyngeal secretions", "DISEASE", 114, 139], ["ear effusion", "DISEASE", 154, 166], ["AOM", "DISEASE", 184, 187], ["RSV and coronavirus", "DISEASE", 203, 222], ["rhinovirus", "ORGANISM", 53, 63], ["nasopharyngeal secretions", "ORGAN", 114, 139], ["ear", "ORGAN", 154, 157], ["children", "ORGANISM", 170, 178], ["RSV", "ORGANISM", 203, 206], ["coronavirus", "ORGANISM", 211, 222], ["children", "ORGANISM", 269, 277], ["children", "SPECIES", 170, 178], ["children", "SPECIES", 269, 277], ["RSV", "SPECIES", 203, 206], ["RT-PCR", "TEST", 28, 34], ["rhinovirus", "PROBLEM", 53, 63], ["common virus", "PROBLEM", 83, 95], ["nasopharyngeal secretions", "PROBLEM", 114, 139], ["middle ear effusion", "PROBLEM", 147, 166], ["AOM", "PROBLEM", 184, 187], ["the rates", "TEST", 189, 198], ["RSV", "PROBLEM", 203, 206], ["coronavirus", "PROBLEM", 211, 222], ["rhinovirus", "OBSERVATION", 53, 63], ["nasopharyngeal", "ANATOMY", 114, 128], ["secretions", "OBSERVATION", 129, 139], ["middle", "ANATOMY_MODIFIER", 147, 153], ["ear", "ANATOMY", 154, 157], ["effusion", "OBSERVATION", 158, 166]]], ["We used more-com-prehensive diagnostic methods than other researchers and more often detected adenovirus during URI; the virus was also associated with the highest rate of AOM-complicated URI.", [["AOM", "DISEASE", 172, 175], ["URI", "DISEASE", 188, 191], ["adenovirus", "ORGANISM", 94, 104], ["adenovirus", "SPECIES", 94, 104], ["adenovirus", "PROBLEM", 94, 104], ["URI", "PROBLEM", 112, 115], ["the virus", "PROBLEM", 117, 126], ["AOM", "PROBLEM", 172, 175], ["complicated URI", "PROBLEM", 176, 191], ["AOM", "OBSERVATION", 172, 175], ["URI", "OBSERVATION", 188, 191]]], ["We were surprised that RSV-associated URI was not diagnosed more frequently; this could be because there was an unusually low prevalence of RSV in our community during the study period or because young children with RSV infection tended to have lower respiratory tract disease rather than URI.", [["respiratory tract", "ANATOMY", 251, 268], ["RSV", "DISEASE", 140, 143], ["RSV infection", "DISEASE", 216, 229], ["respiratory tract disease", "DISEASE", 251, 276], ["RSV", "ORGANISM", 23, 26], ["RSV", "ORGANISM", 140, 143], ["children", "ORGANISM", 202, 210], ["RSV", "ORGANISM", 216, 219], ["tract", "ORGANISM_SUBDIVISION", 263, 268], ["children", "SPECIES", 202, 210], ["RSV", "SPECIES", 23, 26], ["RSV", "SPECIES", 140, 143], ["RSV", "SPECIES", 216, 219], ["RSV", "PROBLEM", 23, 26], ["URI", "PROBLEM", 38, 41], ["RSV", "PROBLEM", 140, 143], ["RSV infection", "PROBLEM", 216, 229], ["lower respiratory tract disease", "PROBLEM", 245, 276], ["URI", "PROBLEM", 289, 292], ["URI", "OBSERVATION", 38, 41], ["unusually", "OBSERVATION_MODIFIER", 112, 121], ["low prevalence", "OBSERVATION_MODIFIER", 122, 136], ["RSV", "OBSERVATION", 140, 143], ["infection", "OBSERVATION", 220, 229], ["lower", "ANATOMY_MODIFIER", 245, 250], ["respiratory tract", "ANATOMY", 251, 268]]], ["Nevertheless, the rate of RSV-associated URI complicated by AOM was among one of the highest; this is consistent with findings from previous reports [24, 28, 29] .", [["RSV", "DISEASE", 26, 29], ["URI", "DISEASE", 41, 44], ["AOM", "DISEASE", 60, 63], ["RSV", "ORGANISM", 26, 29], ["RSV", "SPECIES", 26, 29], ["RSV", "PROBLEM", 26, 29], ["URI", "PROBLEM", 41, 44], ["AOM", "PROBLEM", 60, 63], ["RSV", "OBSERVATION", 26, 29], ["URI", "OBSERVATION", 41, 44], ["AOM", "OBSERVATION", 60, 63], ["consistent with", "UNCERTAINTY", 102, 117]]], ["Our data together suggest that prevention of adenovirus-and RSV-associated URI-if and when possible-has the potential to make a significant impact on the incidence of AOM.DISCUSSIONBecause URI is self-limiting, viral diagnosis is not clinically indicated.", [["AOM", "DISEASE", 167, 170], ["adenovirus", "ORGANISM", 45, 55], ["RSV", "ORGANISM", 60, 63], ["AOM", "PATHOLOGICAL_FORMATION", 167, 170], ["adenovirus", "SPECIES", 45, 55], ["RSV", "SPECIES", 60, 63], ["Our data", "TEST", 0, 8], ["adenovirus", "PROBLEM", 45, 55], ["RSV", "PROBLEM", 60, 63], ["URI", "PROBLEM", 75, 78], ["AOM", "PROBLEM", 167, 170], ["URI", "PROBLEM", 189, 192], ["viral diagnosis", "TEST", 211, 226], ["AOM", "OBSERVATION", 167, 170], ["self-limiting", "OBSERVATION_MODIFIER", 196, 209]]], ["Research studies of viral etiology of URI that use a variety of viral diagnostic methods, including molecular techniques, have provided a virus yield of 42%-73% [26, 30, 31] .", [["URI", "DISEASE", 38, 41], ["Research studies", "TEST", 0, 16], ["URI", "PROBLEM", 38, 41], ["viral diagnostic methods", "TREATMENT", 64, 88], ["molecular techniques", "TEST", 100, 120], ["a virus yield", "TEST", 136, 149], ["viral etiology", "OBSERVATION_MODIFIER", 20, 34], ["URI", "OBSERVATION", 38, 41]]], ["Virus yield depends on many factors, including sensitivity of the technique, specificity of the primers, and the number of viruses targeted.", [["Virus", "ORGANISM", 0, 5], ["Virus yield", "PROBLEM", 0, 11], ["the technique", "TEST", 62, 75], ["the primers", "TEST", 92, 103], ["viruses", "OBSERVATION", 123, 130]]], ["New viruses have recently been discovered as causes of URI and/or OM: human metapneumovirus, bocavirus, and coronavirus NL-63 [32] [33] [34] .", [["human metapneumovirus, bocavirus", "DISEASE", 70, 102], ["NL-63", "CHEMICAL", 120, 125], ["human", "ORGANISM", 70, 75], ["metapneumovirus", "ORGANISM", 76, 91], ["bocavirus", "CANCER", 93, 102], ["human", "SPECIES", 70, 75], ["metapneumovirus", "SPECIES", 76, 91], ["coronavirus", "SPECIES", 108, 119], ["human metapneumovirus", "SPECIES", 70, 91], ["coronavirus NL-63", "SPECIES", 108, 125], ["New viruses", "PROBLEM", 0, 11], ["URI", "PROBLEM", 55, 58], ["human metapneumovirus", "PROBLEM", 70, 91], ["bocavirus", "PROBLEM", 93, 102], ["coronavirus NL", "TEST", 108, 122], ["viruses", "OBSERVATION", 4, 11], ["URI", "OBSERVATION", 55, 58], ["human metapneumovirus", "ANATOMY", 70, 91]]], ["The limited amount of samples and the high cost prohibited us from testing for all Recently, investigators found viruses in respiratory specimens obtained from children with no symptoms [31] ; rhinovirus has also been found to have a prolonged presence in the respiratory tract [35, 36] .", [["samples", "ANATOMY", 22, 29], ["respiratory specimens", "ANATOMY", 124, 145], ["respiratory tract", "ANATOMY", 260, 277], ["respiratory specimens", "CANCER", 124, 145], ["children", "ORGANISM", 160, 168], ["rhinovirus", "ORGANISM", 193, 203], ["respiratory tract", "ORGANISM_SUBDIVISION", 260, 277], ["children", "SPECIES", 160, 168], ["testing", "TEST", 67, 74], ["viruses in respiratory specimens", "PROBLEM", 113, 145], ["symptoms", "PROBLEM", 177, 185], ["rhinovirus", "PROBLEM", 193, 203], ["a prolonged presence in the respiratory tract", "PROBLEM", 232, 277], ["amount", "OBSERVATION_MODIFIER", 12, 18], ["respiratory tract", "ANATOMY", 260, 277]]], ["Because viruses are intracellular pathogens, these cases constitute asymptomatic infections.", [["intracellular", "ANATOMY", 20, 33], ["infections", "DISEASE", 81, 91], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 33], ["viruses", "PROBLEM", 8, 15], ["intracellular pathogens", "PROBLEM", 20, 43], ["asymptomatic infections", "PROBLEM", 68, 91], ["intracellular pathogens", "OBSERVATION", 20, 43], ["asymptomatic", "OBSERVATION_MODIFIER", 68, 80], ["infections", "OBSERVATION", 81, 91]]], ["We studied only symptomatic URI and assumed a cause-and-effect relationship.", [["symptomatic URI", "PROBLEM", 16, 31], ["symptomatic", "OBSERVATION_MODIFIER", 16, 27], ["URI", "OBSERVATION", 28, 31]]], ["We only compared the rate of OM in URI episodes associated with single virus; of these, 11% revealed the same virus as in previous episodes (table 4 ).", [["URI episodes", "PROBLEM", 35, 47], ["single virus", "PROBLEM", 64, 76], ["the same virus", "PROBLEM", 101, 115], ["URI", "OBSERVATION", 35, 38], ["virus", "OBSERVATION", 110, 115]]], ["In addition, 125 (23%) of our 547 virus-positive samples contained \u04432 viruses.", [["samples", "ANATOMY", 49, 56], ["samples", "CANCER", 49, 56], ["\u04432 viruses", "ORGANISM", 67, 77], ["our 547 virus", "TEST", 26, 39]]], ["Other researchers have reported rates of dual-or multiple-virus infection of 5%-20% [26, 30, 31, 37] ; our relatively high rate could be associated with the more-comprehensive assays that we used or with frequent collection of samples from children with recurrent URI.", [["samples", "ANATOMY", 227, 234], ["infection", "DISEASE", 64, 73], ["URI", "DISEASE", 264, 267], ["children", "ORGANISM", 240, 248], ["children", "SPECIES", 240, 248], ["dual-or multiple-virus infection", "PROBLEM", 41, 73], ["recurrent URI", "PROBLEM", 254, 267], ["URI", "OBSERVATION", 264, 267]]], ["In any event, it was possible that the molecular assays may have also detected some of the virus associated with previous URI episodes.", [["the molecular assays", "TEST", 35, 55], ["the virus", "PROBLEM", 87, 96], ["previous URI episodes", "PROBLEM", 113, 134], ["virus", "OBSERVATION", 91, 96]]], ["The role of prolonged presence of viruses in the respiratory tract and that of dual-or multiple-virus infections in OM requires further investigations.DISCUSSIONPositive viral culture results are associated with detection of live virus and are a strong indication of the cause-and-effect relationship (i.e., a viral cause of current symptoms).", [["respiratory tract", "ANATOMY", 49, 66], ["infections", "DISEASE", 102, 112], ["respiratory tract", "ORGANISM_SUBDIVISION", 49, 66], ["viruses in the respiratory tract", "PROBLEM", 34, 66], ["dual-or multiple-virus infections", "PROBLEM", 79, 112], ["further investigations", "TEST", 128, 150], ["DISCUSSIONPositive viral culture", "TEST", 151, 183], ["live virus", "PROBLEM", 225, 235], ["current symptoms", "PROBLEM", 325, 341], ["viruses", "OBSERVATION", 34, 41], ["respiratory tract", "ANATOMY", 49, 66]]], ["The findings of high rates of AOM associated with isolation of adenovirus and RSV help confirm the significance of these viruses in AOM-complicated URI.", [["AOM", "DISEASE", 30, 33], ["AOM", "DISEASE", 132, 135], ["URI", "DISEASE", 148, 151], ["adenovirus", "ORGANISM", 63, 73], ["RSV", "ORGANISM", 78, 81], ["adenovirus", "SPECIES", 63, 73], ["RSV", "SPECIES", 78, 81], ["AOM", "PROBLEM", 30, 33], ["adenovirus", "PROBLEM", 63, 73], ["RSV", "PROBLEM", 78, 81], ["these viruses", "PROBLEM", 115, 128], ["AOM", "PROBLEM", 132, 135], ["complicated URI", "PROBLEM", 136, 151], ["high", "OBSERVATION_MODIFIER", 16, 20], ["viruses", "OBSERVATION", 121, 128], ["URI", "OBSERVATION", 148, 151]]], ["We have also found that, for every virus that both culture and molecular assays detected, the rate of AOM was higher for cases detected by culture.", [["AOM", "DISEASE", 102, 105], ["AOM", "PATHOLOGICAL_FORMATION", 102, 105], ["every virus", "PROBLEM", 29, 40], ["both culture", "TEST", 46, 58], ["molecular assays", "TEST", 63, 79], ["AOM", "PROBLEM", 102, 105], ["culture", "TEST", 139, 146]]], ["Tissue culture is less sensitive than molecular assays and probably detects virus only in larger quantities (i.e., a high viral load).", [["Tissue", "ANATOMY", 0, 6], ["Tissue culture", "TEST", 0, 14], ["molecular assays", "TEST", 38, 54], ["virus", "PROBLEM", 76, 81], ["a high viral load)", "PROBLEM", 115, 133], ["less sensitive", "OBSERVATION_MODIFIER", 18, 32], ["virus", "OBSERVATION", 76, 81], ["viral load", "OBSERVATION", 122, 132]]], ["Therefore, our finding also suggests the role of high viral load in increasing URI severity.", [["high viral load", "PROBLEM", 49, 64], ["increasing URI severity", "PROBLEM", 68, 91], ["high viral load", "OBSERVATION", 49, 64], ["increasing", "OBSERVATION_MODIFIER", 68, 78], ["URI severity", "OBSERVATION", 79, 91]]], ["Correlations between virus concentrations and elevated levels of cytokines/inflammatory mediators (e.g., IL-6, TNF-a, IFN-g, IL-1, IL-8, and macrophage inflammatory protein-1a), and disease severity have been shown previously in respiratory virus infections [38] [39] [40] [41] [42] [43] [44] .", [["respiratory virus infections", "DISEASE", 229, 257], ["IL-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["TNF-a", "GENE_OR_GENE_PRODUCT", 111, 116], ["IFN-g", "GENE_OR_GENE_PRODUCT", 118, 123], ["IL-1", "GENE_OR_GENE_PRODUCT", 125, 129], ["IL-8", "GENE_OR_GENE_PRODUCT", 131, 135], ["macrophage inflammatory protein-1a", "GENE_OR_GENE_PRODUCT", 141, 175], ["respiratory virus", "ORGANISM", 229, 246], ["[38] [39] [40] [41] [42] [43] [44]", "SIMPLE_CHEMICAL", 258, 292], ["cytokines", "PROTEIN", 65, 74], ["inflammatory mediators", "PROTEIN", 75, 97], ["TNF", "PROTEIN", 111, 114], ["IFN", "PROTEIN", 118, 121], ["IL-8", "PROTEIN", 131, 135], ["macrophage inflammatory protein-1a", "PROTEIN", 141, 175], ["respiratory virus", "SPECIES", 229, 246], ["Correlations between virus concentrations", "TEST", 0, 41], ["elevated levels of cytokines/inflammatory mediators", "PROBLEM", 46, 97], ["IL", "TEST", 105, 107], ["TNF", "TEST", 111, 114], ["IFN", "TEST", 118, 121], ["IL", "TEST", 125, 127], ["IL", "TEST", 131, 133], ["macrophage inflammatory protein", "TEST", 141, 172], ["disease severity", "PROBLEM", 182, 198], ["respiratory virus infections", "PROBLEM", 229, 257], ["macrophage", "ANATOMY", 141, 151]]], ["It is likely that, in our cases, higher viral loads generated higher degrees of inflammation, which may have worsened the eustachian tube function, leading to OM complication.DISCUSSIONIn conclusion, we found a high prevalence of symptomatic viral URI among young children, and 160% of cases were complicated by AOM and/or OME.", [["eustachian tube", "ANATOMY", 122, 137], ["inflammation", "DISEASE", 80, 92], ["OM", "DISEASE", 159, 161], ["viral URI", "DISEASE", 242, 251], ["AOM", "DISEASE", 312, 315], ["OME", "DISEASE", 323, 326], ["eustachian tube", "TISSUE", 122, 137], ["children", "ORGANISM", 264, 272], ["children", "SPECIES", 264, 272], ["higher viral loads", "PROBLEM", 33, 51], ["inflammation", "PROBLEM", 80, 92], ["the eustachian tube function", "TREATMENT", 118, 146], ["OM complication", "PROBLEM", 159, 174], ["symptomatic viral URI", "PROBLEM", 230, 251], ["AOM", "PROBLEM", 312, 315], ["OME", "PROBLEM", 323, 326], ["is likely", "UNCERTAINTY", 3, 12], ["viral loads", "OBSERVATION", 40, 51], ["higher degrees", "OBSERVATION_MODIFIER", 62, 76], ["inflammation", "OBSERVATION", 80, 92], ["eustachian tube function", "OBSERVATION", 122, 146]]], ["The risk of AOM development was associated with young age, specific URI-associated viruses, and conventional methods of viral detection.", [["AOM", "DISEASE", 12, 15], ["AOM", "PATHOLOGICAL_FORMATION", 12, 15], ["AOM development", "PROBLEM", 12, 27], ["specific URI-associated viruses", "PROBLEM", 59, 90], ["viral detection", "TEST", 120, 135], ["AOM", "OBSERVATION", 12, 15], ["viruses", "OBSERVATION", 83, 90]]], ["The role of persistence of viral nucleic acids in respiratory secretions obtained from children with symptomatic URI requires further investigations.", [["respiratory secretions", "ANATOMY", 50, 72], ["nucleic acids", "CHEMICAL", 33, 46], ["URI", "DISEASE", 113, 116], ["children", "ORGANISM", 87, 95], ["children", "SPECIES", 87, 95], ["viral nucleic acids", "PROBLEM", 27, 46], ["respiratory secretions", "PROBLEM", 50, 72], ["symptomatic URI", "PROBLEM", 101, 116], ["further investigations", "TEST", 126, 148], ["viral nucleic acids", "OBSERVATION", 27, 46]]]], "PMC7287467": [["IntroductionCOVID-19 is a respiratory illness that spreads from person to person.", [["respiratory illness", "DISEASE", 26, 45], ["person", "SPECIES", 64, 70], ["person", "SPECIES", 74, 80], ["IntroductionCOVID", "TEST", 0, 17], ["a respiratory illness", "PROBLEM", 24, 45], ["respiratory", "ANATOMY", 26, 37], ["illness", "OBSERVATION", 38, 45]]], ["Typically, patients with severe cases of COVID-19 present with non-specific symptoms, which may include fever, cough, and dyspnea [2].", [["fever", "DISEASE", 104, 109], ["cough", "DISEASE", 111, 116], ["dyspnea", "DISEASE", 122, 129], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["COVID", "TEST", 41, 46], ["non-specific symptoms", "PROBLEM", 63, 84], ["fever", "PROBLEM", 104, 109], ["cough", "PROBLEM", 111, 116], ["dyspnea", "PROBLEM", 122, 129]]], ["Indeed, tracing asymptomatic and pre-symptomatic cases is vital in understanding the transmission of this virus, as well as curtailing further spread [4].Case presentationOn 17 April 2020, a 59-year-old incarcerated woman with invasive ductal carcinoma presented to the medical oncology service for both imaging and physical examination in regard to her breast cancer, as her last mammogram in December 2019 suggested progression of the cancer.", [["invasive ductal carcinoma", "ANATOMY", 227, 252], ["breast cancer", "ANATOMY", 354, 367], ["cancer", "ANATOMY", 437, 443], ["invasive ductal carcinoma", "DISEASE", 227, 252], ["breast cancer", "DISEASE", 354, 367], ["cancer", "DISEASE", 437, 443], ["woman", "ORGANISM", 216, 221], ["invasive ductal carcinoma", "CANCER", 227, 252], ["breast cancer", "CANCER", 354, 367], ["cancer", "CANCER", 437, 443], ["woman", "SPECIES", 216, 221], ["pre-symptomatic cases", "PROBLEM", 33, 54], ["this virus", "PROBLEM", 101, 111], ["invasive ductal carcinoma", "PROBLEM", 227, 252], ["both imaging", "TEST", 299, 311], ["physical examination", "TEST", 316, 336], ["her breast cancer", "PROBLEM", 350, 367], ["her last mammogram", "TEST", 372, 390], ["the cancer", "PROBLEM", 433, 443], ["incarcerated", "OBSERVATION_MODIFIER", 203, 215], ["invasive", "OBSERVATION_MODIFIER", 227, 235], ["ductal", "ANATOMY", 236, 242], ["carcinoma", "OBSERVATION", 243, 252], ["breast", "ANATOMY", 354, 360], ["cancer", "OBSERVATION", 361, 367], ["progression", "OBSERVATION_MODIFIER", 418, 429], ["cancer", "OBSERVATION", 437, 443]]], ["She stated she was doing better overall, and denied chest pain, shortness of breath, and fevers.", [["chest", "ANATOMY", 52, 57], ["chest pain", "DISEASE", 52, 62], ["shortness of breath", "DISEASE", 64, 83], ["fevers", "DISEASE", 89, 95], ["chest", "ORGANISM_SUBDIVISION", 52, 57], ["chest pain", "PROBLEM", 52, 62], ["shortness of breath", "PROBLEM", 64, 83], ["fevers", "PROBLEM", 89, 95], ["chest", "ANATOMY", 52, 57], ["fevers", "OBSERVATION", 89, 95]]], ["She complained of intermittent coughs.", [["coughs", "DISEASE", 31, 37], ["intermittent coughs", "PROBLEM", 18, 37], ["intermittent", "OBSERVATION_MODIFIER", 18, 30], ["coughs", "OBSERVATION", 31, 37]]], ["Past medical history includes asthma.Case presentationOn examination, the patient had blood pressure of 102/75, pulse of 76, respiratory rate of 18, SpO2 of 100%, and temperature of 36.2\u00b0C. Physical exam and radiographic findings indicated increased size in masses on the right breast compared to 2017, with pathology reports indicating a low to intermediate nuclear grade (The patient is scheduled later this year to undergo additional testing to rule out metastasis).Case presentationIn addition to masses felt at the right breast, physical examination revealed decreased breath sounds bilaterally with mild expiratory wheezing.", [["blood", "ANATOMY", 86, 91], ["masses", "ANATOMY", 258, 264], ["right breast", "ANATOMY", 272, 284], ["nuclear", "ANATOMY", 359, 366], ["masses", "ANATOMY", 501, 507], ["right breast", "ANATOMY", 520, 532], ["asthma", "DISEASE", 30, 36], ["decreased breath sounds", "DISEASE", 564, 587], ["expiratory wheezing", "DISEASE", 610, 629], ["patient", "ORGANISM", 74, 81], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["masses", "CANCER", 258, 264], ["breast", "ORGAN", 278, 284], ["nuclear", "CELLULAR_COMPONENT", 359, 366], ["patient", "ORGANISM", 378, 385], ["masses", "CANCER", 501, 507], ["breast", "ORGAN", 526, 532], ["patient", "SPECIES", 74, 81], ["patient", "SPECIES", 378, 385], ["asthma", "PROBLEM", 30, 36], ["Case presentationOn examination", "TEST", 37, 68], ["blood pressure", "TEST", 86, 100], ["pulse", "TEST", 112, 117], ["respiratory rate", "TEST", 125, 141], ["SpO2", "TEST", 149, 153], ["temperature", "TEST", 167, 178], ["Physical exam", "TEST", 190, 203], ["radiographic findings", "TEST", 208, 229], ["increased size in masses on the right breast", "PROBLEM", 240, 284], ["pathology", "TEST", 308, 317], ["additional testing", "TEST", 426, 444], ["metastasis", "PROBLEM", 457, 467], ["masses", "PROBLEM", 501, 507], ["physical examination", "TEST", 534, 554], ["decreased breath sounds bilaterally", "PROBLEM", 564, 599], ["mild expiratory wheezing", "PROBLEM", 605, 629], ["asthma", "OBSERVATION", 30, 36], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["size", "OBSERVATION_MODIFIER", 250, 254], ["masses", "OBSERVATION", 258, 264], ["right", "ANATOMY_MODIFIER", 272, 277], ["breast", "ANATOMY", 278, 284], ["metastasis", "OBSERVATION", 457, 467], ["masses", "OBSERVATION", 501, 507], ["right", "ANATOMY_MODIFIER", 520, 525], ["breast", "ANATOMY", 526, 532], ["decreased", "OBSERVATION_MODIFIER", 564, 573], ["breath sounds", "OBSERVATION", 574, 587], ["bilaterally", "ANATOMY_MODIFIER", 588, 599], ["mild", "OBSERVATION_MODIFIER", 605, 609], ["expiratory", "OBSERVATION_MODIFIER", 610, 620], ["wheezing", "OBSERVATION", 621, 629]]], ["Subsequent CT exam of the chest revealed patchy ground glass opacities bilaterally with scattered centrilobular micronodules and a reverse halo sign in the right lower lobe suggestive of atypical viral pneumonia.", [["chest", "ANATOMY", 26, 31], ["centrilobular micronodules", "ANATOMY", 98, 124], ["right lower lobe", "ANATOMY", 156, 172], ["viral pneumonia", "DISEASE", 196, 211], ["chest", "ORGAN", 26, 31], ["centrilobular micronodules", "CANCER", 98, 124], ["lower lobe", "ORGANISM_SUBDIVISION", 162, 172], ["Subsequent CT exam of the chest", "TEST", 0, 31], ["patchy ground glass opacities bilaterally", "PROBLEM", 41, 82], ["scattered centrilobular micronodules", "PROBLEM", 88, 124], ["a reverse halo sign in the right lower lobe", "PROBLEM", 129, 172], ["atypical viral pneumonia", "PROBLEM", 187, 211], ["chest", "ANATOMY", 26, 31], ["patchy", "OBSERVATION_MODIFIER", 41, 47], ["ground glass opacities", "OBSERVATION", 48, 70], ["bilaterally", "ANATOMY_MODIFIER", 71, 82], ["scattered", "OBSERVATION_MODIFIER", 88, 97], ["centrilobular", "OBSERVATION_MODIFIER", 98, 111], ["micronodules", "OBSERVATION", 112, 124], ["reverse halo", "OBSERVATION", 131, 143], ["right lower lobe", "ANATOMY", 156, 172], ["suggestive of", "UNCERTAINTY", 173, 186], ["atypical", "OBSERVATION_MODIFIER", 187, 195], ["viral", "OBSERVATION_MODIFIER", 196, 201], ["pneumonia", "OBSERVATION", 202, 211]]], ["The patient received a test for COVID-19 RT-PCR a day later at the prison facility, which came back positive.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a test", "TEST", 21, 27], ["COVID", "TEST", 32, 37]]], ["She remained asymptomatic after her discharge.", [["asymptomatic", "PROBLEM", 13, 25], ["asymptomatic", "OBSERVATION_MODIFIER", 13, 25]]], ["When the patient came to the emergency department approximately a month later for asthma exacerbations, CT imaging indicated no evidence of multifocal pneumonia and complete resolution of the aforementioned lung findings.", [["lung", "ANATOMY", 207, 211], ["asthma", "DISEASE", 82, 88], ["pneumonia", "DISEASE", 151, 160], ["patient", "ORGANISM", 9, 16], ["lung", "ORGAN", 207, 211], ["patient", "SPECIES", 9, 16], ["asthma exacerbations", "PROBLEM", 82, 102], ["CT imaging", "TEST", 104, 114], ["multifocal pneumonia", "PROBLEM", 140, 160], ["the aforementioned lung findings", "PROBLEM", 188, 220], ["no evidence of", "UNCERTAINTY", 125, 139], ["multifocal", "OBSERVATION_MODIFIER", 140, 150], ["pneumonia", "OBSERVATION", 151, 160], ["resolution", "OBSERVATION_MODIFIER", 174, 184], ["aforementioned", "OBSERVATION_MODIFIER", 192, 206], ["lung", "ANATOMY", 207, 211], ["findings", "OBSERVATION", 212, 220]]], ["During this hospitalization, she denied chest pain, coughing, and the RT-PCR test came back negative.Case presentationAfter both of her appointments, the CT room underwent deep cleaning under standard protocols that had already existed following guidelines by the Philadelphia Health department and the hospital.", [["chest", "ANATOMY", 40, 45], ["chest pain", "DISEASE", 40, 50], ["coughing", "DISEASE", 52, 60], ["chest", "ORGANISM_SUBDIVISION", 40, 45], ["chest pain", "PROBLEM", 40, 50], ["coughing", "PROBLEM", 52, 60], ["the RT-PCR test", "TEST", 66, 81], ["deep cleaning under standard protocols", "TREATMENT", 172, 210], ["chest", "ANATOMY", 40, 45]]], ["None of the faculty who interacted with the patient directly became ill or positive with the virus, and they were equipped (Including the patient) with personal protective equipment (PPE).DiscussionKnowledge of COVID-19 continues to expand, but our understanding of the radiologic features of COVID-19 is still inadequate.", [["patient", "ORGANISM", 44, 51], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 138, 145], ["the virus", "PROBLEM", 89, 98], ["personal protective equipment", "TREATMENT", 152, 181], ["COVID", "TEST", 211, 216], ["COVID", "TEST", 293, 298]]], ["Particularly concerning are asymptomatic or pre-symptomatic subjects who are accelerating transmission.", [["asymptomatic", "PROBLEM", 28, 40], ["asymptomatic", "OBSERVATION_MODIFIER", 28, 40]]], ["Shohei Inui et al. [5] described that of the 76 cases who were asymptomatic (73%), 41 (54%) displayed findings on CT scan including ground-glass opacities (GGO) and lung consolidations.", [["lung", "ANATOMY", 165, 169], ["GGO", "DISEASE", 156, 159], ["lung consolidations", "DISEASE", 165, 184], ["lung", "ORGAN", 165, 169], ["CT scan", "TEST", 114, 121], ["ground-glass opacities", "PROBLEM", 132, 154], ["GGO", "PROBLEM", 156, 159], ["lung consolidations", "PROBLEM", 165, 184], ["glass opacities", "OBSERVATION", 139, 154], ["GGO", "OBSERVATION_MODIFIER", 156, 159], ["lung", "ANATOMY", 165, 169], ["consolidations", "OBSERVATION", 170, 184]]], ["Unfortunately, there is currently no clear answer for this clinical-radiologic dissociation.", [["this clinical-radiologic dissociation", "PROBLEM", 54, 91]]], ["One is asymptomatic patients undergoing the \u201chealing phase\u201d of COVID-19 and symptoms subsiding by the time of admission and scan [6].", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 63, 68], ["symptoms", "PROBLEM", 76, 84], ["scan", "TEST", 124, 128], ["asymptomatic", "OBSERVATION_MODIFIER", 7, 19]]], ["Another is the timeline of the patients\u2019 infections in an \u201cincubation period\u201d between the moment of exposure and appearance of signs and symptoms of the disease [7].DiscussionRegardless of the exact cause, these findings have important implications for infection control.", [["infections", "DISEASE", 41, 51], ["infection", "DISEASE", 253, 262], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["infections", "PROBLEM", 41, 51], ["signs and symptoms", "PROBLEM", 127, 145], ["the disease", "PROBLEM", 149, 160], ["infection control", "TREATMENT", 253, 270], ["infections", "OBSERVATION", 41, 51], ["infection", "OBSERVATION", 253, 262]]], ["There will inevitably be incidental detections in asymptomatic patients undergoing scans for other indications.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["scans", "TEST", 83, 88]]], ["A study in Italy found that six of 65 asymptomatic patients who underwent 18F-FDG-PET/CT or 131I-SPECT/CT for standard oncologic indications showed unexpected signs of interstitial pneumonia on CT and elevated regional FDG-avidity [8].", [["interstitial", "ANATOMY", 168, 180], ["interstitial pneumonia", "DISEASE", 168, 190], ["18F-FDG", "CHEMICAL", 74, 81], ["patients", "ORGANISM", 51, 59], ["18F-FDG", "SIMPLE_CHEMICAL", 74, 81], ["FDG", "SIMPLE_CHEMICAL", 219, 222], ["patients", "SPECIES", 51, 59], ["A study", "TEST", 0, 7], ["FDG-PET/CT", "TEST", 78, 88], ["SPECT/CT", "TEST", 97, 105], ["standard oncologic indications", "TEST", 110, 140], ["interstitial pneumonia", "PROBLEM", 168, 190], ["CT", "TEST", 194, 196], ["elevated regional FDG-avidity", "PROBLEM", 201, 230], ["interstitial", "ANATOMY_MODIFIER", 168, 180], ["pneumonia", "OBSERVATION", 181, 190]]], ["Radiology departments and staff may face significant risk when performing diagnostic imaging on patients who may not be suspected of harboring COVID-19 due to the subclinical nature of incidental COVID-19 infections.", [["infections", "DISEASE", 205, 215], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["diagnostic imaging", "TEST", 74, 92], ["harboring COVID", "PROBLEM", 133, 148], ["incidental COVID-19 infections", "PROBLEM", 185, 215]]], ["This is because a large proportion of patients who enter a hospital through the emergency department will ultimately receive some sort of diagnostic imaging [9].", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["diagnostic imaging", "TEST", 138, 156], ["large", "OBSERVATION_MODIFIER", 18, 23]]], ["Imaging procedures during an outbreak can also be impeded secondarily to the necessity of adhering to more stringent infection control protocols leading to longer scan times and decreased patient turnover [10].", [["infection", "DISEASE", 117, 126], ["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195], ["Imaging procedures", "TEST", 0, 18], ["stringent infection control protocols", "TREATMENT", 107, 144], ["infection", "OBSERVATION", 117, 126]]], ["Ultimately, the financial, human and clinical implications of incidental COVID-19 infections may not yet be apparent to radiology departments.DiscussionThe goal for radiology departments during this pandemic should be focused on protecting health care workers (HCW), patients, and the general public while providing critical patient care services.", [["infections", "DISEASE", 82, 92], ["human", "ORGANISM", 27, 32], ["patients", "ORGANISM", 267, 275], ["patient", "ORGANISM", 325, 332], ["human", "SPECIES", 27, 32], ["patients", "SPECIES", 267, 275], ["patient", "SPECIES", 325, 332], ["human", "SPECIES", 27, 32], ["incidental COVID-19 infections", "PROBLEM", 62, 92]]], ["Zixing Huang et al. [11] outlined a protocol to reconfigure the radiology department, enact personal protection and training of staff, and further process patients suspected of or confirmed with COVID-19.", [["COVID-19", "CHEMICAL", 195, 203], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["a protocol", "TREATMENT", 34, 44], ["COVID", "TEST", 195, 200]]], ["As a result of this protocol, 3,083 people with fever underwent CT exams between January 21 and March 9 with no radiology staff showing signs of infection.", [["fever", "DISEASE", 48, 53], ["infection", "DISEASE", 145, 154], ["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["this protocol", "TREATMENT", 15, 28], ["fever", "PROBLEM", 48, 53], ["CT exams", "TEST", 64, 72], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 145, 154]]], ["Lastly, Mossa-Basha et al. [13] outlined a set of guidelines that acts to maintain the \u201ccritical radiology functions and [preserve] PPE and other critical care resources\u201d whilst also protecting the health care workers and general public from exposure and dissemination of COVID-19.DiscussionAt Temple University Hospital, scheduling of patients has been altered to include COVID-19 testing as part of the pre-test protocol for certain imaging studies.", [["COVID-19", "CHEMICAL", 272, 280], ["patients", "ORGANISM", 336, 344], ["patients", "SPECIES", 336, 344], ["COVID", "TEST", 272, 277], ["COVID", "TEST", 373, 378], ["the pre-test protocol", "TEST", 401, 422], ["certain imaging studies", "TEST", 427, 450]]], ["Postponement of non-urgent imaging is also encouraged.", [["non-urgent imaging", "TEST", 16, 34]]], ["At our institution, some tools of first-line screening include controlled entry into hospital facilities alongside temperature checks (Non-contact infrared thermometer), with surgical masks provided to every hospital patient and employee.", [["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 217, 224], ["first-line screening", "TREATMENT", 34, 54], ["temperature checks", "TEST", 115, 133], ["Non-contact infrared thermometer", "TREATMENT", 135, 167], ["surgical masks", "TREATMENT", 175, 189]]], ["No visitors are allowed in any imaging areas.", [["any imaging areas", "TEST", 27, 44]]], ["Patients are further screened at the radiology front desk for any signs and symptoms related to COVID-19.", [["COVID-19", "CHEMICAL", 96, 104], ["Patients", "ORGANISM", 0, 8], ["COVID-19", "DNA", 96, 104], ["Patients", "SPECIES", 0, 8], ["any signs and symptoms", "PROBLEM", 62, 84], ["COVID", "TEST", 96, 101]]], ["If patients are positive for any of these signs and symptoms, the infectious disease team is contacted for the patient to be further evaluated.", [["patients", "ORGANISM", 3, 11], ["patient", "ORGANISM", 111, 118], ["patients", "SPECIES", 3, 11], ["patient", "SPECIES", 111, 118], ["these signs and symptoms", "PROBLEM", 36, 60]]], ["All imaging is performed with appropriate PPE to ensure minimal exposure in the event that the patient is positive for COVID-19.DiscussionIn the case of incidental identification of lung findings consistent for atypical viral pneumonia, these findings are relayed to the ordering physician(s) and lead CT technologist.", [["lung", "ANATOMY", 182, 186], ["viral pneumonia", "DISEASE", 220, 235], ["COVID-19", "CHEMICAL", 119, 127], ["patient", "ORGANISM", 95, 102], ["lung", "ORGAN", 182, 186], ["patient", "SPECIES", 95, 102], ["All imaging", "TEST", 0, 11], ["appropriate PPE", "TREATMENT", 30, 45], ["COVID", "TEST", 119, 124], ["lung findings", "PROBLEM", 182, 195], ["atypical viral pneumonia", "PROBLEM", 211, 235], ["minimal", "OBSERVATION_MODIFIER", 56, 63], ["exposure", "OBSERVATION", 64, 72], ["lung", "ANATOMY", 182, 186], ["consistent for", "UNCERTAINTY", 196, 210], ["atypical", "OBSERVATION_MODIFIER", 211, 219], ["viral", "OBSERVATION_MODIFIER", 220, 225], ["pneumonia", "OBSERVATION", 226, 235]]], ["Occupational health service is contacted to ensure the CT technologists who were involved are evaluated and further quarantined if they develop symptoms.", [["symptoms", "PROBLEM", 144, 152]]], ["These decisions have been based on the critically low staffing numbers being experienced at our institution due to the illness and quarantining.", [["illness", "DISEASE", 119, 126], ["the illness", "PROBLEM", 115, 126]]], ["All quarantining decisions are based on a number of factors that include staffing number and symptoms, based on the Philadelphia Department of Public Health guidelines.", [["symptoms", "PROBLEM", 93, 101]]], ["These include no work exclusions for asymptomatic health care workers with twice daily symptom monitoring, temperature checks, and it being mandatory to wear masks.", [["symptom monitoring", "TEST", 87, 105], ["temperature checks", "TEST", 107, 125], ["masks", "TREATMENT", 158, 163]]], ["If symptomatic (Fever and/or lower respiratory symptoms), there is immediate work exclusion with testing for COVID-19.DiscussionIndeed, a combination of the physical restructuring of hospitals and use of online communications can be most effective in preventing unnecessary spread of infection at such a critical point in the timeline of this disease.Learning points", [["respiratory", "ANATOMY", 35, 46], ["Fever and/or lower respiratory symptoms", "DISEASE", 16, 55], ["infection", "DISEASE", 284, 293], ["COVID-19", "CHEMICAL", 109, 117], ["symptomatic", "PROBLEM", 3, 14], ["Fever", "PROBLEM", 16, 21], ["lower respiratory symptoms", "PROBLEM", 29, 55], ["COVID", "TEST", 109, 114], ["online communications", "TREATMENT", 204, 225], ["infection", "PROBLEM", 284, 293], ["this disease", "PROBLEM", 338, 350], ["infection", "OBSERVATION", 284, 293], ["disease", "OBSERVATION", 343, 350]]]], "9b572b4daa4221f13d85bf260ceefe285cf878c2": [["IntroductionThe World Health Organization (WHO) has described the Ebola virus disease in the West African subregion as the largest widespread unprecedented outbreak in the history of the disease [1] .IntroductionOne year since the outbreak started, more than 20 000 positive cases have been reported with an average case fatality rate of 50%.", [["Ebola virus disease", "DISEASE", 66, 85], ["Ebola virus", "ORGANISM", 66, 77], ["Ebola virus", "SPECIES", 66, 77], ["Ebola virus", "SPECIES", 66, 77], ["the Ebola virus disease", "PROBLEM", 62, 85], ["the disease", "PROBLEM", 183, 194], ["Ebola virus disease", "OBSERVATION", 66, 85], ["largest", "OBSERVATION_MODIFIER", 123, 130], ["widespread", "OBSERVATION_MODIFIER", 131, 141], ["unprecedented", "OBSERVATION_MODIFIER", 142, 155], ["outbreak", "OBSERVATION", 156, 164]]], ["As of the 27th September 2015, 28 388 cases were confirmed, suspected or probable and 11 296 deaths have been reported [2] .", [["deaths", "DISEASE", 93, 99]]], ["In the three most affected countries, the disease has halted socioeconomic activities and further weakened the already dysfunctional health system.IntroductionLocal health authorities and their international partners of these countries have been able to drastically reduce the spread of the virus through effective and sustained case investigation, contact tracing, rapid isolation and treatment and community engagement [2] .", [["the disease", "PROBLEM", 38, 49], ["further weakened the already dysfunctional health system", "PROBLEM", 90, 146], ["the virus", "PROBLEM", 287, 296], ["contact tracing", "TEST", 349, 364], ["rapid isolation", "TREATMENT", 366, 381], ["treatment", "TREATMENT", 386, 395], ["most affected", "OBSERVATION_MODIFIER", 13, 26], ["disease", "OBSERVATION", 42, 49]]], ["With the current outbreak almost at its end, there is a possibility for another to occur if the underlying factors that led to the start of the outbreak in the first place are not addressed.IntroductionThe local health authorities and the international communities were initially ill-prepared to effectively respond to an outbreak of such magnitude [3, 4] .", [["the underlying factors", "PROBLEM", 92, 114]]], ["Poor knowledge about the disease among most healthcare professionals including pharmacists and the populace combined with a dysfunctional health system due to the prolonged civil conflicts and an initial piece-meal response from the international community led to the spread of Ebola [1] .IntroductionProvision of pharmaceutical care by pharmacists through assessment of patient therapeutic needs, monitoring medication adherence and prevention of medication errors has been documented in the literature.", [["Ebola", "DISEASE", 278, 283], ["Ebola", "ORGANISM", 278, 283], ["patient", "ORGANISM", 371, 378], ["patient", "SPECIES", 371, 378], ["a dysfunctional health system", "PROBLEM", 122, 151], ["monitoring medication adherence", "TREATMENT", 398, 429], ["medication errors", "PROBLEM", 448, 465]]], ["In addition, pharmacists have been involved in public health related activities such as immunization, contraception, prevention and control of infectious and non-communicable diseases and emergency preparedness [5] .", [["infectious and non-communicable diseases", "DISEASE", 143, 183], ["immunization", "TREATMENT", 88, 100], ["contraception", "TREATMENT", 102, 115], ["prevention", "TREATMENT", 117, 127], ["infectious and non-communicable diseases", "PROBLEM", 143, 183], ["infectious", "OBSERVATION_MODIFIER", 143, 153]]], ["In Africa, these expandedIntroductionIn its forty years history (1976-2016), the West African region has recorded the most devastating form of the Ebola virus disease.", [["Ebola virus disease", "DISEASE", 147, 166], ["Ebola virus", "ORGANISM", 147, 158], ["Ebola virus", "SPECIES", 147, 158], ["Ebola virus", "SPECIES", 147, 158], ["the Ebola virus disease", "PROBLEM", 143, 166], ["most devastating", "OBSERVATION_MODIFIER", 118, 134], ["Ebola virus disease", "OBSERVATION", 147, 166]]], ["The sparse knowledge of healthcare professionals and general public combined with lesser responses from international community are major factors for the dissemination of the disease.", [["the disease", "PROBLEM", 171, 182], ["sparse", "OBSERVATION_MODIFIER", 4, 10], ["disease", "OBSERVATION", 175, 182]]], ["Moreover, the prerequisite of diagnostic kits for the timely detection of the infection as well as pharmacists' awareness of the current therapeutic regimen are recommended.Introductionroles are hardly practiced due to pharmacist's lack of knowledge and expertise coupled with the unwillingness to take up new roles and responsibilities.", [["infection", "DISEASE", 78, 87], ["the infection", "PROBLEM", 74, 87], ["the current therapeutic regimen", "TREATMENT", 125, 156], ["Introductionroles", "TREATMENT", 173, 190], ["infection", "OBSERVATION", 78, 87]]], ["In the context of the current outbreak, the pharmacist role can be described as minimal.How can pharmacists contribute?In an emergency disease outbreak like Ebola, pharmacists can involve in any of the key response areas, i.e. planning community and institutional response, disease surveillance, community and stakeholders engagement and mobilization, logistics and supplies and clinical management [6] .", [["Ebola", "DISEASE", 157, 162], ["Ebola", "ORGANISM", 157, 162], ["disease surveillance", "TEST", 274, 294], ["mobilization", "TREATMENT", 338, 350], ["clinical management", "TREATMENT", 379, 398], ["outbreak", "OBSERVATION", 30, 38], ["minimal", "OBSERVATION_MODIFIER", 80, 87]]], ["Other areas include preclinical and clinical investigation, quality assurance of new drugs or vaccination.How can pharmacists contribute?Pharmacists must be proactive in taking up leadership roles in national and regional pharmacy organizations and collaborating with other international health partners to formulate workable policy guidelines and programs for training pharmacists in Africa to effectively respond in the future [7, 8] .", [["clinical investigation", "TEST", 36, 58], ["new drugs", "TREATMENT", 81, 90], ["vaccination", "TREATMENT", 94, 105]]], ["In the light of the current epidemic, curricula in pharmacy schools in Africa should be tailored to foster public health by including specialized training in infectious disease epidemiology [7] .", [["infectious disease", "DISEASE", 158, 176]]], ["In Africa, a pharmacy is always the first port of call for sick patients.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["Pharmacists are well positioned for early disease detection within the community and provide referrals to patients for hospitals or isolation centres.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["early disease detection", "PROBLEM", 36, 59], ["isolation centres", "TREATMENT", 132, 149]]], ["Pharmacists at the community level are also well placed to educate and advise consumers on available and effective prevention and control measures, including information of new investigational drugs for the management of Ebola [7] .", [["Ebola", "DISEASE", 221, 226], ["Ebola", "ORGANISM", 221, 226], ["control measures", "TREATMENT", 130, 146], ["new investigational drugs", "TREATMENT", 173, 198]]], ["Also, as trusted health care professionals, they are in the right position to dispel myths or false rumors that have the potential to ferment the beginning of another outbreak.", [["false rumors", "PROBLEM", 94, 106], ["right", "ANATOMY_MODIFIER", 60, 65]]], ["Furthermore, as promising vaccine candidates for Ebola are in the horizon [9] , pharmacists could serve as a valuable resource in vaccinating patients as it has been shown in other disease prevention programs [6] .How can pharmacists contribute?Pharmacists working in the hospital settings, especially in critical care, emergency and infectious departments, should develop workable policies and standard operating procedures to prepare for any future outbreak [10] .", [["Ebola", "DISEASE", 49, 54], ["Ebola", "ORGANISM", 49, 54], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["Ebola", "SPECIES", 49, 54], ["Ebola", "PROBLEM", 49, 54], ["standard operating procedures", "TREATMENT", 395, 424]]], ["Guidelines and standard operating procedures should address staff protection, patient isolation, handling of orders, dispensing of medications and proper disposal of chemicals, including medications from isolation units [10] [12] .", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["standard operating procedures", "TREATMENT", 15, 44], ["staff protection", "TREATMENT", 60, 76], ["medications", "TREATMENT", 131, 142], ["medications", "TREATMENT", 187, 198]]], ["Last but not the least, future research efforts need to be exhaustively directed towards the formulation of diagnostic kits for early detection of infection [13] .", [["infection", "DISEASE", 147, 156], ["diagnostic kits", "TEST", 108, 123], ["infection", "PROBLEM", 147, 156], ["infection", "OBSERVATION", 147, 156]]]], "f292065adeb0ae2b1c80643ed3d3c7ca8aadb438": [["J o u r n a l P r e -p r o o fRodriguez Lozano R (1)., Alcocer Ojeda M.A. (2), Moreno Mart\u00ednez M.(3), S\u00e1enz Espinosa N.(4)(1) Universidad Publica de Navarra.", [["J", "TEST", 0, 1]]], ["Logro\u00f1o. rafael.r.lozano@unavarra.es (2) Fisiomechanics.", [["Logro\u00f1o", "TREATMENT", 0, 7]]], ["Logro\u00f1o miguel.moreno@unavarra.es (4)SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19En el a\u00f1o 1990 el n\u00famero de fisioterapeutas en Espa\u00f1a no superaba los 5.000 profesionales, desarrollando la mayor parte de ellos, su actividad laboral sanitaria en el Sistema P\u00fablico de Salud.", [["moreno@unavarra.es (4)SPANISH", "CHEMICAL", 15, 44]]], ["30 a\u00f1os despu\u00e9s alcanzamos los 55.000 profesionales(1), de los que el 90% desarrolla su trabajo en el \u00e1mbito privado.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19A los ojos del sistema p\u00fablico de salud, seguimos siendo pr\u00e1cticamente el mismo n\u00famero, para cubrir las necesidades asistenciales de una poblaci\u00f3n de 47 millones de habitantes La ratio en el \u00e1mbito p\u00fablico sigue siendo 1/8000 habitantes, cuando la OMS recomienda 1/1.000 habitantes (2).", [["desarrolla su trabajo en el \u00e1mbito privado", "TREATMENT", 74, 116], ["La ratio", "TEST", 347, 355]]], ["En la actualidad, hay suficientes fisioterapeutas en Espa\u00f1a, que podr\u00edan pasar al Sistema Nacional de Salud, para cumplir esta recomendaci\u00f3n.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Ante la nula ampliaci\u00f3n de plazas en el \u00e1mbito p\u00fablico, la gran mayor\u00eda de los Fisioterapeutas, nos hemos visto obligados al emprendimiento y al autoempleo, estableci\u00e9ndonos en consultas privadas, en donde se lleva a cabo la asistencia de la poblaci\u00f3n que demanda nuestros servicios, cubiertos deficitariamente por el Sistema P\u00fablico de Salud.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Con unas tasas de paro por debajo del 5%, (3) estamos hablando de una elevada ocupaci\u00f3n en el \u00e1mbito privado, unos 48.000 fisioterapeutas, frente a los 5.000 del \u00e1mbito p\u00fablico.", [["la nula ampliaci\u00f3n", "TREATMENT", 200, 218], ["a cabo la asistencia", "TREATMENT", 410, 430], ["Con unas tasas de paro por debajo del", "TREATMENT", 592, 629], ["en el \u00e1mbito privado", "TREATMENT", 680, 700]]], ["Somos necesarios, la sociedad lo expresa, no as\u00ed las Instituciones p\u00fablicas, que ante la amenaza del COVID19, no cuenta con nosotros y nos deja en ca\u00edda libre, desamparados.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19El decreto del estado de Alarma del d\u00eda 14 de marzo, (4) establec\u00eda que los centros de fisioterapia, como establecimientos sanitarios, deb\u00edan permanecer abiertos.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Nuestra profesi\u00f3n requiere el contacto con el paciente y la escasez de suministro de Equipos de protecci\u00f3n Individual (EPI) nos imped\u00eda realizar nuestro trabajo en condiciones de garantizar la salud de los pacientes y los profesionales; por lo que nos impusimos el cierre de nuestra actividad de forma individual, y como colectivo, a trav\u00e9s del llamamiento de los Colegios Profesionales y de la Asociaci\u00f3n Espa\u00f1ola de Fisioterapeutas (AEF), excepto en los tratamientos de urgencia donde la atenci\u00f3n ha sido imprescindible.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Esta decisi\u00f3n valiente y acertada de la profesi\u00f3n, lanz\u00e1ndose al vac\u00edo sin paraca\u00eddas, sin una claridad en la concesi\u00f3n de Expedientes de Regulaci\u00f3n Temporal de Empleo (ERTE), sin ayudas a nuestros aut\u00f3nomos por suspensi\u00f3n de actividad, restringido por la Clasificaci\u00f3n Nacional de Actividades Econ\u00f3micas (CNAE), ha contribuido significativamente para que la famosa curva de contagio vaya aplan\u00e1ndose y bajando.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Cerrando los centros privados de fisioterapia m\u00e1s de 48.000 fisioterapeutas hemos contribuido a limitar la movilidad de m\u00e1s de 500.000 personas al d\u00eda, que, con una tasa media de contagio, que ha oscilado del 25% inicial, al 3% al d\u00eda de la fecha, hubiera sido inadmisible.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Los autores de esta carta hemos realizado una encuesta sobre 843 centros de fisioterapia, que incluyen a 2279 fisioterapeutas, para conocer su situaci\u00f3n actual.", [["a trav\u00e9s del llamamiento", "TREATMENT", 775, 799], ["excepto en los tratamientos", "TREATMENT", 884, 911], ["que ha oscilado del", "TREATMENT", 1673, 1692]]], ["Los resultados preliminares de la encuesta nos indican que el 53% de estos centros est\u00e1n formados por aut\u00f3nomos sin trabajadores.", [["Los resultados", "TEST", 0, 14], ["que el", "TEST", 55, 61]]], ["El 94,3 % de los centros est\u00e1n completamente cerrados y sin nada de actividad, con atenci\u00f3n telef\u00f3nica, solo el 3,2 % mantienen actividad parcial telem\u00e1tica de atenci\u00f3n a pacientes.", [["El", "TEST", 0, 2]]], ["El 86% de los centros no facturan nada y el 11,2 % tienen una facturaci\u00f3n entre el 0 y el 20% de la facturaci\u00f3n habitual.", [["El", "TEST", 0, 2], ["centros", "TEST", 14, 21]]], ["El 74% opinan que las medidas del Gobierno no les ayudaran al mantenimiento de la empresa ni de los puestos de trabajo, el 15,5% opinan que les ayudaran poco y solo el 5,6% est\u00e1n totalmente de acuerdo o parcialmente de acuerdo con las ayudas ofrecidas por el Gobierno.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Los fisioterapeutas que trabajan en el \u00e1mbito p\u00fablico (aproximadamente, el 10% de la profesi\u00f3n), han suspendido las actividades asistenciales ambulatorias y hemos visto c\u00f3mo se han transformado las instalaciones de Fisioterapia, en salas de recepci\u00f3n y acogida de pacientes COVID19.", [["El", "TEST", 0, 2], ["THE COVID PANDEMIC19Los fisioterapeutas", "TREATMENT", 302, 341], ["trabajan en el \u00e1mbito p\u00fablico (aproximadamente", "TREATMENT", 346, 392]]], ["Esperamos que nuestro sistema p\u00fablico sea consciente que, entre todas las debilidades manifestadas, se debe recoger la necesidad de una inversi\u00f3n en fisioterapeutas suficientes en las UCIS, plantas de hospitalizaci\u00f3n y sistema p\u00fablico en general para alcanzar la ratio de 1/1000 recomendada internacionalmente.SPANISH PHYSIOTHERAPY IN TIMES OF THE COVID PANDEMIC19Pese a todas las dificultades econ\u00f3micas, laborales y asistenciales los fisioterapeutas que nos hemos visto obligados a quedarnos en casa, con la vista puesta en el medio y largo plazo, arrimaremos el hombro, en la atenci\u00f3n de los pacientes que han sufrido la infecci\u00f3n, pero tambi\u00e9n de las personas mayores confinadas y de las personas con movilidad reducida, que no han podido seguir sus rutinas de actividad y que han sufrido p\u00e9rdidas en sus capacidades funcionales, porque la escasez de fisioterapeutas en el sector p\u00fablico tampoco permitir\u00e1 la atenci\u00f3n eficiente de todas las personas que lo necesitaran en esa siguiente fase.", [["porque la escasez", "TREATMENT", 834, 851]]]], "PMC7351556": [["This preprint explores the ability of SARS-CoV-2 to infect and replicate in neural tissues of mouse and human origin.", [["neural tissues", "ANATOMY", 76, 90], ["SARS-CoV-2", "ORGANISM", 38, 48], ["neural tissues", "TISSUE", 76, 90], ["mouse", "ORGANISM", 94, 99], ["human", "ORGANISM", 104, 109], ["mouse", "SPECIES", 94, 99], ["human", "SPECIES", 104, 109], ["SARS-CoV", "SPECIES", 38, 46], ["mouse", "SPECIES", 94, 99], ["human", "SPECIES", 104, 109], ["SARS", "PROBLEM", 38, 42], ["CoV", "PROBLEM", 43, 46], ["infect", "PROBLEM", 52, 58], ["neural tissues", "ANATOMY", 76, 90]]], ["Induced pluripotent stem cell lines derived from healthy donors were used to generate human brain organoids for modelling SARS-CoV-2 infection.", [["pluripotent stem cell lines", "ANATOMY", 8, 35], ["brain organoids", "ANATOMY", 92, 107], ["SARS-CoV-2 infection", "DISEASE", 122, 142], ["pluripotent stem cell lines", "CELL", 8, 35], ["donors", "ORGANISM", 57, 63], ["human", "ORGANISM", 86, 91], ["brain organoids", "TISSUE", 92, 107], ["SARS-CoV-2", "ORGANISM", 122, 132], ["Induced pluripotent stem cell lines", "CELL_LINE", 0, 35], ["human brain organoids", "CELL_TYPE", 86, 107], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["SARS-CoV-2", "SPECIES", 122, 132], ["Induced pluripotent stem cell lines", "TREATMENT", 0, 35], ["healthy donors", "TREATMENT", 49, 63], ["modelling SARS", "PROBLEM", 112, 126], ["CoV-2 infection", "PROBLEM", 127, 142], ["pluripotent stem cell lines", "OBSERVATION", 8, 35], ["infection", "OBSERVATION", 133, 142]]], ["Extensive cell death and metabolic changes occurred in both infected and neighbouring neurons, inducing locally hypoxic regions with no evidence of a type I interferon response.", [["cell", "ANATOMY", 10, 14], ["neurons", "ANATOMY", 86, 93], ["death", "DISEASE", 15, 20], ["cell", "CELL", 10, 14], ["neurons", "CELL", 86, 93], ["type I interferon", "GENE_OR_GENE_PRODUCT", 150, 167], ["interferon", "PROTEIN", 157, 167], ["Extensive cell death", "PROBLEM", 0, 20], ["metabolic changes", "PROBLEM", 25, 42], ["locally hypoxic regions", "PROBLEM", 104, 127], ["a type I interferon response", "PROBLEM", 148, 176], ["cell death", "OBSERVATION", 10, 20], ["metabolic changes", "OBSERVATION", 25, 42], ["both", "OBSERVATION_MODIFIER", 55, 59], ["infected", "OBSERVATION", 60, 68], ["neighbouring neurons", "OBSERVATION", 73, 93], ["locally", "OBSERVATION_MODIFIER", 104, 111], ["hypoxic", "OBSERVATION", 112, 119], ["no evidence of", "UNCERTAINTY", 133, 147]]], ["Organoids incubated with antibodies to ACE2 or to viral spike protein from the cerebrospinal fluid of patients with COVID-19 had decreased SARS-CoV-2 infection.", [["cerebrospinal fluid", "ANATOMY", 79, 98], ["COVID-19", "CHEMICAL", 116, 124], ["infection", "DISEASE", 150, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 79, 98], ["patients", "ORGANISM", 102, 110], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 139, 149], ["antibodies", "PROTEIN", 25, 35], ["ACE2", "PROTEIN", 39, 43], ["viral spike protein", "PROTEIN", 50, 69], ["patients", "SPECIES", 102, 110], ["antibodies", "TREATMENT", 25, 35], ["ACE2", "TEST", 39, 43], ["viral spike protein", "TEST", 50, 69], ["the cerebrospinal fluid", "TEST", 75, 98], ["COVID", "TEST", 116, 121], ["decreased SARS", "PROBLEM", 129, 143], ["CoV-2 infection", "PROBLEM", 144, 159], ["cerebrospinal", "ANATOMY", 79, 92], ["fluid", "OBSERVATION", 93, 98], ["decreased", "OBSERVATION_MODIFIER", 129, 138], ["SARS", "OBSERVATION", 139, 143], ["infection", "OBSERVATION", 150, 159]]], ["Transgenic mice overexpressing human ACE2 (hACE2) in the brain had decreased survival after SARS-CoV-2 infection compared with those expressing hACE2 in lungs.", [["brain", "ANATOMY", 57, 62], ["lungs", "ANATOMY", 153, 158], ["infection", "DISEASE", 103, 112], ["mice", "ORGANISM", 11, 15], ["human", "ORGANISM", 31, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["hACE2", "GENE_OR_GENE_PRODUCT", 43, 48], ["brain", "ORGAN", 57, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 92, 102], ["hACE2", "GENE_OR_GENE_PRODUCT", 144, 149], ["lungs", "ORGAN", 153, 158], ["human ACE2", "PROTEIN", 31, 41], ["hACE2", "PROTEIN", 43, 48], ["hACE2", "PROTEIN", 144, 149], ["mice", "SPECIES", 11, 15], ["human", "SPECIES", 31, 36], ["mice", "SPECIES", 11, 15], ["human", "SPECIES", 31, 36], ["SARS-CoV", "SPECIES", 92, 100], ["Transgenic mice overexpressing human ACE2 (hACE2) in the brain", "PROBLEM", 0, 62], ["SARS", "PROBLEM", 92, 96], ["CoV-2 infection", "PROBLEM", 97, 112], ["brain", "ANATOMY", 57, 62], ["decreased", "OBSERVATION_MODIFIER", 67, 76], ["survival", "OBSERVATION_MODIFIER", 77, 85], ["infection", "OBSERVATION", 103, 112], ["lungs", "ANATOMY", 153, 158]]], ["This study provides insight into the neuroinvasive potential of SARS-CoV-2, which could explain neurological symptoms experienced by some patients.", [["neurological", "ANATOMY", 96, 108], ["SARS", "DISEASE", 64, 68], ["neurological symptoms", "DISEASE", 96, 117], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 64, 72], ["This study", "TEST", 0, 10], ["SARS", "PROBLEM", 64, 68], ["neurological symptoms", "PROBLEM", 96, 117]]]], "PMC7120436": [["IntroductionEarly studies in plants showed that small RNA-induced gene silencing is a potent antiviral mechanism that plants need to survive viral infection (1).", [["viral infection", "DISEASE", 141, 156], ["IntroductionEarly studies", "TEST", 0, 25], ["small RNA", "PROBLEM", 48, 57], ["viral infection", "PROBLEM", 141, 156], ["small", "OBSERVATION_MODIFIER", 48, 53], ["RNA", "OBSERVATION", 54, 57]]], ["Since then, it has become clear that there are many more aspects to the interaction between the RNA silencing mechanism \u2013 in plants, insects and mammals \u2013 and viral infection.", [["viral infection", "DISEASE", 159, 174], ["viral infection", "PROBLEM", 159, 174], ["clear", "OBSERVATION", 26, 31], ["many", "OBSERVATION_MODIFIER", 47, 51], ["more aspects", "OBSERVATION_MODIFIER", 52, 64], ["RNA silencing", "OBSERVATION", 96, 109], ["viral", "OBSERVATION_MODIFIER", 159, 164], ["infection", "OBSERVATION", 165, 174]]], ["Since RNA silencing is a central regulatory mechanism in eukaryotic cell biology, it is involved in many different cellular processes.", [["cell", "ANATOMY", 68, 72], ["cellular", "ANATOMY", 115, 123], ["cell", "CELL", 68, 72], ["cellular", "CELL", 115, 123], ["RNA silencing", "PROBLEM", 6, 19], ["RNA silencing", "OBSERVATION", 6, 19], ["central regulatory", "OBSERVATION", 25, 43], ["eukaryotic cell biology", "OBSERVATION", 57, 80], ["cellular processes", "OBSERVATION", 115, 133]]], ["These processes not only include cell development, differentiation and proliferation, but also cell death, metabolism, transposon silencing and antiviral defences (2).", [["cell", "ANATOMY", 33, 37], ["cell", "ANATOMY", 95, 99], ["cell", "CELL", 33, 37], ["cell", "CELL", 95, 99], ["proliferation", "PROBLEM", 71, 84], ["cell death", "PROBLEM", 95, 105], ["transposon silencing", "TREATMENT", 119, 139], ["antiviral defences", "TREATMENT", 144, 162], ["not only include", "UNCERTAINTY", 16, 32], ["proliferation", "OBSERVATION_MODIFIER", 71, 84], ["cell death", "OBSERVATION", 95, 105]]], ["Viruses, being strictly dependent on cellular resources for their replication, therefore interact with the RNA silencing machinery at multiple levels.IntroductionRNA silencing represents a general cellular phenomenon in which small RNA molecules of 20\u201330 nucleotides associate with Argonaute or Piwi proteins to trigger sequence-specific inhibition of gene expression (3).", [["cellular", "ANATOMY", 37, 45], ["cellular", "ANATOMY", 197, 205], ["nucleotides", "CHEMICAL", 255, 266], ["cellular", "CELL", 37, 45], ["cellular", "CELL", 197, 205], ["Argonaute", "GENE_OR_GENE_PRODUCT", 282, 291], ["Piwi", "GENE_OR_GENE_PRODUCT", 295, 299], ["Argonaute", "PROTEIN", 282, 291], ["Piwi proteins", "PROTEIN", 295, 308], ["Viruses", "PROBLEM", 0, 7], ["cellular resources", "TREATMENT", 37, 55], ["IntroductionRNA silencing", "PROBLEM", 150, 175], ["a general cellular phenomenon", "PROBLEM", 187, 216], ["small RNA molecules", "PROBLEM", 226, 245], ["Piwi proteins", "PROBLEM", 295, 308], ["trigger sequence", "TEST", 312, 328], ["strictly dependent", "OBSERVATION_MODIFIER", 15, 33], ["cellular phenomenon", "OBSERVATION", 197, 216], ["small", "OBSERVATION_MODIFIER", 226, 231], ["RNA molecules", "OBSERVATION", 232, 245], ["Piwi proteins", "OBSERVATION", 295, 308]]], ["Currently, three classes of small RNAs that are involved in silencing have been identified in mammals, namely microRNAs (miRNAs), endogenous small interfering RNAs (endo-siRNAs) and piwi-associated RNAs (piRNAs).", [["endogenous small interfering RNAs (endo-siRNAs", "GENE_OR_GENE_PRODUCT", 130, 176], ["piwi-associated RNAs", "GENE_OR_GENE_PRODUCT", 182, 202], ["small RNAs", "RNA", 28, 38], ["microRNAs (miRNAs), endogenous small interfering RNAs", "RNA", 110, 163], ["endo-siRNAs", "RNA", 165, 176], ["piwi-associated RNAs", "RNA", 182, 202], ["piRNAs", "RNA", 204, 210], ["small RNAs", "PROBLEM", 28, 38], ["endogenous small interfering RNAs (endo-siRNAs)", "PROBLEM", 130, 177], ["piwi-associated RNAs (piRNAs)", "PROBLEM", 182, 211], ["small RNAs", "OBSERVATION", 28, 38], ["miRNAs", "ANATOMY", 121, 127], ["endogenous", "OBSERVATION_MODIFIER", 130, 140], ["small", "OBSERVATION_MODIFIER", 141, 146], ["interfering RNAs", "OBSERVATION", 147, 163], ["endo-siRNAs", "OBSERVATION_MODIFIER", 165, 176]]], ["Endo-siRNAs and piRNAs are primarily involved in the repression of transposons, whereas miRNAs regulate cellular gene expression (4).", [["cellular", "ANATOMY", 104, 112], ["cellular", "CELL", 104, 112], ["Endo-siRNAs", "RNA", 0, 11], ["piRNAs", "DNA", 16, 22], ["transposons", "DNA", 67, 78], ["miRNAs", "DNA", 88, 94], ["Endo-siRNAs and piRNAs", "TREATMENT", 0, 22], ["siRNAs", "OBSERVATION", 5, 11], ["piRNAs", "OBSERVATION", 16, 22], ["cellular gene expression", "OBSERVATION", 104, 128]]], ["In recent years, miRNA-mediated gene regulation has received much attention.", [["miRNA-mediated gene regulation", "TREATMENT", 17, 47]]], ["So far, over 700 human miRNAs have been cloned, which are estimated to regulate the expression of at least 30% of human genes (5).", [["human", "ORGANISM", 17, 22], ["human", "ORGANISM", 114, 119], ["human miRNAs", "DNA", 17, 29], ["human genes", "DNA", 114, 125], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 114, 119]]], ["This regulation involves miRNA-guided targeting of the multi-protein RNA-induced silencing complex (RISC) to partially complementary sequences in the 3\u2032 untranslated region (3\u2032UTR) of target mRNAs.", [["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 69, 98], ["RISC", "GENE_OR_GENE_PRODUCT", 100, 104], ["multi-protein RNA-induced silencing complex", "PROTEIN", 55, 98], ["RISC", "PROTEIN", 100, 104], ["3\u2032 untranslated region", "DNA", 150, 172], ["3\u2032UTR", "DNA", 174, 179], ["target mRNAs", "RNA", 184, 196], ["the multi-protein RNA", "PROBLEM", 51, 72], ["induced silencing complex (RISC) to partially complementary sequences in the 3\u2032 untranslated region", "PROBLEM", 73, 172]]], ["Once RISC is bound to the target site, it triggers mRNA translational inhibition or destabilization (6).IntroductionBesides mediating regulation of gene expression, RNA silencing in plants, insects, nematodes and fungi plays an essential role in the antiviral \u201cimmune\u201d response via virus-specific siRNAs (1, 7\u20139).", [["RISC", "GENE_OR_GENE_PRODUCT", 5, 9], ["RISC", "PROTEIN", 5, 9], ["target site", "DNA", 26, 37], ["gene expression", "TREATMENT", 148, 163], ["RNA silencing", "TREATMENT", 165, 178], ["the antiviral", "TREATMENT", 246, 259], ["gene expression", "OBSERVATION", 148, 163]]], ["Despite the fact that the RNA silencing or RNA interference (RNAi) mechanism and machinery is highly conserved in eukaryotes, researchers failed to detect virus-specific siRNAs in virus-infected mammalian cells (10).", [["cells", "ANATOMY", 205, 210], ["mammalian cells", "CELL", 195, 210], ["virus-infected mammalian cells", "CELL_TYPE", 180, 210], ["the RNA silencing", "PROBLEM", 22, 39], ["RNA interference (RNAi) mechanism", "PROBLEM", 43, 76], ["virus", "PROBLEM", 155, 160], ["specific siRNAs in virus", "PROBLEM", 161, 185], ["infected mammalian cells", "PROBLEM", 186, 210], ["mammalian cells", "OBSERVATION", 195, 210]]], ["This initially suggested that RNAi does not have an antiviral role in mammals (11).", [["antiviral", "OBSERVATION", 52, 61]]], ["Interestingly, recent studies used novel and very sensitive deep sequencing technology to show that small virus-derived RNAs do accumulate in virus-infected mammalian cells (12, 13).", [["mammalian cells", "ANATOMY", 157, 172], ["mammalian cells", "CELL", 157, 172], ["virus-infected mammalian cells", "CELL_TYPE", 142, 172], ["recent studies", "TEST", 15, 29], ["deep sequencing technology", "TEST", 60, 86], ["small virus-derived RNAs", "PROBLEM", 100, 124], ["infected mammalian cells", "PROBLEM", 148, 172], ["small", "OBSERVATION_MODIFIER", 100, 105], ["virus", "OBSERVATION", 106, 111], ["infected", "OBSERVATION_MODIFIER", 148, 156], ["mammalian cells", "OBSERVATION", 157, 172]]], ["It currently remains unclear to what extent these RNA molecules contribute to the antiviral defence response.IntroductionAn increasing number of studies have addressed novel aspects of the interaction between mammalian viruses and small RNA-induced silencing mechanisms.", [["mammalian viruses", "ORGANISM", 209, 226], ["RNA molecules", "PROTEIN", 50, 63], ["these RNA molecules", "PROBLEM", 44, 63], ["the antiviral defence response", "PROBLEM", 78, 108], ["mammalian viruses", "PROBLEM", 209, 226], ["small RNA-induced silencing mechanisms", "PROBLEM", 231, 269], ["antiviral defence", "OBSERVATION", 82, 99], ["viruses", "OBSERVATION", 219, 226], ["small RNA", "OBSERVATION", 231, 240]]], ["It has become clear that cellular miRNAs and other components of the miRNA pathway can interact with viruses at multiple levels to influence viral replication (Fig. 1).", [["cellular", "ANATOMY", 25, 33], ["cellular", "CELL", 25, 33], ["the miRNA pathway", "PROBLEM", 65, 82], ["viral replication", "TREATMENT", 141, 158], ["clear", "OBSERVATION", 14, 19], ["cellular miRNAs", "OBSERVATION", 25, 40], ["viral replication", "OBSERVATION", 141, 158]]], ["For a good understanding of the way in which viruses interact with cellular miRNAs in mammals, we will first give a brief overview of different aspects of the miRNA and small interfering RNA (siRNA) pathways.", [["cellular", "ANATOMY", 67, 75], ["cellular", "CELL", 67, 75], ["small interfering RNA", "GENE_OR_GENE_PRODUCT", 169, 190], ["small interfering RNA", "RNA", 169, 190], ["the miRNA", "PROBLEM", 155, 164], ["small interfering RNA (siRNA) pathways", "PROBLEM", 169, 207], ["miRNA", "ANATOMY", 159, 164], ["small", "OBSERVATION_MODIFIER", 169, 174], ["interfering", "OBSERVATION", 175, 186]]], ["Subsequently, we will discuss the effect of cellular miRNAs on viral gene expression, cellular miRNAs as determinants of the viral tropism for certain cell types, virus-encoded RNA silencing suppressors (RSS), and virus-induced changes in the cellular miRNA expression profile.", [["cellular", "ANATOMY", 44, 52], ["cellular", "ANATOMY", 86, 94], ["cell", "ANATOMY", 151, 155], ["cellular", "ANATOMY", 243, 251], ["cellular", "CELL", 44, 52], ["cellular", "CELL", 86, 94], ["cell", "CELL", 151, 155], ["cellular", "CELL", 243, 251], ["cellular miRNAs", "RNA", 44, 59], ["cellular miRNAs", "RNA", 86, 101], ["RNA silencing suppressors", "DNA", 177, 202], ["RSS", "DNA", 204, 207], ["cellular miRNAs", "PROBLEM", 44, 59], ["viral gene expression", "PROBLEM", 63, 84], ["cellular miRNAs", "PROBLEM", 86, 101], ["the viral tropism", "PROBLEM", 121, 138], ["certain cell types", "PROBLEM", 143, 161], ["virus", "PROBLEM", 163, 168], ["encoded RNA silencing suppressors", "TREATMENT", 169, 202], ["virus", "PROBLEM", 214, 219], ["cellular miRNAs", "OBSERVATION", 44, 59], ["viral gene expression", "OBSERVATION", 63, 84], ["cellular miRNAs", "OBSERVATION", 86, 101], ["viral tropism", "OBSERVATION", 125, 138], ["cellular miRNA expression", "OBSERVATION", 243, 268]]], ["Finally, we will discuss the use of miRNAs or miRNA-inactivating compounds in novel antiviral therapeutic strategies.", [["miRNAs or miRNA", "TREATMENT", 36, 51], ["novel antiviral therapeutic strategies", "TREATMENT", 78, 116]]], ["Virus-encoded miRNAs, as expressed by the herpes virus family and other DNA viruses (14), will be discussed in Chap.", [["Virus", "ORGANISM", 0, 5], ["herpes virus", "ORGANISM", 42, 54], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["herpes virus", "SPECIES", 42, 54], ["herpes virus", "SPECIES", 42, 54], ["Virus", "PROBLEM", 0, 5], ["other DNA viruses", "PROBLEM", 66, 83]]]], "cf7fde0d086be35d2a3173719eb49298257d3127": [["G ene transfer to airway and alveolar epithelial cells in vivo continues to offer hope as a therapeutic approach for genetic diseases such as cystic fibrosis (CF), as a pharmaceutical delivery technique for acute and acquired lung injuries, and as a powerful research tool.", [["airway", "ANATOMY", 18, 24], ["alveolar epithelial cells", "ANATOMY", 29, 54], ["cystic", "ANATOMY", 142, 148], ["lung", "ANATOMY", 226, 230], ["cystic fibrosis", "DISEASE", 142, 157], ["CF", "DISEASE", 159, 161], ["lung injuries", "DISEASE", 226, 239], ["G ene", "GENE_OR_GENE_PRODUCT", 0, 5], ["airway", "CELL", 18, 24], ["alveolar epithelial cells", "CELL", 29, 54], ["lung", "ORGAN", 226, 230], ["airway and alveolar epithelial cells", "CELL_TYPE", 18, 54], ["alveolar epithelial cells", "PROBLEM", 29, 54], ["a therapeutic approach", "TREATMENT", 90, 112], ["genetic diseases", "PROBLEM", 117, 133], ["cystic fibrosis", "PROBLEM", 142, 157], ["a pharmaceutical delivery technique", "TREATMENT", 167, 202], ["acute and acquired lung injuries", "PROBLEM", 207, 239], ["airway", "ANATOMY", 18, 24], ["alveolar epithelial", "ANATOMY", 29, 48], ["cystic", "OBSERVATION_MODIFIER", 142, 148], ["fibrosis", "OBSERVATION", 149, 157], ["lung", "ANATOMY", 226, 230], ["injuries", "OBSERVATION", 231, 239]]], ["However, successful and sustained gene expression in the epithelium has often been limited by factors associated with effective vector delivery, particularly in injured or diseased lungs; innate inflammatory and immune responses to vectors; and longevity of gene expression.", [["epithelium", "ANATOMY", 57, 67], ["lungs", "ANATOMY", 181, 186], ["epithelium", "TISSUE", 57, 67], ["lungs", "ORGAN", 181, 186], ["sustained gene expression in the epithelium", "PROBLEM", 24, 67], ["effective vector delivery", "TREATMENT", 118, 143], ["injured or diseased lungs", "PROBLEM", 161, 186], ["innate inflammatory", "PROBLEM", 188, 207], ["gene expression", "OBSERVATION", 34, 49], ["diseased", "OBSERVATION", 172, 180], ["lungs", "ANATOMY", 181, 186], ["inflammatory", "OBSERVATION_MODIFIER", 195, 207]]], ["1 One hypothetical means of overcoming the last limitation would be to target endogenous progenitor cells in the lung, cells that would subsequently provide sustained and widespread gene expression in the daughter cells arising from the progenitor-cell populations.", [["progenitor cells", "ANATOMY", 89, 105], ["lung", "ANATOMY", 113, 117], ["cells", "ANATOMY", 119, 124], ["daughter cells", "ANATOMY", 205, 219], ["progenitor-cell populations", "ANATOMY", 237, 264], ["progenitor cells", "CELL", 89, 105], ["lung", "ORGAN", 113, 117], ["cells", "CELL", 119, 124], ["daughter cells", "CELL", 205, 219], ["progenitor-cell populations", "CELL", 237, 264], ["endogenous progenitor cells", "CELL_TYPE", 78, 105], ["daughter cells", "CELL_TYPE", 205, 219], ["progenitor-cell populations", "CELL_TYPE", 237, 264], ["endogenous progenitor cells", "OBSERVATION", 78, 105], ["lung", "ANATOMY", 113, 117], ["widespread", "OBSERVATION_MODIFIER", 171, 181], ["gene expression", "OBSERVATION", 182, 197], ["cell populations", "OBSERVATION", 248, 264]]], ["However, specific targeting of endogenous airway progenitor cells has not previously been described.", [["airway progenitor cells", "ANATOMY", 42, 65], ["airway progenitor cells", "CELL", 42, 65], ["endogenous airway progenitor cells", "CELL_TYPE", 31, 65], ["endogenous airway progenitor cells", "PROBLEM", 31, 65], ["endogenous airway progenitor cells", "OBSERVATION", 31, 65]]]], "PMC3245449": [["BackgroundNeuNAc is the most prevalent exponent of sialic acids [1].", [["sialic acids", "CHEMICAL", 51, 63], ["sialic acids", "CHEMICAL", 51, 63], ["NeuNAc", "GENE_OR_GENE_PRODUCT", 10, 16], ["sialic acids", "SIMPLE_CHEMICAL", 51, 63], ["NeuNAc", "PROTEIN", 10, 16], ["sialic acids", "TREATMENT", 51, 63]]], ["In mammals, sialic acids are usually found as terminal residues of glycol conjugates on the outermost cell surface.", [["cell surface", "ANATOMY", 102, 114], ["sialic acids", "CHEMICAL", 12, 24], ["sialic acids", "CHEMICAL", 12, 24], ["glycol", "CHEMICAL", 67, 73], ["sialic acids", "SIMPLE_CHEMICAL", 12, 24], ["glycol conjugates", "SIMPLE_CHEMICAL", 67, 84], ["outermost cell surface", "CELLULAR_COMPONENT", 92, 114], ["sialic acids", "TREATMENT", 12, 24], ["terminal residues of glycol conjugates", "PROBLEM", 46, 84], ["sialic acids", "OBSERVATION", 12, 24], ["terminal", "OBSERVATION_MODIFIER", 46, 54], ["residues", "OBSERVATION_MODIFIER", 55, 63], ["glycol conjugates", "OBSERVATION", 67, 84], ["outermost", "ANATOMY_MODIFIER", 92, 101], ["cell", "OBSERVATION", 102, 106], ["surface", "OBSERVATION_MODIFIER", 107, 114]]], ["As a result of their location and their negative carboxylate functionality, sialic acids play important roles in mediating cellular recognition and adhesion processes [2] and in the infection cycles of severe viral diseases, such as influenza viruses A and B [3].", [["cellular", "ANATOMY", 123, 131], ["sialic acids", "CHEMICAL", 76, 88], ["infection", "DISEASE", 182, 191], ["viral diseases", "DISEASE", 209, 223], ["influenza viruses", "DISEASE", 233, 250], ["carboxylate", "CHEMICAL", 49, 60], ["sialic acids", "CHEMICAL", 76, 88], ["sialic acids", "SIMPLE_CHEMICAL", 76, 88], ["cellular", "CELL", 123, 131], ["sialic acids", "TREATMENT", 76, 88], ["adhesion processes", "PROBLEM", 148, 166], ["the infection cycles", "TREATMENT", 178, 198], ["severe viral diseases", "PROBLEM", 202, 223], ["influenza viruses", "PROBLEM", 233, 250], ["severe", "OBSERVATION_MODIFIER", 202, 208], ["viral diseases", "OBSERVATION", 209, 223]]], ["In these cases, de novo-synthesized viral particles attach to their respective sialic acids at the cell surface.", [["cell surface", "ANATOMY", 99, 111], ["sialic acids", "CHEMICAL", 79, 91], ["sialic acids", "CHEMICAL", 79, 91], ["sialic acids", "SIMPLE_CHEMICAL", 79, 91], ["cell surface", "CELLULAR_COMPONENT", 99, 111], ["novo-synthesized viral particles", "TREATMENT", 19, 51], ["sialic acids", "OBSERVATION", 79, 91], ["cell surface", "OBSERVATION", 99, 111]]], ["Neuraminidase (sialidase) activity is needed for the propagation of the virus in the host.", [["Neuraminidase", "GENE_OR_GENE_PRODUCT", 0, 13], ["sialidase", "GENE_OR_GENE_PRODUCT", 15, 24], ["sialidase", "PROTEIN", 15, 24], ["Neuraminidase (sialidase) activity", "TREATMENT", 0, 34]]], ["Consequently, sialic acid derivatives are successfully applied in the therapy of such virus-related diseases.", [["sialic acid", "CHEMICAL", 14, 25], ["sialic acid", "CHEMICAL", 14, 25], ["sialic acid derivatives", "SIMPLE_CHEMICAL", 14, 37], ["sialic acid derivatives", "TREATMENT", 14, 37], ["the therapy", "TREATMENT", 66, 77], ["such virus", "PROBLEM", 81, 91], ["related diseases", "PROBLEM", 92, 108]]], ["One well-known product that functions as a neuraminidase inhibitor is Relenza.", [["Relenza", "SIMPLE_CHEMICAL", 70, 77], ["a neuraminidase inhibitor", "TREATMENT", 41, 66]]], ["Its active pharmaceutical ingredient is Zanamivir, which is a direct derivative of the NeuNAc precursor [4].BackgroundTraditionally, NeuNAc is prepared through extraction from natural sources, such as bird nests, milk, or eggs [5], through the hydrolysis of colominic acid (a homopolymer of NeuNAc) in a culture broth of Escherichia coli K1 [6], or through chemical synthesis [7].", [["milk", "ANATOMY", 213, 217], ["Zanamivir", "CHEMICAL", 40, 49], ["NeuNAc", "CHEMICAL", 133, 139], ["colominic acid", "CHEMICAL", 258, 272], ["NeuNAc", "CHEMICAL", 291, 297], ["Zanamivir", "CHEMICAL", 40, 49], ["NeuNAc", "CHEMICAL", 87, 93], ["colominic acid", "CHEMICAL", 258, 272], ["NeuNAc", "CHEMICAL", 291, 297], ["Zanamivir", "SIMPLE_CHEMICAL", 40, 49], ["NeuNAc", "SIMPLE_CHEMICAL", 87, 93], ["NeuNAc", "SIMPLE_CHEMICAL", 133, 139], ["milk", "ORGANISM_SUBSTANCE", 213, 217], ["colominic acid", "SIMPLE_CHEMICAL", 258, 272], ["NeuNAc", "SIMPLE_CHEMICAL", 291, 297], ["Escherichia coli", "ORGANISM", 321, 337], ["Escherichia coli", "SPECIES", 321, 337], ["Escherichia coli", "SPECIES", 321, 337], ["Zanamivir", "TREATMENT", 40, 49], ["the hydrolysis of colominic acid", "TREATMENT", 240, 272], ["a homopolymer of NeuNAc)", "TREATMENT", 274, 298], ["a culture broth", "TEST", 302, 317], ["Escherichia coli K1", "PROBLEM", 321, 340], ["active", "OBSERVATION_MODIFIER", 4, 10], ["pharmaceutical", "OBSERVATION_MODIFIER", 11, 25], ["Escherichia coli", "OBSERVATION", 321, 337]]], ["Methods for NeuNAc production have included a chemo-enzymatic process [8,9], a two-enzyme reaction process [10,11], a biotransformation process using E. coli [12], and an E. coli whole-cell system [13].", [["NeuNAc", "CHEMICAL", 12, 18], ["NeuNAc", "SIMPLE_CHEMICAL", 12, 18], ["E. coli", "ORGANISM", 150, 157], ["E. coli", "ORGANISM", 171, 178], ["E. coli", "SPECIES", 150, 157], ["E. coli", "SPECIES", 171, 178], ["E. coli", "SPECIES", 150, 157], ["E. coli", "SPECIES", 171, 178], ["NeuNAc production", "PROBLEM", 12, 29], ["a chemo-enzymatic process", "TREATMENT", 44, 69], ["a two-enzyme reaction process", "PROBLEM", 77, 106], ["a biotransformation process", "PROBLEM", 116, 143], ["E. coli", "PROBLEM", 150, 157], ["an E. coli", "TEST", 168, 178]]], ["However, the requirement for ATP or an excess of pyruvate and the subsequent expensive downstream processing has kept the costs of NeuNAc production considerably high (current market price is $100/g).BackgroundChitin is considered the second most abundant biomass available on earth [14].", [["ATP", "CHEMICAL", 29, 32], ["pyruvate", "CHEMICAL", 49, 57], ["BackgroundChitin", "CHEMICAL", 200, 216], ["ATP", "CHEMICAL", 29, 32], ["pyruvate", "CHEMICAL", 49, 57], ["ATP", "SIMPLE_CHEMICAL", 29, 32], ["pyruvate", "SIMPLE_CHEMICAL", 49, 57], ["NeuNAc", "SIMPLE_CHEMICAL", 131, 137], ["BackgroundChitin", "GENE_OR_GENE_PRODUCT", 200, 216], ["ATP", "PROBLEM", 29, 32], ["an excess of pyruvate", "PROBLEM", 36, 57], ["the subsequent expensive downstream processing", "PROBLEM", 62, 108], ["NeuNAc production", "PROBLEM", 131, 148], ["biomass", "OBSERVATION", 256, 263]]], ["The estimated annual biosynthesis of chitin is more than 1011 tons in marine waters alone [15].", [["chitin", "CHEMICAL", 37, 43], ["chitin", "SIMPLE_CHEMICAL", 37, 43], ["The estimated annual biosynthesis of chitin", "TREATMENT", 0, 43]]], ["Unlike cellulose, the other dominant biopolymer, chitin can serve as a source for both carbon and nitrogen (C:N = 8:1) [16].", [["chitin", "CHEMICAL", 49, 55], ["carbon and nitrogen", "CHEMICAL", 87, 106], ["carbon", "CHEMICAL", 87, 93], ["nitrogen", "CHEMICAL", 98, 106], ["cellulose", "SIMPLE_CHEMICAL", 7, 16], ["chitin", "SIMPLE_CHEMICAL", 49, 55], ["carbon", "SIMPLE_CHEMICAL", 87, 93], ["nitrogen", "SIMPLE_CHEMICAL", 98, 106], ["cellulose", "TREATMENT", 7, 16], ["both carbon and nitrogen", "TREATMENT", 82, 106]]], ["This property suggests that chitin is an optimal resource for the production of NeuNAc (C:N = 11:1) because no additional nitrogen would need to be applied as it would be if glucose or cellulose were used as raw material.", [["chitin", "CHEMICAL", 28, 34], ["NeuNAc", "CHEMICAL", 80, 86], ["nitrogen", "CHEMICAL", 122, 130], ["glucose", "CHEMICAL", 174, 181], ["NeuNAc", "CHEMICAL", 80, 86], ["nitrogen", "CHEMICAL", 122, 130], ["glucose", "CHEMICAL", 174, 181], ["chitin", "SIMPLE_CHEMICAL", 28, 34], ["NeuNAc", "SIMPLE_CHEMICAL", 80, 86], ["C:N = 11:1", "SIMPLE_CHEMICAL", 88, 98], ["nitrogen", "SIMPLE_CHEMICAL", 122, 130], ["glucose", "SIMPLE_CHEMICAL", 174, 181], ["cellulose", "SIMPLE_CHEMICAL", 185, 194], ["chitin", "TREATMENT", 28, 34], ["additional nitrogen", "TREATMENT", 111, 130], ["glucose or cellulose", "TREATMENT", 174, 194]]], ["Chitin is found in the exoskeletons of arthropods, such as crustaceans (including crab, lobster, and shrimp) and insects (including ants and beetles), the cell walls of fungi, the radula of mollusks, and the beaks of cephalopods (including squid and octopi).", [["cell walls", "ANATOMY", 155, 165], ["Chitin", "CHEMICAL", 0, 6], ["Chitin", "GENE_OR_GENE_PRODUCT", 0, 6], ["crab", "ORGANISM_SUBDIVISION", 82, 86], ["lobster", "ORGANISM_SUBDIVISION", 88, 95], ["shrimp", "ORGANISM_SUBDIVISION", 101, 107], ["cell walls", "CELLULAR_COMPONENT", 155, 165], ["shrimp", "SPECIES", 101, 107], ["Chitin", "TREATMENT", 0, 6], ["shrimp", "ANATOMY", 101, 107], ["cell", "ANATOMY", 155, 159], ["walls", "ANATOMY_MODIFIER", 160, 165], ["fungi", "OBSERVATION", 169, 174]]], ["This polymer is composed of \u03b2-(1,4)-linked units of the amino sugar N-acetylglucosamine (GlcNAc) that is currently produced using hydrolysis of deproteinized and demineralized crustacean shells [17].", [["\u03b2-(1,4", "CHEMICAL", 28, 34], ["amino sugar N-acetylglucosamine", "CHEMICAL", 56, 87], ["GlcNAc", "CHEMICAL", 89, 95], ["amino sugar N-acetylglucosamine", "CHEMICAL", 56, 87], ["GlcNAc", "CHEMICAL", 89, 95], ["\u03b2-(1,4)", "SIMPLE_CHEMICAL", 28, 35], ["amino sugar N-acetylglucosamine", "SIMPLE_CHEMICAL", 56, 87], ["GlcNAc", "SIMPLE_CHEMICAL", 89, 95], ["the amino sugar N-acetylglucosamine (GlcNAc", "TREATMENT", 52, 95], ["hydrolysis of deproteinized and demineralized crustacean shells", "TREATMENT", 130, 193]]], ["Chitinolytic enzymes from fungi of the genus Hypocrea have been extensively studied for decades [18].", [["Chitinolytic enzymes", "PROTEIN", 0, 20], ["Chitinolytic enzymes", "TEST", 0, 20]]], ["More recently, the chitinolytic enzyme system of H. jecorina has been studied using genome-wide analysis [19,20].", [["H. jecorina", "ORGANISM", 49, 60], ["chitinolytic enzyme", "PROTEIN", 19, 38], ["H. jecorina", "SPECIES", 49, 60], ["H. jecorina", "SPECIES", 49, 60], ["the chitinolytic enzyme system", "TEST", 15, 45], ["H. jecorina", "PROBLEM", 49, 60], ["wide analysis", "TEST", 91, 104]]], ["Unlike their bacterial counterparts (e.g., Serratia marcescens [21]), Hypocrea chitinolytic preparations have a high ratio of exochitinase to endochitinase activity and almost exclusively release monomeric GlcNAc from chitin [22], which is another advantageous aspect of chitin compared to cellulose.", [["chitin [22]", "CHEMICAL", 218, 229], ["chitin", "CHEMICAL", 271, 277], ["GlcNAc", "CHEMICAL", 206, 212], ["Serratia marcescens", "ORGANISM", 43, 62], ["Hypocrea chitinolytic preparations", "ORGANISM", 70, 104], ["exochitinase", "SIMPLE_CHEMICAL", 126, 138], ["endochitinase", "SIMPLE_CHEMICAL", 142, 155], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 206, 212], ["chitin [22]", "SIMPLE_CHEMICAL", 218, 229], ["chitin", "SIMPLE_CHEMICAL", 271, 277], ["cellulose", "SIMPLE_CHEMICAL", 290, 299], ["Serratia marcescens", "SPECIES", 43, 62], ["Serratia marcescens", "SPECIES", 43, 62], ["their bacterial counterparts", "PROBLEM", 7, 35], ["Serratia marcescens", "PROBLEM", 43, 62], ["Hypocrea chitinolytic preparations", "TREATMENT", 70, 104], ["endochitinase activity", "TREATMENT", 142, 164], ["chitin", "TREATMENT", 271, 277], ["bacterial counterparts", "OBSERVATION", 13, 35]]], ["Therefore, the basic premise of this study was to exploit the potential of a saprophytic fungus to degrade the cheap biowaste chitin to its monomer GlcNAc and to further metabolize this product to NeuNAc.Engineering a NeuNAc synthesis pathway into Hypocrea ::: Results and DiscussionThe biosynthesis of NeuNAc begins with the formation of N-acetylmannosamine (ManNAc) from GlcNAc or UDP-N-acetylglucosamine (UDP-GlcNAc).", [["chitin", "CHEMICAL", 126, 132], ["NeuNAc", "CHEMICAL", 197, 203], ["NeuNAc", "CHEMICAL", 303, 309], ["N-acetylmannosamine", "CHEMICAL", 339, 358], ["ManNAc", "CHEMICAL", 360, 366], ["UDP-N-acetylglucosamine", "CHEMICAL", 383, 406], ["UDP-GlcNAc", "CHEMICAL", 408, 418], ["GlcNAc", "CHEMICAL", 148, 154], ["NeuNAc", "CHEMICAL", 197, 203], ["N-acetylmannosamine", "CHEMICAL", 339, 358], ["ManNAc", "CHEMICAL", 360, 366], ["GlcNAc", "CHEMICAL", 373, 379], ["UDP", "CHEMICAL", 383, 386], ["N-acetylglucosamine", "CHEMICAL", 387, 406], ["UDP", "CHEMICAL", 408, 411], ["GlcNAc", "CHEMICAL", 412, 418], ["chitin", "SIMPLE_CHEMICAL", 126, 132], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 148, 154], ["NeuNAc", "SIMPLE_CHEMICAL", 197, 203], ["NeuNAc", "GENE_OR_GENE_PRODUCT", 218, 224], ["NeuNAc", "SIMPLE_CHEMICAL", 303, 309], ["N-acetylmannosamine", "SIMPLE_CHEMICAL", 339, 358], ["ManNAc", "SIMPLE_CHEMICAL", 360, 366], ["GlcNAc", "SIMPLE_CHEMICAL", 373, 379], ["UDP-N-acetylglucosamine", "SIMPLE_CHEMICAL", 383, 406], ["UDP-GlcNAc", "SIMPLE_CHEMICAL", 408, 418], ["NeuNAc", "PROTEIN", 197, 203], ["NeuNAc", "PROTEIN", 303, 309], ["this study", "TEST", 32, 42], ["a saprophytic fungus", "PROBLEM", 75, 95], ["the cheap biowaste chitin", "TREATMENT", 107, 132], ["its monomer GlcNAc", "TREATMENT", 136, 154], ["NeuNAc", "TREATMENT", 303, 309], ["N-acetylmannosamine (ManNAc", "TREATMENT", 339, 366], ["GlcNAc", "TEST", 373, 379], ["UDP", "TEST", 383, 386], ["acetylglucosamine", "TREATMENT", 389, 406], ["saprophytic fungus", "OBSERVATION", 77, 95]]], ["In mammals, ManNAc is then phosphorylated to give ManNAc-6-phosphate (ManNAc-6P).", [["ManNAc-6-phosphate", "CHEMICAL", 50, 68], ["ManNAc-6P", "CHEMICAL", 70, 79], ["ManNAc-6-phosphate", "CHEMICAL", 50, 68], ["ManNAc-6P", "CHEMICAL", 70, 79], ["ManNAc", "GENE_OR_GENE_PRODUCT", 12, 18], ["ManNAc-6-phosphate", "SIMPLE_CHEMICAL", 50, 68], ["ManNAc-6P", "SIMPLE_CHEMICAL", 70, 79], ["ManNAc", "PROTEIN", 12, 18], ["ManNAc", "TEST", 50, 56]]], ["The second step involves the condensation of either ManNAc (in bacteria) or MacNAc-6P (in mammals) with phosphoenolpyruvate (PEP) to give NeuNAc or NeuNAc-9P, respectively.", [["ManNAc", "CHEMICAL", 52, 58], ["MacNAc-6P", "CHEMICAL", 76, 85], ["phosphoenolpyruvate", "CHEMICAL", 104, 123], ["NeuNAc-9P", "CHEMICAL", 148, 157], ["ManNAc", "CHEMICAL", 52, 58], ["MacNAc-6P", "CHEMICAL", 76, 85], ["phosphoenolpyruvate", "CHEMICAL", 104, 123], ["PEP", "CHEMICAL", 125, 128], ["NeuNAc", "CHEMICAL", 138, 144], ["NeuNAc-9P", "CHEMICAL", 148, 157], ["ManNAc", "SIMPLE_CHEMICAL", 52, 58], ["MacNAc-6P", "SIMPLE_CHEMICAL", 76, 85], ["phosphoenolpyruvate", "SIMPLE_CHEMICAL", 104, 123], ["PEP", "SIMPLE_CHEMICAL", 125, 128], ["NeuNAc", "SIMPLE_CHEMICAL", 138, 144], ["NeuNAc-9P", "SIMPLE_CHEMICAL", 148, 157], ["6P", "PROTEIN", 83, 85], ["MacNAc", "TEST", 76, 82], ["phosphoenolpyruvate (PEP", "TREATMENT", 104, 128], ["NeuNAc", "TEST", 138, 144]]], ["In mammals, NeuNAc-9P is then dephosphorylated to generate NeuNAc (see Figure 1).", [["NeuNAc-9P", "GENE_OR_GENE_PRODUCT", 12, 21], ["NeuNAc", "PROTEIN", 12, 18], ["9P", "PROTEIN", 19, 21], ["NeuNAc", "PROTEIN", 59, 65], ["NeuNAc", "TEST", 12, 18]]], ["Hypocrea naturally degrades chitin almost exclusively to GlcNAc [22].", [["GlcNAc", "CHEMICAL", 57, 63], ["chitin", "SIMPLE_CHEMICAL", 28, 34], ["GlcNAc [22]", "SIMPLE_CHEMICAL", 57, 68], ["GlcNAc", "TEST", 57, 63]]], ["Therefore, the challenge was to engineer a pathway to convert GlcNAc to NeuNAc via ManNAc, which would enable the use of Hypocrea as a whole-cell catalyst.Engineering a NeuNAc synthesis pathway into Hypocrea ::: Results and DiscussionLee and coworkers found that whole-cell extracts of several photobacteria could convert GlcNAc to ManNAc [13].", [["whole-cell", "ANATOMY", 135, 145], ["whole-cell extracts", "ANATOMY", 263, 282], ["ManNAc", "CHEMICAL", 83, 89], ["GlcNAc", "CHEMICAL", 62, 68], ["NeuNAc", "CHEMICAL", 72, 78], ["GlcNAc", "CHEMICAL", 322, 328], ["ManNAc", "CHEMICAL", 332, 338], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 62, 68], ["NeuNAc", "SIMPLE_CHEMICAL", 72, 78], ["ManNAc", "SIMPLE_CHEMICAL", 83, 89], ["NeuNAc", "SIMPLE_CHEMICAL", 169, 175], ["cell extracts", "ORGANISM_SUBSTANCE", 269, 282], ["photobacteria", "SIMPLE_CHEMICAL", 294, 307], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 322, 328], ["GlcNAc", "TREATMENT", 62, 68], ["NeuNAc via ManNAc", "TREATMENT", 72, 89], ["a whole-cell catalyst", "TREATMENT", 133, 154], ["whole-cell extracts", "TREATMENT", 263, 282], ["several photobacteria", "PROBLEM", 286, 307]]], ["Among them, Anabaena sp.", [["Anabaena sp", "ORGANISM", 12, 23]]], ["CH1 exhibited the highest GlcNAc 2-epimerase activity; consequently, they cloned and characterized a gene encoding GlcNAc 2-epimerase from Anabaena sp.", [["GlcNAc", "CHEMICAL", 26, 32], ["GlcNAc", "CHEMICAL", 115, 121], ["GlcNAc 2-epimerase", "GENE_OR_GENE_PRODUCT", 26, 44], ["GlcNAc 2-epimerase", "GENE_OR_GENE_PRODUCT", 115, 133], ["Anabaena sp", "ORGANISM", 139, 150], ["CH1", "PROTEIN", 0, 3], ["epimerase", "PROTEIN", 35, 44], ["GlcNAc 2-epimerase", "PROTEIN", 115, 133]]], ["CH1 (E.C. 5.1.3.8), which was used in the present study as a Hypocrea codon-optimized gene.", [["E.C. 5.1.3.8", "GENE_OR_GENE_PRODUCT", 5, 17], ["CH1", "CELL_LINE", 0, 3], ["Hypocrea codon-optimized gene", "DNA", 61, 90], ["a Hypocrea codon", "TREATMENT", 59, 75]]], ["For the second step (the condensation of ManNAc to NeuNAc), the currently used enzyme-catalyzed processes use a lyase, which requires an excess of pyruvate.", [["ManNAc", "CHEMICAL", 41, 47], ["NeuNAc", "CHEMICAL", 51, 57], ["pyruvate", "CHEMICAL", 147, 155], ["ManNAc", "CHEMICAL", 41, 47], ["NeuNAc", "CHEMICAL", 51, 57], ["pyruvate", "CHEMICAL", 147, 155], ["ManNAc", "SIMPLE_CHEMICAL", 41, 47], ["NeuNAc", "SIMPLE_CHEMICAL", 51, 57], ["lyase", "SIMPLE_CHEMICAL", 112, 117], ["pyruvate", "SIMPLE_CHEMICAL", 147, 155], ["NeuNAc", "PROTEIN", 51, 57], ["enzyme", "PROTEIN", 79, 85], ["lyase", "PROTEIN", 112, 117], ["enzyme-catalyzed processes", "TREATMENT", 79, 105], ["a lyase", "TREATMENT", 110, 117], ["an excess of pyruvate", "TREATMENT", 134, 155]]], ["Therefore, we used the NeuNAc synthase (EC 2.5.1.56) from Campylobacter jejuni [23] in the Hyprocrea process.", [["Campylobacter jejuni", "DISEASE", 58, 78], ["NeuNAc synthase", "GENE_OR_GENE_PRODUCT", 23, 38], ["Campylobacter jejuni", "ORGANISM", 58, 78], ["NeuNAc synthase", "PROTEIN", 23, 38], ["EC 2.5", "PROTEIN", 40, 46], ["Campylobacter jejuni", "SPECIES", 58, 78], ["Campylobacter jejuni", "SPECIES", 58, 78], ["the NeuNAc synthase (EC", "TREATMENT", 19, 42], ["Campylobacter jejuni", "PROBLEM", 58, 78], ["Campylobacter jejuni", "OBSERVATION", 58, 78]]], ["This enzymatic step entails the use of PEP instead of pyruvate, which in the intended in vivo process is supplied by the fungus, thereby leading to an irreversible and more efficient reaction towards NeuNAc [24].", [["pyruvate", "CHEMICAL", 54, 62], ["NeuNAc", "CHEMICAL", 200, 206], ["PEP", "CHEMICAL", 39, 42], ["pyruvate", "CHEMICAL", 54, 62], ["NeuNAc", "CHEMICAL", 200, 206], ["PEP", "SIMPLE_CHEMICAL", 39, 42], ["pyruvate", "SIMPLE_CHEMICAL", 54, 62], ["PEP", "TREATMENT", 39, 42], ["pyruvate", "TREATMENT", 54, 62], ["the fungus", "PROBLEM", 117, 127], ["an irreversible and more efficient reaction", "PROBLEM", 148, 191], ["fungus", "OBSERVATION", 121, 127], ["irreversible", "OBSERVATION_MODIFIER", 151, 163]]], ["Moreover, the need for an excess of pyruvate becomes obsolete, and the resulting downstream process is significantly simplified.", [["pyruvate", "CHEMICAL", 36, 44], ["pyruvate", "CHEMICAL", 36, 44], ["pyruvate", "SIMPLE_CHEMICAL", 36, 44], ["an excess of pyruvate", "TREATMENT", 23, 44], ["the resulting downstream process", "PROBLEM", 67, 99]]], ["Similar to the GlcNAc 2-epimerase, the coding sequence for the NeuNAc synthase was codon-optimized for the usage in Hypocrea.", [["GlcNAc", "CHEMICAL", 15, 21], ["GlcNAc 2-epimerase", "GENE_OR_GENE_PRODUCT", 15, 33], ["NeuNAc synthase", "GENE_OR_GENE_PRODUCT", 63, 78], ["GlcNAc 2-epimerase", "PROTEIN", 15, 33], ["NeuNAc synthase", "PROTEIN", 63, 78], ["the GlcNAc", "TEST", 11, 21], ["the NeuNAc synthase", "TREATMENT", 59, 78], ["codon", "TREATMENT", 83, 88]]], ["The complete nucleotide sequences for both genes encoding the recombinant enzymes, tbage and tneub, are shown in additional file 1.Metabolization or uptake of NeuNAc can not be observed in Hypocrea ::: Results and DiscussionAs the ability of the fungus to metabolize NeuNAc is an important issue, a possible uptake of NeuNAc by H. jecorina was investigated.", [["nucleotide", "CHEMICAL", 13, 23], ["NeuNAc", "CHEMICAL", 267, 273], ["NeuNAc", "CHEMICAL", 318, 324], ["nucleotide", "CHEMICAL", 13, 23], ["tbage", "GENE_OR_GENE_PRODUCT", 83, 88], ["tneub", "GENE_OR_GENE_PRODUCT", 93, 98], ["NeuNAc", "SIMPLE_CHEMICAL", 159, 165], ["NeuNAc", "GENE_OR_GENE_PRODUCT", 267, 273], ["NeuNAc", "SIMPLE_CHEMICAL", 318, 324], ["H. jecorina", "ORGANISM", 328, 339], ["recombinant enzymes", "PROTEIN", 62, 81], ["tbage", "PROTEIN", 83, 88], ["tneub", "PROTEIN", 93, 98], ["NeuNAc", "PROTEIN", 159, 165], ["H. jecorina", "SPECIES", 328, 339], ["H. jecorina", "SPECIES", 328, 339], ["The complete nucleotide sequences", "TEST", 0, 33], ["the recombinant enzymes", "TEST", 58, 81], ["NeuNAc", "TREATMENT", 159, 165], ["the fungus", "PROBLEM", 242, 252]]], ["Therefore, the fungus was pre-grown on glycerol in liquid culture, and half of the mycelium was autoclaved and half of it was harvested.", [["mycelium", "ANATOMY", 83, 91], ["glycerol", "CHEMICAL", 39, 47], ["glycerol", "CHEMICAL", 39, 47], ["glycerol", "SIMPLE_CHEMICAL", 39, 47], ["the fungus", "PROBLEM", 11, 21], ["glycerol in liquid culture", "TEST", 39, 65], ["the mycelium", "TREATMENT", 79, 91], ["fungus", "OBSERVATION", 15, 21], ["harvested", "OBSERVATION", 126, 135]]], ["The dead and living mycelia were transferred to glycerol-containing medium to study growth conditions or to medium without a carbon source to study resting cell conditions.", [["mycelia", "ANATOMY", 20, 27], ["cell", "ANATOMY", 156, 160], ["glycerol", "CHEMICAL", 48, 56], ["glycerol", "CHEMICAL", 48, 56], ["carbon", "CHEMICAL", 125, 131], ["glycerol", "SIMPLE_CHEMICAL", 48, 56], ["cell", "CELL", 156, 160], ["The dead and living mycelia", "TREATMENT", 0, 27], ["glycerol", "TREATMENT", 48, 56]]], ["NeuNAc was added to both media, and cultures were incubated for 8 h.", [["NeuNAc", "CHEMICAL", 0, 6], ["NeuNAc", "SIMPLE_CHEMICAL", 0, 6], ["NeuNAc", "PROTEIN", 0, 6], ["NeuNAc", "TREATMENT", 0, 6], ["cultures", "TEST", 36, 44]]], ["Supernatants from all conditions were analyzed after incubation for 0 and 8 h by HPLC after derivatization using 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride (DMB).", [["Supernatants", "ANATOMY", 0, 12], ["1,2-diamino-4,5-methylenedioxybenzene dihydrochloride", "CHEMICAL", 113, 166], ["DMB", "CHEMICAL", 168, 171], ["1,2-diamino-4,5-methylenedioxybenzene dihydrochloride", "CHEMICAL", 113, 166], ["DMB", "CHEMICAL", 168, 171], ["1,2-diamino-4,5-methylenedioxybenzene dihydrochloride", "SIMPLE_CHEMICAL", 113, 166], ["DMB", "SIMPLE_CHEMICAL", 168, 171], ["derivatization", "TEST", 92, 106], ["diamino", "TREATMENT", 117, 124], ["methylenedioxybenzene dihydrochloride (DMB", "TREATMENT", 129, 171]]], ["Similar amounts of NeuNAc were present under all conditions regardless of whether the fungus was alive or dead (Figure 2a).", [["NeuNAc", "GENE_OR_GENE_PRODUCT", 19, 25], ["NeuNAc", "PROTEIN", 19, 25], ["the fungus", "PROBLEM", 82, 92], ["amounts", "OBSERVATION_MODIFIER", 8, 15]]], ["This result indicates that NeuNAc uptake does not occur in H. jecorina.", [["NeuNAc", "CHEMICAL", 27, 33], ["NeuNAc", "CHEMICAL", 27, 33], ["NeuNAc", "SIMPLE_CHEMICAL", 27, 33], ["H. jecorina", "ORGANISM", 59, 70], ["NeuNAc", "PROTEIN", 27, 33], ["H. jecorina", "SPECIES", 59, 70], ["H. jecorina", "SPECIES", 59, 70], ["NeuNAc uptake", "PROBLEM", 27, 40]]], ["As a positive control experiment we did a similar experiment but instead of NeuNAc, GlcNAc was added to the media.", [["NeuNAc", "CHEMICAL", 76, 82], ["NeuNAc", "CHEMICAL", 76, 82], ["GlcNAc", "CHEMICAL", 84, 90], ["NeuNAc", "SIMPLE_CHEMICAL", 76, 82], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 84, 90], ["NeuNAc, GlcNAc", "TREATMENT", 76, 90]]], ["As can be inferred from Figure 2b GlcNAc was completely consumed after eight hours under both growth and resting cell conditions when the mycelium was viable.Characterization of the recombinant H. jecorina strain ::: Results and DiscussionRecombinant Hypocrea strains were generated using protoplast transformation of H. jecorina QM9414.", [["cell", "ANATOMY", 113, 117], ["mycelium", "ANATOMY", 138, 146], ["protoplast", "ANATOMY", 289, 299], ["GlcNAc", "CHEMICAL", 34, 40], ["Figure 2b GlcNAc", "GENE_OR_GENE_PRODUCT", 24, 40], ["cell", "CELL", 113, 117], ["H. jecorina", "ORGANISM", 194, 205], ["strain", "ORGANISM", 206, 212], ["H. jecorina QM9414", "ORGANISM", 318, 336], ["H. jecorina", "SPECIES", 194, 205], ["H. jecorina", "SPECIES", 318, 329], ["H. jecorina", "SPECIES", 194, 205], ["H. jecorina QM9414", "SPECIES", 318, 336], ["Figure 2b GlcNAc", "TREATMENT", 24, 40], ["resting cell conditions", "TREATMENT", 105, 128], ["the mycelium", "TREATMENT", 134, 146], ["DiscussionRecombinant Hypocrea strains", "PROBLEM", 229, 267], ["protoplast transformation", "TREATMENT", 289, 314], ["resting cell conditions", "OBSERVATION", 105, 128]]], ["In the derived strains, the two Hypocrea codon-optimized genes (without GST-tag) were placed under the control of either the H. jecorina pyruvate kinase (pki) promoter, which is a strong constitutive promoter, or the H. jecorina xylanase 1 (xyn1) promoter, which is a strict shut-off system if an inducer (e.g. D-xylose) is missing.", [["pyruvate", "CHEMICAL", 137, 145], ["D-xylose", "CHEMICAL", 311, 319], ["pyruvate", "CHEMICAL", 137, 145], ["D-xylose", "CHEMICAL", 311, 319], ["GST-tag", "GENE_OR_GENE_PRODUCT", 72, 79], ["jecorina pyruvate kinase", "GENE_OR_GENE_PRODUCT", 128, 152], ["pki", "GENE_OR_GENE_PRODUCT", 154, 157], ["jecorina xylanase 1", "GENE_OR_GENE_PRODUCT", 220, 239], ["xyn1", "GENE_OR_GENE_PRODUCT", 241, 245], ["D-xylose", "SIMPLE_CHEMICAL", 311, 319], ["Hypocrea codon-optimized genes", "DNA", 32, 62], ["GST", "PROTEIN", 72, 75], ["H. jecorina pyruvate kinase (pki) promoter", "DNA", 125, 167], ["constitutive promoter", "DNA", 187, 208], ["H. jecorina xylanase 1 (xyn1) promoter", "DNA", 217, 255], ["H. jecorina", "SPECIES", 125, 136], ["H. jecorina", "SPECIES", 217, 228], ["H. jecorina", "SPECIES", 125, 136], ["H. jecorina", "SPECIES", 217, 228], ["the two Hypocrea codon", "TREATMENT", 24, 46], ["GST-tag", "TREATMENT", 72, 79], ["the H. jecorina pyruvate kinase (pki) promoter", "TREATMENT", 121, 167], ["a strong constitutive promoter", "TREATMENT", 178, 208], ["the H. jecorina xylanase", "TREATMENT", 213, 237]]], ["Such a system was used to avoid interference of the introduced recombinant pathway with cell wall biosynthesis and consequently, biomass formation.", [["cell wall", "ANATOMY", 88, 97], ["cell", "CELL", 88, 92], ["the introduced recombinant pathway", "TREATMENT", 48, 82], ["cell wall biosynthesis", "TREATMENT", 88, 110], ["biomass formation", "OBSERVATION", 129, 146]]], ["However, when comparing both promoter systems the strong pki promoter did not lead to decreased growth, diminished cell integrity or other adverse effects (data not shown).", [["cell", "ANATOMY", 115, 119], ["pki", "GENE_OR_GENE_PRODUCT", 57, 60], ["cell", "CELL", 115, 119], ["pki promoter", "DNA", 57, 69], ["decreased growth", "PROBLEM", 86, 102], ["diminished cell integrity", "PROBLEM", 104, 129], ["other adverse effects", "PROBLEM", 133, 154]]], ["Therefore, we used strains in which both genes were under the control of the pki promoter for further studies as we observed a remarkably higher NeuNAc formation.Characterization of the recombinant H. jecorina strain ::: Results and DiscussionTranscriptional analysis of the recombinant H. jecorina strains was done by RT-qPCR to compare expression of both inserted genes using sar1 (SAR/ARF-type small GTPase) as a stable reference gene [25].", [["pki", "GENE_OR_GENE_PRODUCT", 77, 80], ["NeuNAc", "SIMPLE_CHEMICAL", 145, 151], ["H. jecorina", "ORGANISM", 198, 209], ["strain", "ORGANISM", 210, 216], ["H. jecorina", "ORGANISM", 287, 298], ["strains", "ORGANISM", 299, 306], ["sar1", "GENE_OR_GENE_PRODUCT", 378, 382], ["ARF-type small GTPase", "GENE_OR_GENE_PRODUCT", 388, 409], ["pki promoter", "DNA", 77, 89], ["NeuNAc", "PROTEIN", 145, 151], ["inserted genes", "DNA", 357, 371], ["sar1", "DNA", 378, 382], ["SAR/ARF-type small GTPase", "DNA", 384, 409], ["H. jecorina", "SPECIES", 198, 209], ["H. jecorina", "SPECIES", 287, 298], ["H. jecorina", "SPECIES", 198, 209], ["H. jecorina", "SPECIES", 287, 298], ["strains", "PROBLEM", 19, 26], ["the pki promoter", "TREATMENT", 73, 89], ["further studies", "TEST", 94, 109], ["a remarkably higher NeuNAc formation", "PROBLEM", 125, 161], ["Transcriptional analysis", "TEST", 243, 267], ["the recombinant H. jecorina strains", "TREATMENT", 271, 306], ["sar1 (SAR/ARF", "PROBLEM", 378, 391], ["type small GTPase", "PROBLEM", 392, 409], ["higher", "OBSERVATION_MODIFIER", 138, 144], ["NeuNAc formation", "OBSERVATION", 145, 161]]], ["Furthermore, the copy numbers of both genes was measured by qPCR of genomic DNA using pki as a reference, which in the native H. jecorina genome is present as a single copy gene.", [["DNA", "CELLULAR_COMPONENT", 76, 79], ["pki", "GENE_OR_GENE_PRODUCT", 86, 89], ["H. jecorina", "ORGANISM", 126, 137], ["genomic DNA", "DNA", 68, 79], ["pki", "DNA", 86, 89], ["native H. jecorina genome", "DNA", 119, 144], ["single copy gene", "DNA", 161, 177], ["H. jecorina", "SPECIES", 126, 137], ["H. jecorina", "SPECIES", 126, 137], ["jecorina genome", "OBSERVATION", 129, 144]]], ["Based on these analyses a strain (termed PEC/PSC1) was chosen for further investigations because it showed the highest equal expression of both inserted genes.", [["PEC/PSC1", "CELL", 41, 49], ["PSC1", "DNA", 45, 49], ["inserted genes", "DNA", 144, 158], ["a strain (termed PEC/PSC1)", "TREATMENT", 24, 50], ["further investigations", "TEST", 66, 88], ["both", "OBSERVATION_MODIFIER", 139, 143], ["inserted genes", "OBSERVATION", 144, 158]]], ["This was confirmed by the finding that this strain bears two copies of each recombinant gene in the genome.", [["recombinant gene", "DNA", 76, 92]]], ["These data were also supported using Southern blot analysis (data not shown).GlcNAc 2-epimerase and NeuNAc synthase are fully functional as GST-fusion proteins ::: Results and DiscussionBoth recombinant enzymes were heterologously expressed as glutathione S-transferase (GST) fusion proteins in E. coli; the affinity chromatography purified proteins were used to confirm that their enzymatic capability was not altered by the codon usage adaptation and to provide a positive control for the enzymatic assays later on.GlcNAc 2-epimerase and NeuNAc synthase are fully functional as GST-fusion proteins ::: Results and DiscussionTo determine if the recombinant enzymes were functional, both GST fusion proteins were used in an enzymatic assay.", [["glutathione", "CHEMICAL", 244, 255], ["GlcNAc", "CHEMICAL", 77, 83], ["glutathione", "CHEMICAL", 244, 255], ["GlcNAc", "CHEMICAL", 517, 523], ["GlcNAc 2-epimerase", "GENE_OR_GENE_PRODUCT", 77, 95], ["NeuNAc synthase", "GENE_OR_GENE_PRODUCT", 100, 115], ["GST", "GENE_OR_GENE_PRODUCT", 140, 143], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 244, 269], ["GST", "GENE_OR_GENE_PRODUCT", 271, 274], ["E. coli", "ORGANISM", 295, 302], ["GlcNAc 2-epimerase", "GENE_OR_GENE_PRODUCT", 517, 535], ["NeuNAc synthase", "GENE_OR_GENE_PRODUCT", 540, 555], ["GST", "GENE_OR_GENE_PRODUCT", 580, 583], ["GST", "GENE_OR_GENE_PRODUCT", 688, 691], ["GlcNAc 2-epimerase", "PROTEIN", 77, 95], ["NeuNAc synthase", "PROTEIN", 100, 115], ["GST", "PROTEIN", 140, 143], ["fusion proteins", "PROTEIN", 144, 159], ["DiscussionBoth recombinant enzymes", "PROTEIN", 176, 210], ["glutathione S-transferase (GST) fusion proteins", "PROTEIN", 244, 291], ["affinity chromatography purified proteins", "PROTEIN", 308, 349], ["GlcNAc 2-epimerase", "PROTEIN", 517, 535], ["NeuNAc synthase", "PROTEIN", 540, 555], ["GST", "PROTEIN", 580, 583], ["fusion proteins", "PROTEIN", 584, 599], ["recombinant enzymes", "PROTEIN", 646, 665], ["GST fusion proteins", "PROTEIN", 688, 707], ["E. coli", "SPECIES", 295, 302], ["E. coli", "SPECIES", 295, 302], ["Southern blot analysis", "TEST", 37, 59], ["GlcNAc", "TEST", 77, 83], ["epimerase", "TEST", 86, 95], ["NeuNAc synthase", "TREATMENT", 100, 115], ["DiscussionBoth recombinant enzymes", "TEST", 176, 210], ["glutathione S-transferase (GST) fusion proteins in E. coli", "PROBLEM", 244, 302], ["the affinity chromatography purified proteins", "TEST", 304, 349], ["their enzymatic capability", "PROBLEM", 376, 402], ["a positive control", "TREATMENT", 464, 482], ["the enzymatic assays", "TEST", 487, 507], ["GlcNAc", "TEST", 517, 523], ["epimerase", "TEST", 526, 535], ["NeuNAc synthase", "TREATMENT", 540, 555], ["the recombinant enzymes", "TEST", 642, 665], ["both GST fusion proteins", "TEST", 683, 707], ["an enzymatic assay", "TEST", 721, 739], ["E. coli", "OBSERVATION", 295, 302]]], ["The presence of GlcNAc and the formation of the intermediate product ManNAc and the final product NeuNAc were monitored using HPLC-MS analysis and results are presented in Figure 3.", [["ManNAc", "CHEMICAL", 69, 75], ["GlcNAc", "CHEMICAL", 16, 22], ["ManNAc", "CHEMICAL", 69, 75], ["NeuNAc", "CHEMICAL", 98, 104], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 16, 22], ["ManNAc", "SIMPLE_CHEMICAL", 69, 75], ["NeuNAc", "SIMPLE_CHEMICAL", 98, 104], ["ManNAc", "PROTEIN", 69, 75], ["GlcNAc", "TREATMENT", 16, 22], ["HPLC", "TEST", 126, 130], ["MS analysis", "TEST", 131, 142], ["GlcNAc", "OBSERVATION", 16, 22], ["intermediate", "OBSERVATION_MODIFIER", 48, 60], ["product ManNAc", "OBSERVATION", 61, 75]]], ["Application of the GST-fusion proteins of both enzymes in the in vitro assay led to the formation of ManNAc and NeuNAc demonstrating that the synthetic genes are expressed as functional proteins (Figure 3a1 and 3b1).NeuNAc synthesis in vitro by recombinant H. jecorina strains ::: Results and DiscussionAccording to the GST-fusion proteins, cell-free extracts of the recombinant H. jecorina strain PEC/PSC1 were applied in the enzymatic assay.", [["cell", "ANATOMY", 341, 345], ["extracts", "ANATOMY", 351, 359], ["NeuNAc", "CHEMICAL", 216, 222], ["ManNAc", "CHEMICAL", 101, 107], ["GST", "GENE_OR_GENE_PRODUCT", 19, 22], ["ManNAc", "GENE_OR_GENE_PRODUCT", 101, 107], ["NeuNAc", "SIMPLE_CHEMICAL", 112, 118], ["Figure 3a1", "GENE_OR_GENE_PRODUCT", 196, 206], ["3b1", "GENE_OR_GENE_PRODUCT", 211, 214], ["NeuNAc", "SIMPLE_CHEMICAL", 216, 222], ["H. jecorina", "ORGANISM", 257, 268], ["strains", "ORGANISM", 269, 276], ["GST", "GENE_OR_GENE_PRODUCT", 320, 323], ["cell", "CELL", 341, 345], ["extracts", "ORGANISM_SUBSTANCE", 351, 359], ["H. jecorina", "ORGANISM", 379, 390], ["strain PEC", "ORGANISM", 391, 401], ["PSC1", "GENE_OR_GENE_PRODUCT", 402, 406], ["GST", "PROTEIN", 19, 22], ["fusion proteins", "PROTEIN", 23, 38], ["enzymes", "PROTEIN", 47, 54], ["ManNAc", "PROTEIN", 101, 107], ["NeuNAc", "PROTEIN", 112, 118], ["synthetic genes", "DNA", 142, 157], ["functional proteins", "PROTEIN", 175, 194], ["3a1", "PROTEIN", 203, 206], ["3b1", "PROTEIN", 211, 214], ["NeuNAc", "PROTEIN", 216, 222], ["GST", "PROTEIN", 320, 323], ["fusion proteins", "PROTEIN", 324, 339], ["H. jecorina", "SPECIES", 257, 268], ["H. jecorina", "SPECIES", 379, 390], ["H. jecorina", "SPECIES", 257, 268], ["H. jecorina", "SPECIES", 379, 390], ["the GST-fusion proteins", "TREATMENT", 15, 38], ["both enzymes", "TEST", 42, 54], ["NeuNAc", "TREATMENT", 112, 118], ["the GST-fusion proteins", "TEST", 316, 339], ["cell-free extracts", "TREATMENT", 341, 359], ["the recombinant H. jecorina strain PEC/PSC1", "TREATMENT", 363, 406], ["the enzymatic assay", "TEST", 423, 442]]], ["The formation of ManNAc (Figure 3a2) and NeuNAc could be detected (Figure 3b2).", [["ManNAc", "CHEMICAL", 17, 23], ["ManNAc", "SIMPLE_CHEMICAL", 17, 23], ["NeuNAc", "SIMPLE_CHEMICAL", 41, 47], ["ManNAc", "PROTEIN", 17, 23], ["Figure 3a2", "PROTEIN", 25, 35], ["NeuNAc", "PROTEIN", 41, 47], ["NeuNAc", "TEST", 41, 47]]], ["This demonstrates that both enzymes are also fully functionally expressed in the recombinant H. jecorina strain PEC/PSC1.", [["H. jecorina", "ORGANISM", 93, 104], ["PSC1", "GENE_OR_GENE_PRODUCT", 116, 120], ["enzymes", "PROTEIN", 28, 35], ["PSC1", "CELL_LINE", 116, 120], ["H. jecorina", "SPECIES", 93, 104], ["H. jecorina", "SPECIES", 93, 104]]], ["Neither ManNAc nor NeuNAc was detected using cell-free extracts from the parental strain in the assay (Figure 3a3 and 3b3), indicating that these pathways are normally not active in Hypocrea.NeuNAc synthesis in vitro by recombinant H. jecorina strains ::: Results and DiscussionTo investigate the stability of NeuNAc in cell-free extracts of the recombinant strain, according cell-free extracts obtained from the cultivation in a bioreactor on chitin (vide infra) were spiked with NeuNAc and incubated for 24 h.", [["cell", "ANATOMY", 45, 49], ["extracts", "ANATOMY", 55, 63], ["cell", "ANATOMY", 320, 324], ["extracts", "ANATOMY", 330, 338], ["strain", "ANATOMY", 358, 364], ["cell", "ANATOMY", 376, 380], ["extracts", "ANATOMY", 386, 394], ["ManNAc", "CHEMICAL", 8, 14], ["NeuNAc", "CHEMICAL", 19, 25], ["NeuNAc", "CHEMICAL", 191, 197], ["NeuNAc", "CHEMICAL", 310, 316], ["chitin", "CHEMICAL", 444, 450], ["NeuNAc", "CHEMICAL", 481, 487], ["ManNAc", "CHEMICAL", 8, 14], ["NeuNAc", "CHEMICAL", 310, 316], ["NeuNAc", "CHEMICAL", 481, 487], ["ManNAc", "GENE_OR_GENE_PRODUCT", 8, 14], ["NeuNAc", "GENE_OR_GENE_PRODUCT", 19, 25], ["cell", "CELL", 45, 49], ["extracts", "ORGANISM_SUBSTANCE", 55, 63], ["NeuNAc", "SIMPLE_CHEMICAL", 191, 197], ["H. jecorina", "ORGANISM", 232, 243], ["strains", "ORGANISM", 244, 251], ["NeuNAc", "SIMPLE_CHEMICAL", 310, 316], ["cell", "CELL", 320, 324], ["extracts", "ORGANISM_SUBSTANCE", 330, 338], ["cell", "CELL", 376, 380], ["extracts", "ORGANISM_SUBSTANCE", 386, 394], ["chitin", "SIMPLE_CHEMICAL", 444, 450], ["NeuNAc", "SIMPLE_CHEMICAL", 481, 487], ["ManNAc", "PROTEIN", 8, 14], ["NeuNAc", "PROTEIN", 19, 25], ["NeuNAc", "PROTEIN", 191, 197], ["NeuNAc", "PROTEIN", 310, 316], ["NeuNAc", "PROTEIN", 481, 487], ["H. jecorina", "SPECIES", 232, 243], ["H. jecorina", "SPECIES", 232, 243], ["NeuNAc", "TEST", 19, 25], ["NeuNAc in cell", "PROBLEM", 310, 324], ["the recombinant strain", "PROBLEM", 342, 364], ["a bioreactor on chitin", "TREATMENT", 428, 450]]], ["As a control, a heat-inactivated cell-free extract was similarly treated.", [["cell", "ANATOMY", 33, 37], ["extract", "ANATOMY", 43, 50], ["cell", "CELL", 33, 37], ["a heat-inactivated cell-free extract", "TREATMENT", 14, 50]]], ["Using HPLC analysis after derivatization with DMB, similar amounts of NeuNAc were detected in both extract preparations (Figure 3c), suggesting that components of the cell-free extract do not actively degrade NeuNAc.", [["extract", "ANATOMY", 99, 106], ["cell", "ANATOMY", 167, 171], ["extract", "ANATOMY", 177, 184], ["DMB", "CHEMICAL", 46, 49], ["NeuNAc", "CHEMICAL", 70, 76], ["NeuNAc", "CHEMICAL", 209, 215], ["DMB", "CHEMICAL", 46, 49], ["NeuNAc", "CHEMICAL", 70, 76], ["NeuNAc", "CHEMICAL", 209, 215], ["DMB", "SIMPLE_CHEMICAL", 46, 49], ["NeuNAc", "SIMPLE_CHEMICAL", 70, 76], ["cell", "CELL", 167, 171], ["NeuNAc", "SIMPLE_CHEMICAL", 209, 215], ["NeuNAc", "PROTEIN", 209, 215], ["HPLC analysis", "TEST", 6, 19], ["derivatization", "TREATMENT", 26, 40], ["DMB", "TREATMENT", 46, 49], ["NeuNAc", "TREATMENT", 70, 76]]], ["In addition, a similar amount of NeuNAc was measured in a NeuNAc-spiked cell-free extract of the recombinant strain that was not incubated, assuming that the 24-h incubation period at 30\u00b0C did not decrease the NeuNAc levels.", [["cell", "ANATOMY", 72, 76], ["extract", "ANATOMY", 82, 89], ["NeuNAc", "CHEMICAL", 33, 39], ["NeuNAc", "CHEMICAL", 58, 64], ["NeuNAc", "CHEMICAL", 33, 39], ["NeuNAc", "SIMPLE_CHEMICAL", 33, 39], ["NeuNAc", "SIMPLE_CHEMICAL", 58, 64], ["cell", "CELL", 72, 76], ["NeuNAc", "SIMPLE_CHEMICAL", 210, 216], ["NeuNAc", "PROTEIN", 33, 39], ["NeuNAc", "PROTEIN", 210, 216], ["a NeuNAc", "TEST", 56, 64], ["the recombinant strain", "PROBLEM", 93, 115], ["the NeuNAc levels", "TEST", 206, 223], ["similar", "OBSERVATION_MODIFIER", 15, 22], ["amount", "OBSERVATION_MODIFIER", 23, 29], ["free extract", "OBSERVATION_MODIFIER", 77, 89], ["recombinant strain", "OBSERVATION", 97, 115]]], ["As a final control, a cell-free extract without NeuNAc was also analyzed after a 24-h incubation period and, as expected, showed a lower amount of NeuNAc, which could only have resulted from its formation during the cultivation on chitin.", [["cell", "ANATOMY", 22, 26], ["extract", "ANATOMY", 32, 39], ["NeuNAc", "CHEMICAL", 48, 54], ["NeuNAc", "CHEMICAL", 147, 153], ["chitin", "CHEMICAL", 231, 237], ["cell", "CELL", 22, 26], ["NeuNAc", "SIMPLE_CHEMICAL", 48, 54], ["NeuNAc", "SIMPLE_CHEMICAL", 147, 153], ["chitin", "SIMPLE_CHEMICAL", 231, 237], ["NeuNAc", "PROTEIN", 147, 153], ["a lower amount of NeuNAc", "PROBLEM", 129, 153], ["chitin", "TREATMENT", 231, 237], ["lower", "OBSERVATION_MODIFIER", 131, 136], ["amount", "OBSERVATION_MODIFIER", 137, 143]]], ["In summary, we did not observe degradation of NeuNAc by H. jecorina.", [["NeuNAc", "GENE_OR_GENE_PRODUCT", 46, 52], ["H. jecorina", "ORGANISM", 56, 67], ["NeuNAc", "PROTEIN", 46, 52], ["H. jecorina", "SPECIES", 56, 67], ["H. jecorina", "SPECIES", 56, 67]]], ["These data suggest that NeuNAc is not metabolized by the recombinant Hypocrea strain.NeuNAc synthesis in vivo by the recombinant H. jecorina strain ::: Results and DiscussionWe next addressed whether the recombinant H. jecorina strain had the ability to produce NeuNAc in vivo.", [["NeuNAc", "CHEMICAL", 24, 30], ["NeuNAc", "CHEMICAL", 85, 91], ["NeuNAc", "CHEMICAL", 262, 268], ["NeuNAc", "SIMPLE_CHEMICAL", 24, 30], ["Hypocrea strain", "ORGANISM", 69, 84], ["NeuNAc", "SIMPLE_CHEMICAL", 85, 91], ["H. jecorina", "ORGANISM", 129, 140], ["strain", "ORGANISM", 141, 147], ["H. jecorina strain", "ORGANISM", 216, 234], ["NeuNAc", "GENE_OR_GENE_PRODUCT", 262, 268], ["NeuNAc", "PROTEIN", 85, 91], ["NeuNAc", "PROTEIN", 262, 268], ["H. jecorina", "SPECIES", 129, 140], ["H. jecorina", "SPECIES", 216, 227], ["H. jecorina", "SPECIES", 129, 140], ["H. jecorina", "SPECIES", 216, 227], ["These data", "TEST", 0, 10], ["the recombinant Hypocrea strain", "PROBLEM", 53, 84], ["NeuNAc synthesis", "TREATMENT", 85, 101], ["the recombinant H. jecorina strain", "PROBLEM", 200, 234], ["NeuNAc in vivo", "TREATMENT", 262, 276]]], ["To test this, the strain was grown on GlcNAc in shake flasks and cultivated on colloidal chitin in a bioreactor.", [["colloidal chitin", "CHEMICAL", 79, 95], ["GlcNAc", "CHEMICAL", 38, 44], ["GlcNAc", "SIMPLE_CHEMICAL", 38, 44], ["colloidal chitin", "SIMPLE_CHEMICAL", 79, 95], ["the strain", "PROBLEM", 14, 24], ["GlcNAc in shake flasks", "TREATMENT", 38, 60], ["colloidal chitin", "TREATMENT", 79, 95], ["a bioreactor", "TREATMENT", 99, 111], ["colloidal chitin", "OBSERVATION_MODIFIER", 79, 95]]], ["Data on the corresponding cultivation monitoring are provided in additional file 2.", [["the corresponding cultivation monitoring", "TEST", 8, 48]]], ["As a positive control, an enzyme assay using the GST fusion proteins was again performed and resulted in the detection of ManNAc using HPLC-MS analysis as shown in Figure 4a1.", [["GST", "GENE_OR_GENE_PRODUCT", 49, 52], ["ManNAc", "SIMPLE_CHEMICAL", 122, 128], ["GST fusion proteins", "PROTEIN", 49, 68], ["a positive control", "TREATMENT", 3, 21], ["an enzyme assay", "TEST", 23, 38], ["the GST fusion proteins", "TEST", 45, 68], ["ManNAc", "TEST", 122, 128], ["HPLC", "TEST", 135, 139], ["MS analysis", "TEST", 140, 151]]], ["Notably, the intermediate ManNAc was detected in the recombinant strain, regardless of the carbon source (Figure 4a2 und Figure 4a4), whereas the parental strain did not form ManNAc (Figure 4a3).", [["ManNAc", "CHEMICAL", 26, 32], ["carbon", "CHEMICAL", 91, 97], ["ManNAc", "GENE_OR_GENE_PRODUCT", 26, 32], ["ManNAc", "PROTEIN", 26, 32], ["ManNAc", "PROTEIN", 175, 181], ["Figure 4a3", "PROTEIN", 183, 193], ["the recombinant strain", "PROBLEM", 49, 71], ["intermediate", "OBSERVATION_MODIFIER", 13, 25], ["ManNAc", "OBSERVATION_MODIFIER", 26, 32]]], ["In the parental strain, only the first metabolite, GlcNAc, was detected, and it was present because it was either directly used as a carbon source or formed by degradation of the biopolymer chitin due to the native chitinolytic activity of the fungus.", [["biopolymer chitin", "CHEMICAL", 179, 196], ["GlcNAc", "CHEMICAL", 51, 57], ["carbon", "CHEMICAL", 133, 139], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 51, 57], ["biopolymer chitin", "SIMPLE_CHEMICAL", 179, 196], ["GlcNAc", "TEST", 51, 57], ["a carbon source", "PROBLEM", 131, 146], ["the biopolymer chitin", "TREATMENT", 175, 196], ["the native chitinolytic activity of the fungus", "PROBLEM", 204, 250], ["chitinolytic activity", "OBSERVATION", 215, 236], ["fungus", "OBSERVATION", 244, 250]]], ["The synthesis of the product NeuNAc was analyzed using HPLC-MS/MS analysis (Figure 4b).", [["NeuNAc", "CHEMICAL", 29, 35], ["NeuNAc", "SIMPLE_CHEMICAL", 29, 35], ["HPLC", "TEST", 55, 59], ["MS analysis", "TEST", 63, 74]]], ["As a positive control, the reaction products (ManNAc, NeuNAc) generated by the use of the GST fusion proteins in an enzymatic assay are shown (Figure 4b1).", [["NeuNAc", "CHEMICAL", 54, 60], ["ManNAc", "SIMPLE_CHEMICAL", 46, 52], ["NeuNAc", "SIMPLE_CHEMICAL", 54, 60], ["GST", "GENE_OR_GENE_PRODUCT", 90, 93], ["reaction products", "PROTEIN", 27, 44], ["ManNAc", "PROTEIN", 46, 52], ["NeuNAc", "PROTEIN", 54, 60], ["GST fusion proteins", "PROTEIN", 90, 109], ["a positive control", "TREATMENT", 3, 21], ["the reaction products", "TREATMENT", 23, 44], ["the GST fusion proteins", "TREATMENT", 86, 109], ["an enzymatic assay", "TEST", 113, 131]]], ["Importantly, the recombinant H. jecorina strain formed NeuNAc using either carbon source, GlcNAc or chitin (Figure 4b2 and 4b4), whereas in the parental strain no formation of NeuNAc was detected (Figure 4b3).", [["NeuNAc", "CHEMICAL", 55, 61], ["chitin", "CHEMICAL", 100, 106], ["carbon", "CHEMICAL", 75, 81], ["GlcNAc", "CHEMICAL", 90, 96], ["H. jecorina", "ORGANISM", 29, 40], ["strain", "ORGANISM", 41, 47], ["NeuNAc", "SIMPLE_CHEMICAL", 55, 61], ["GlcNAc", "SIMPLE_CHEMICAL", 90, 96], ["chitin", "SIMPLE_CHEMICAL", 100, 106], ["4b4", "SIMPLE_CHEMICAL", 123, 126], ["NeuNAc", "GENE_OR_GENE_PRODUCT", 176, 182], ["NeuNAc", "PROTEIN", 55, 61], ["NeuNAc", "PROTEIN", 176, 182], ["H. jecorina", "SPECIES", 29, 40], ["H. jecorina", "SPECIES", 29, 40], ["GlcNAc or chitin", "TREATMENT", 90, 106], ["NeuNAc", "TEST", 176, 182]]], ["This analysis allowed us to estimate that 13 \u03bcg NeuNAc per g mycelium (dry weight) was formed in the recombinant strain.", [["NeuNAc", "CHEMICAL", 48, 54], ["This analysis", "TEST", 0, 13], ["the recombinant strain", "PROBLEM", 97, 119], ["recombinant strain", "OBSERVATION", 101, 119]]], ["Thus, on its own, this would not be a competitive production process, but it does demonstrate the possibility for engineering a saprophyte and using it as a whole-cell catalyst that expresses a bacterial enzyme cascade.", [["cell", "ANATOMY", 163, 167], ["cell", "CELL", 163, 167], ["bacterial enzyme", "PROTEIN", 194, 210], ["a competitive production process", "PROBLEM", 36, 68], ["engineering a saprophyte", "PROBLEM", 114, 138], ["a whole-cell catalyst", "TREATMENT", 155, 176], ["a bacterial enzyme cascade", "TREATMENT", 192, 218], ["saprophyte", "OBSERVATION", 128, 138], ["bacterial enzyme cascade", "OBSERVATION", 194, 218]]], ["This method has enormous potential considering its use of a cheap starting material and the relatively simple, inexpensive cultivation of a fungus.ConclusionsTaken together, we successfully engineered Hypocrea in a way that this fungus now produces NeuNAc from the biopolymer chitin by employing its natural saprophytic activity in combination with the introduction of a bacterial enzyme cascade.", [["NeuNAc", "CHEMICAL", 249, 255], ["biopolymer chitin", "CHEMICAL", 265, 282], ["NeuNAc", "SIMPLE_CHEMICAL", 249, 255], ["chitin", "SIMPLE_CHEMICAL", 276, 282], ["a cheap starting material", "TREATMENT", 58, 83], ["a fungus", "PROBLEM", 138, 146], ["this fungus", "PROBLEM", 224, 235], ["NeuNAc", "TREATMENT", 249, 255], ["the biopolymer chitin", "TREATMENT", 261, 282], ["a bacterial enzyme cascade", "TREATMENT", 369, 395], ["biopolymer chitin", "OBSERVATION", 265, 282], ["saprophytic activity", "OBSERVATION", 308, 328]]], ["Because human society will face severe bottlenecks in the supply of energy and in obtaining certain raw materials in the upcoming years, we hope that this study will highlight the potential advantages of biopolymers, such as chitin, and stimulate their efficient usage.", [["chitin", "CHEMICAL", 225, 231], ["human", "ORGANISM", 8, 13], ["chitin", "SIMPLE_CHEMICAL", 225, 231], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["this study", "TEST", 150, 160], ["biopolymers", "TREATMENT", 204, 215], ["chitin", "TREATMENT", 225, 231]]], ["Furthermore, we anticipate that such strategies will support efforts to create sustainable production processes.Strains and cultivation conditions ::: MethodsThe parental strain H. jecorina (T. reesei [26]) QM9414 (ATCC 26921) was maintained on malt extract (MEX) agar.Strains and cultivation conditions ::: MethodsMycelia for the enzymatic assay were cultivated in 3% (w/v) MEX medium using 108 conidia/L at 30\u00b0C.Strains and cultivation conditions ::: MethodsCultivation of H. jecorina on colloidal chitin was performed in a bench top bioreactor (Bioengineering, Wald, Switzerland) as previously described [27].", [["ATCC 26921", "ANATOMY", 215, 225], ["ATCC 26921", "CHEMICAL", 215, 225], ["malt extract", "CHEMICAL", 245, 257], ["MEX", "CHEMICAL", 259, 262], ["colloidal chitin", "CHEMICAL", 490, 506], ["H. jecorina", "ORGANISM", 178, 189], ["T. reesei [26]", "ORGANISM", 191, 205], ["ATCC 26921", "CELL", 215, 225], ["malt extract", "ORGANISM_SUBSTANCE", 245, 257], ["MEX", "SIMPLE_CHEMICAL", 259, 262], ["MethodsMycelia", "SIMPLE_CHEMICAL", 308, 322], ["H. jecorina", "ORGANISM", 475, 486], ["colloidal chitin", "SIMPLE_CHEMICAL", 490, 506], ["H. jecorina", "SPECIES", 178, 189], ["T. reesei", "SPECIES", 191, 200], ["H. jecorina", "SPECIES", 475, 486], ["H. jecorina", "SPECIES", 178, 189], ["T. reesei", "SPECIES", 191, 200], ["ATCC 26921)", "SPECIES", 215, 226], ["H. jecorina", "SPECIES", 475, 486], ["sustainable production processes", "PROBLEM", 79, 111], ["Methods", "TREATMENT", 151, 158], ["ATCC", "TEST", 215, 219], ["MethodsMycelia", "TREATMENT", 308, 322], ["the enzymatic assay", "TEST", 327, 346], ["MEX medium", "TREATMENT", 375, 385], ["colloidal chitin", "TREATMENT", 490, 506], ["a bench top bioreactor", "TREATMENT", 524, 546], ["H. jecorina", "OBSERVATION", 475, 486]]], ["Briefly, 500 mL Mandels-Andreotti (MA) [28] medium containing 1% (w/v) colloidal chitin [29], 0.5% GlcNAc, and 0.1% (w/v) bacto peptone (Difco, Detroit, US) was inoculated with 108 conidia/L. Some drops glanapon (Becker, Wien, Austria) were added to the medium to avoid excessive foam formation.", [["foam", "ANATOMY", 280, 284], ["Mandels-Andreotti", "CHEMICAL", 16, 33], ["chitin", "CHEMICAL", 81, 87], ["bacto peptone", "CHEMICAL", 122, 135], ["glanapon", "CHEMICAL", 203, 211], ["GlcNAc", "CHEMICAL", 99, 105], ["colloidal chitin [29]", "SIMPLE_CHEMICAL", 71, 92], ["GlcNAc", "SIMPLE_CHEMICAL", 99, 105], ["/v) bacto peptone", "SIMPLE_CHEMICAL", 118, 135], ["Difco", "SIMPLE_CHEMICAL", 137, 142], ["foam", "TISSUE", 280, 284], ["w/v) colloidal chitin", "TREATMENT", 66, 87], ["GlcNAc", "TEST", 99, 105], ["bacto peptone", "TREATMENT", 122, 135], ["excessive foam formation", "TREATMENT", 270, 294], ["foam", "OBSERVATION", 280, 284]]], ["Cultivation was performed at 30\u00b0C temperature, pH 5, 0.3 vvm aeration rate, and 500 rpm agitation rate for 96 h.", [["Cultivation", "TEST", 0, 11], ["temperature", "TEST", 34, 45], ["pH", "TEST", 47, 49], ["aeration rate", "TEST", 61, 74], ["agitation rate", "TEST", 88, 102]]], ["Each sample drawing was followed by a microscopic analysis for infection control.", [["sample", "ANATOMY", 5, 11], ["infection", "DISEASE", 63, 72], ["Each sample", "TEST", 0, 11], ["a microscopic analysis", "TEST", 36, 58], ["infection control", "TREATMENT", 63, 80], ["infection", "OBSERVATION", 63, 72]]], ["Culture supernatant and mycelia were separated by filtration through GF/F glass microfiber filters (Whatman, Brentford, UK).", [["supernatant", "ANATOMY", 8, 19], ["mycelia", "ANATOMY", 24, 31], ["Culture supernatant", "TEST", 0, 19], ["mycelia", "PROBLEM", 24, 31], ["GF/F glass microfiber filters", "TREATMENT", 69, 98]]], ["All strains (parental, recombinant) showed similar growth on rich media as well as MA medium.Plasmid construction ::: MethodsThe synthetic gene tbage (for sequence see additional file 1) is based on the protein sequence of Anabaena sp.", [["Anabaena sp", "ORGANISM", 223, 234], ["synthetic gene tbage", "DNA", 129, 149], ["All strains", "PROBLEM", 0, 11], ["Methods", "TREATMENT", 118, 125]]], ["CH1 GlcNAc-2-epimerase (GenBank: ABG57042) and was reverse translated into a nucleotide sequence using the GeneOptimizer\u00ae software (Geneart, Regensburg, Germany).", [["CH1 GlcNAc-2-epimerase", "CHEMICAL", 0, 22], ["nucleotide", "CHEMICAL", 77, 87], ["GlcNAc", "CHEMICAL", 4, 10], ["nucleotide", "CHEMICAL", 77, 87], ["CH1 GlcNAc-2-epimerase", "GENE_OR_GENE_PRODUCT", 0, 22], ["CH1 GlcNAc-2-epimerase", "PROTEIN", 0, 22], ["CH1 GlcNAc", "TEST", 0, 10], ["a nucleotide sequence", "TREATMENT", 75, 96]]], ["The codon usage was optimized for H. jecorina (http://www.kazusa.or.jp/codon).", [["H. jecorina", "ORGANISM", 34, 45], ["H. jecorina", "SPECIES", 34, 45], ["The codon usage", "TREATMENT", 0, 15], ["H. jecorina", "PROBLEM", 34, 45]]], ["The synthetic gene tneub (for sequence see additional file 1) was similarly obtained based on the protein sequence from Campylobacter jejuni NCTC11168 NeuNAc synthase (http://old.genedb.org/genedb/cjejuni/index.jsp, Cj1141).Plasmid construction ::: MethodsThe synthetic genes tbage and tneub were excised from the production plasmid using XbaI/NsiI digestion and inserted into pRLMex30 [30] to generate the plasmids pMS-PEC and pMS-PSC.Plasmid construction ::: MethodsFor the construction of pGEX-epi and pGEX-syn, the oligonucleotides GEXfw and GEXrev (Table 1) were used to introduce an XbaI and NsiI site into plasmid pGEX4T-2 (GE Healthcare, Chalfont St Giles, UK), yielding pGEX-MS. tbage and tneub were inserted into pGEX-MS via XbaI/NsiI digestion to yield the plasmids pGEX-epi and pGEX-syn.Protoplast transformation ::: MethodsThe protoplast transformation of H. jecorina was performed as described previously [31].", [["plasmid", "ANATOMY", 325, 332], ["plasmids", "ANATOMY", 407, 415], ["pMS-PSC", "ANATOMY", 428, 435], ["plasmids", "ANATOMY", 768, 776], ["Protoplast", "ANATOMY", 799, 809], ["protoplast", "ANATOMY", 840, 850], ["PEC", "CHEMICAL", 420, 423], ["NeuNAc synthase", "GENE_OR_GENE_PRODUCT", 151, 166], ["tbage", "GENE_OR_GENE_PRODUCT", 276, 281], ["tneub", "GENE_OR_GENE_PRODUCT", 286, 291], ["XbaI", "GENE_OR_GENE_PRODUCT", 339, 343], ["NsiI", "GENE_OR_GENE_PRODUCT", 344, 348], ["pMS-PEC", "CELL", 416, 423], ["pMS-PSC", "CELL", 428, 435], ["pGEX-epi", "GENE_OR_GENE_PRODUCT", 492, 500], ["pGEX-syn", "SIMPLE_CHEMICAL", 505, 513], ["XbaI", "GENE_OR_GENE_PRODUCT", 589, 593], ["NsiI", "GENE_OR_GENE_PRODUCT", 598, 602], ["UK", "GENE_OR_GENE_PRODUCT", 665, 667], ["pGEX", "GENE_OR_GENE_PRODUCT", 679, 683], ["tneub", "SIMPLE_CHEMICAL", 698, 703], ["XbaI", "GENE_OR_GENE_PRODUCT", 735, 739], ["NsiI", "GENE_OR_GENE_PRODUCT", 740, 744], ["pGEX-epi", "GENE_OR_GENE_PRODUCT", 777, 785], ["pGEX-syn", "GENE_OR_GENE_PRODUCT", 790, 798], ["H. jecorina", "ORGANISM", 869, 880], ["synthetic gene tneub", "DNA", 4, 24], ["Campylobacter jejuni NCTC11168 NeuNAc synthase", "PROTEIN", 120, 166], ["synthetic genes tbage", "DNA", 260, 281], ["tneub", "DNA", 286, 291], ["production plasmid", "DNA", 314, 332], ["XbaI", "DNA", 339, 343], ["NsiI", "DNA", 344, 348], ["pMS", "DNA", 416, 419], ["PEC", "CELL_TYPE", 420, 423], ["pMS", "DNA", 428, 431], ["pGEX", "PROTEIN", 492, 496], ["epi", "PROTEIN", 497, 500], ["pGEX", "PROTEIN", 505, 509], ["XbaI and NsiI site", "DNA", 589, 607], ["plasmid pGEX4T-2", "DNA", 613, 629], ["pGEX", "DNA", 679, 683], ["MS. tbage", "DNA", 684, 693], ["tneub", "DNA", 698, 703], ["pGEX", "DNA", 723, 727], ["XbaI", "DNA", 735, 739], ["NsiI", "DNA", 740, 744], ["plasmids", "DNA", 768, 776], ["pGEX", "DNA", 777, 781], ["epi", "DNA", 782, 785], ["pGEX", "DNA", 790, 794], ["Campylobacter jejuni NCTC", "SPECIES", 120, 145], ["H. jecorina", "SPECIES", 869, 880], ["Campylobacter jejuni", "SPECIES", 120, 140], ["H. jecorina", "SPECIES", 869, 880], ["the protein sequence", "TEST", 94, 114], ["Methods", "TREATMENT", 249, 256], ["XbaI/NsiI digestion", "TREATMENT", 339, 358], ["the plasmids pMS", "TREATMENT", 403, 419], ["PSC", "PROBLEM", 432, 435], ["pGEX", "TEST", 492, 496], ["epi", "TREATMENT", 497, 500], ["pGEX", "TEST", 505, 509], ["the oligonucleotides GEXfw", "TREATMENT", 515, 541], ["GEXrev (Table 1)", "TREATMENT", 546, 562], ["an XbaI", "TREATMENT", 586, 593], ["NsiI site", "TREATMENT", 598, 607], ["plasmid pGEX4T", "TREATMENT", 613, 627], ["NsiI digestion", "TREATMENT", 740, 754], ["the plasmids pGEX", "TREATMENT", 764, 781], ["epi", "TREATMENT", 782, 785], ["Methods", "TREATMENT", 829, 836], ["PSC", "OBSERVATION", 432, 435], ["syn", "ANATOMY", 795, 798], ["protoplast transformation", "OBSERVATION", 840, 865]]], ["The plasmid pHylox2 (2 \u03bcg) [32], which confers hygromycin B resistance [30], and 4 \u03bcg of each plasmid pMS-PEC and pMS-PSC were co-transformed into the fungal genome.DNA analysis ::: MethodsFungal genomic DNA was isolated as described previously [31].", [["plasmid", "ANATOMY", 4, 11], ["plasmid", "ANATOMY", 94, 101], ["pHylox2", "CHEMICAL", 12, 19], ["hygromycin B", "CHEMICAL", 47, 59], ["hygromycin B", "CHEMICAL", 47, 59], ["PEC", "CHEMICAL", 106, 109], ["hygromycin B", "SIMPLE_CHEMICAL", 47, 59], ["pMS-PSC", "CELL", 114, 121], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["hygromycin B", "DNA", 47, 59], ["pMS", "DNA", 102, 105], ["PEC", "DNA", 106, 109], ["pMS", "DNA", 114, 117], ["PSC", "DNA", 118, 121], ["fungal genome", "DNA", 151, 164], ["MethodsFungal genomic DNA", "DNA", 182, 207], ["The plasmid pHylox2", "TREATMENT", 0, 19], ["each plasmid pMS", "TEST", 89, 105], ["PEC", "TEST", 106, 109], ["pMS", "TEST", 114, 117], ["PSC", "PROBLEM", 118, 121], ["DNA analysis", "TEST", 165, 177], ["MethodsFungal genomic DNA", "PROBLEM", 182, 207], ["PSC", "ANATOMY", 118, 121], ["fungal genome", "OBSERVATION", 151, 164]]], ["Southern hybridization and detection were performed using the DIG High Prime DNA Labeling and Detection Starter Kit II following the manufacturer's instructions (Roche, Basel, Switzerland).Transcriptional analysis ::: MethodsRNA extraction, cDNA synthesis and qPCR analysis were performed as described elsewhere [25].", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["Southern hybridization", "TEST", 0, 22], ["the DIG", "TEST", 58, 65], ["Transcriptional analysis", "TEST", 189, 213], ["MethodsRNA extraction", "TREATMENT", 218, 239], ["cDNA synthesis", "TEST", 241, 255], ["qPCR analysis", "TEST", 260, 273]]], ["Primer sequences are given in Table 1.Glutathione S-transferase (GST) fusion proteins ::: MethodsGST fusion proteins of GlcNAc-2-epimerase and NeuNAc synthase were generated using plasmids pGEX-epi and pGEX-syn in E. coli BL21 (DE3).", [["Glutathione", "CHEMICAL", 38, 49], ["Glutathione", "CHEMICAL", 38, 49], ["GlcNAc", "CHEMICAL", 120, 126], ["Glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 38, 63], ["GST", "GENE_OR_GENE_PRODUCT", 65, 68], ["GlcNAc-2-epimerase", "GENE_OR_GENE_PRODUCT", 120, 138], ["NeuNAc synthase", "GENE_OR_GENE_PRODUCT", 143, 158], ["pGEX-epi", "GENE_OR_GENE_PRODUCT", 189, 197], ["pGEX-syn", "GENE_OR_GENE_PRODUCT", 202, 210], ["E. coli BL21", "ORGANISM", 214, 226], ["DE3", "CELL", 228, 231], ["Primer sequences", "DNA", 0, 16], ["Glutathione S-transferase (GST) fusion proteins", "PROTEIN", 38, 85], ["MethodsGST fusion proteins", "PROTEIN", 90, 116], ["GlcNAc-2-epimerase", "PROTEIN", 120, 138], ["NeuNAc synthase", "PROTEIN", 143, 158], ["pGEX", "PROTEIN", 189, 193], ["epi", "DNA", 194, 197], ["pGEX", "DNA", 202, 206], ["E. coli BL21", "SPECIES", 214, 226], ["E. coli BL21", "SPECIES", 214, 226], ["DE3", "SPECIES", 228, 231], ["Primer sequences", "TEST", 0, 16], ["Glutathione S-transferase", "TEST", 38, 63], ["MethodsGST fusion proteins", "TEST", 90, 116], ["GlcNAc", "TEST", 120, 126], ["epimerase", "TEST", 129, 138], ["NeuNAc synthase", "TEST", 143, 158], ["plasmids pGEX", "TEST", 180, 193], ["epi", "TEST", 194, 197], ["pGEX", "TEST", 202, 206], ["coli BL21", "OBSERVATION", 217, 226]]], ["Purification of the proteins was performed using GSTrap\u2122FF (GE Healthcare) according to standard procedures.Enzymatic assay ::: MethodsHarvested mycelia were ground into fine powder and resuspended in 0.1 M Bicine buffer (pH 8) containing protease inhibitors (2 \u03bcM leupeptin, 1 \u03bcM pepstatin A, and 10 \u03bcM PMSF) (0.3 g mycelia/mL).", [["mycelia", "ANATOMY", 145, 152], ["pepstatin A", "CHEMICAL", 281, 292], ["Bicine", "CHEMICAL", 207, 213], ["leupeptin", "CHEMICAL", 265, 274], ["pepstatin A", "CHEMICAL", 281, 292], ["PMSF", "CHEMICAL", 304, 308], ["leupeptin", "SIMPLE_CHEMICAL", 265, 274], ["pepstatin A", "SIMPLE_CHEMICAL", 281, 292], ["PMSF", "SIMPLE_CHEMICAL", 304, 308], ["the proteins", "TEST", 16, 28], ["GSTrap\u2122FF (GE Healthcare", "TREATMENT", 49, 73], ["standard procedures", "TREATMENT", 88, 107], ["Enzymatic assay", "TEST", 108, 123], ["MethodsHarvested mycelia", "TREATMENT", 128, 152], ["Bicine buffer (pH", "TREATMENT", 207, 224], ["protease inhibitors", "TREATMENT", 239, 258], ["leupeptin", "TREATMENT", 265, 274], ["1 \u03bcM pepstatin A", "TREATMENT", 276, 292]]], ["The suspension was sonicated using a Sonifier\u00ae 250 Cell Disruptor (Branson, Danbury, US) (power 40%, duty cycle 50%, power 20 sec, 40 sec pause, 10 cycles).", [["The suspension", "TREATMENT", 0, 14], ["a Sonifier\u00ae", "TREATMENT", 35, 46], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["Enzymatic analysis was performed according to a previously described modified protocol [33].", [["Enzymatic analysis", "TEST", 0, 18]]], ["The assay was performed in a total volume of 100 \u03bcL containing 10 mM GlcNAc, 10 mM PEP, 12.5 mM MnCl2, 100 mM Bicine buffer (pH 8) and 40 \u03bcL cell-free extract.", [["cell", "ANATOMY", 141, 145], ["extract", "ANATOMY", 151, 158], ["MnCl2", "CHEMICAL", 96, 101], ["GlcNAc", "CHEMICAL", 69, 75], ["MnCl2", "CHEMICAL", 96, 101], ["Bicine", "CHEMICAL", 110, 116], ["GlcNAc", "SIMPLE_CHEMICAL", 69, 75], ["PEP", "SIMPLE_CHEMICAL", 83, 86], ["MnCl2", "SIMPLE_CHEMICAL", 96, 101], ["cell", "CELL", 141, 145], ["The assay", "TEST", 0, 9], ["a total volume", "TEST", 27, 41], ["10 mM PEP", "TREATMENT", 77, 86], ["pH", "TEST", 125, 127]]], ["As a positive control, 5 \u03bcL of both GST fusion proteins were applied in place of the cell-free extracts.Enzymatic assay ::: MethodsThe stability of NeuNAc in the cell-free extract was determined by adding NeuNAc (150 \u03bcM) and incubating for 24 h at 30\u00b0C. After derivatization with DMB [34], the NeuNAc quantity was measured using HPLC.Detection of NeuNAc synthesis in vivo ::: MethodsHarvested H. jecorina mycelia were ground into fine powder and resuspended in water (0.3 g mycelia/mL).", [["cell", "ANATOMY", 85, 89], ["extracts", "ANATOMY", 95, 103], ["cell", "ANATOMY", 162, 166], ["extract", "ANATOMY", 172, 179], ["mycelia", "ANATOMY", 405, 412], ["NeuNAc", "CHEMICAL", 148, 154], ["NeuNAc", "CHEMICAL", 205, 211], ["DMB", "CHEMICAL", 280, 283], ["NeuNAc", "CHEMICAL", 148, 154], ["NeuNAc", "CHEMICAL", 205, 211], ["DMB", "CHEMICAL", 280, 283], ["GST", "GENE_OR_GENE_PRODUCT", 36, 39], ["cell", "CELL", 85, 89], ["extracts", "ORGANISM_SUBSTANCE", 95, 103], ["NeuNAc", "SIMPLE_CHEMICAL", 148, 154], ["cell", "CELL", 162, 166], ["NeuNAc", "SIMPLE_CHEMICAL", 205, 211], ["DMB [34]", "SIMPLE_CHEMICAL", 280, 288], ["NeuNAc", "SIMPLE_CHEMICAL", 294, 300], ["NeuNAc", "GENE_OR_GENE_PRODUCT", 347, 353], ["jecorina mycelia", "ORGANISM", 396, 412], ["GST fusion proteins", "PROTEIN", 36, 55], ["NeuNAc", "PROTEIN", 148, 154], ["NeuNAc", "PROTEIN", 347, 353], ["H. jecorina", "SPECIES", 393, 404], ["H. jecorina", "SPECIES", 393, 404], ["a positive control", "TREATMENT", 3, 21], ["both GST fusion proteins", "TREATMENT", 31, 55], ["Enzymatic assay", "TEST", 104, 119], ["Methods", "TREATMENT", 124, 131], ["the NeuNAc quantity", "TEST", 290, 309], ["MethodsHarvested H. jecorina mycelia", "TREATMENT", 376, 412], ["free extracts", "OBSERVATION", 90, 103], ["stability", "OBSERVATION_MODIFIER", 135, 144], ["cell", "ANATOMY", 162, 166]]], ["The suspension was sonicated using a Sonifier\u00ae 250 Cell Disruptor (Branson) (power 70%, duty cycle 50%, power for 1 min, 1 min pause, 3 cycles).", [["The suspension", "TREATMENT", 0, 14], ["a Sonifier\u00ae 250 Cell Disruptor (Branson)", "TREATMENT", 35, 75]]], ["Insoluble compounds were separated using centrifugation (10 min, 13000 g, 4\u00b0C), and the supernatant was analyzed using HPLC-MS/MS.NeuNAc and GlcNAc uptake ::: MethodsH. jecorina mycelia were pre-grown on MA containing 1% glycerol, transferred to MA medium containing 1% glycerol or no carbon source, spiked with 30 \u03bcM NeuNAc or GlcNAc, respectively, and incubated for 8 h at 30\u00b0C. Autoclaved mycelia served as a negative control.", [["supernatant", "ANATOMY", 88, 99], ["mycelia", "ANATOMY", 178, 185], ["mycelia", "ANATOMY", 392, 399], ["MA", "CHEMICAL", 204, 206], ["glycerol", "CHEMICAL", 221, 229], ["glycerol", "CHEMICAL", 270, 278], ["GlcNAc", "CHEMICAL", 141, 147], ["glycerol", "CHEMICAL", 221, 229], ["glycerol", "CHEMICAL", 270, 278], ["carbon", "CHEMICAL", 285, 291], ["NeuNAc", "CHEMICAL", 318, 324], ["GlcNAc", "CHEMICAL", 328, 334], ["NeuNAc", "SIMPLE_CHEMICAL", 130, 136], ["GlcNAc", "SIMPLE_CHEMICAL", 141, 147], ["jecorina mycelia", "CELL", 169, 185], ["glycerol", "SIMPLE_CHEMICAL", 221, 229], ["glycerol", "SIMPLE_CHEMICAL", 270, 278], ["NeuNAc", "SIMPLE_CHEMICAL", 318, 324], ["GlcNAc", "SIMPLE_CHEMICAL", 328, 334], ["HPLC", "TEST", 119, 123], ["MS", "PROBLEM", 127, 129], ["jecorina mycelia", "PROBLEM", 169, 185], ["1% glycerol", "TREATMENT", 218, 229], ["1% glycerol", "TREATMENT", 267, 278], ["carbon source", "PROBLEM", 285, 298], ["GlcNAc", "TREATMENT", 328, 334], ["Autoclaved mycelia", "TREATMENT", 381, 399], ["GlcNAc uptake", "OBSERVATION", 141, 154], ["negative", "OBSERVATION", 412, 420]]], ["After derivatization with DMB [34], the NeuNAc quantity was measured using HPLC.HPLC and HPLC-MS/MS analysis ::: MethodsNeuNAc, ManNAc and GlcNAc formation was measured using LC-MS (IT-TOF-MS) (Shimadzu, Kyoto, Japan) with a Rezex\u2122 RHM-Monosaccharide H+-column (8%, 300 \u00d7 7.8 mm) (Phenomenex, Torrance, USA).", [["DMB", "CHEMICAL", 26, 29], ["DMB", "CHEMICAL", 26, 29], ["GlcNAc", "CHEMICAL", 139, 145], ["DMB [34]", "SIMPLE_CHEMICAL", 26, 34], ["NeuNAc", "SIMPLE_CHEMICAL", 40, 46], ["MethodsNeuNAc", "SIMPLE_CHEMICAL", 113, 126], ["ManNAc", "SIMPLE_CHEMICAL", 128, 134], ["GlcNAc", "SIMPLE_CHEMICAL", 139, 145], ["the NeuNAc quantity", "TEST", 36, 55], ["HPLC", "TEST", 80, 84], ["HPLC", "TEST", 89, 93], ["MS", "PROBLEM", 94, 96], ["MS analysis", "TEST", 97, 108], ["MethodsNeuNAc", "TREATMENT", 113, 126], ["GlcNAc formation", "TREATMENT", 139, 155], ["LC", "TEST", 175, 177], ["MS", "TEST", 178, 180], ["IT", "TEST", 182, 184], ["a Rezex", "TEST", 223, 230], ["column", "TEST", 254, 260]]], ["The mobile phase consisted of water with 0.1% (v/v) trifluoroacetic acid, the flow was 0.6 mL/min, the column temperature was 80\u00b0C, and the injected volume was 10 \u03bcL.", [["trifluoroacetic acid", "CHEMICAL", 52, 72], ["trifluoroacetic acid", "CHEMICAL", 52, 72], ["v/v) trifluoroacetic acid", "SIMPLE_CHEMICAL", 47, 72], ["v/v) trifluoroacetic acid", "TREATMENT", 47, 72], ["the flow", "TEST", 74, 82], ["the column temperature", "TEST", 99, 121], ["the injected volume", "TREATMENT", 136, 155], ["mobile phase", "OBSERVATION_MODIFIER", 4, 16]]], ["MS detection was performed in ESI+ mode, covering a scan range of 60-600 amu.", [["MS detection", "TEST", 0, 12], ["a scan range", "TEST", 50, 62]]], ["The retention times were determined using pure standard substances.", [["retention", "OBSERVATION_MODIFIER", 4, 13]]], ["The identity of NeuNAc was confirmed by both, chromatographic retention time and mass spectral signal, which are very well matched by authentic standards of NeuNAc.", [["NeuNAc", "GENE_OR_GENE_PRODUCT", 16, 22], ["NeuNAc", "SIMPLE_CHEMICAL", 157, 163], ["NeuNAc", "PROTEIN", 16, 22], ["NeuNAc", "PROTEIN", 157, 163], ["mass spectral signal", "TEST", 81, 101], ["mass", "OBSERVATION", 81, 85]]], ["The better the mass accuracy obtained from exact mass determination by HR-MS, the lower is the number of possible isobaric candidates (e.g. [35]).", [["the mass accuracy", "TEST", 11, 28], ["HR", "TEST", 71, 73], ["mass", "OBSERVATION", 15, 19], ["mass", "OBSERVATION", 49, 53], ["lower", "OBSERVATION_MODIFIER", 82, 87], ["possible", "UNCERTAINTY", 105, 113], ["isobaric candidates", "OBSERVATION", 114, 133]]], ["In this case the mass accuracy is better than 2 ppm, leading to the number of candidates reduced to less than 10, with an even further reduction in the number of potential candidates because the isotopic pattern is also taken into account (what the software of the used IT-TOF-MS instrument does automatically).HPLC and HPLC-MS/MS analysis ::: MethodsDMB derivatives of NeuNAc were separated on a Kinetex RP C18 (Phenomenex) at 0.75 mL/min with a 40\u00b0C column temperature and a mobile phase of water:methanol:trifluoroacetic acid (74.25:25:0.75).", [["NeuNAc", "CHEMICAL", 370, 376], ["Kinetex RP C18", "CHEMICAL", 397, 411], ["methanol:trifluoroacetic acid", "CHEMICAL", 499, 528], ["MethodsDMB", "CHEMICAL", 344, 354], ["NeuNAc", "CHEMICAL", 370, 376], ["methanol", "CHEMICAL", 499, 507], ["trifluoroacetic acid", "CHEMICAL", 508, 528], ["NeuNAc", "SIMPLE_CHEMICAL", 370, 376], ["water", "SIMPLE_CHEMICAL", 493, 498], ["methanol:trifluoroacetic acid", "SIMPLE_CHEMICAL", 499, 528], ["the mass accuracy", "PROBLEM", 13, 30], ["the isotopic pattern", "TEST", 191, 211], ["MS instrument", "PROBLEM", 277, 290], ["HPLC", "TEST", 311, 315], ["HPLC", "TEST", 320, 324], ["MethodsDMB derivatives", "TREATMENT", 344, 366], ["NeuNAc", "TREATMENT", 370, 376], ["a Kinetex RP C18 (Phenomenex)", "TREATMENT", 395, 424], ["C column temperature", "TEST", 450, 470], ["trifluoroacetic acid", "TREATMENT", 508, 528], ["mass", "OBSERVATION", 17, 21], ["reduction", "OBSERVATION_MODIFIER", 135, 144]]], ["A Shimadzu RF-20AXS fluorescence detector (excitation 373 nm, emission 448 nm) was used for detection.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsMGS produced and characterized the recombinant strains and contributed to the manuscript.", [["A Shimadzu RF", "TEST", 0, 13], ["the recombinant strains", "PROBLEM", 232, 255]]], ["ARMA prepared the manuscript and contributed to the design of the study.", [["the study", "TEST", 62, 71]]], ["RG established enzymatic assays.", [["enzymatic assays", "OBSERVATION", 15, 31]]], ["EER performed HPLC-MS/MS analyses; MDM suggested the target substance and supported analytics; RLM contributed to the design and coordination of the study.", [["MDM", "CELL_TYPE", 35, 38], ["EER", "TEST", 0, 3], ["HPLC", "TEST", 14, 18], ["MS/MS analyses", "PROBLEM", 19, 33], ["the study", "TEST", 145, 154]]]]}